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ACR American College of Rheumatology 
ACPA Anti-citrullinated Protein Antibody 
ADD Anterior Disc Displacement 
AJR Alloplastic joint reconstruction 
CT Computed Tomography 
CHAQ Child Health Assessment Questionnaire 
CHQ Child Health Questionnaire 
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DO Distraction osteogenesis 
DMARDs Disease-modifying anti-rheumatic drugs 
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EULAR European League Against Rheumatism 
GBI Gingival Bleeding Index 
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HLA Human leukocyte antigen 
HRQoL Health Related Quality of Life 
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IACs Intraarticular corticosteroids 
JADAS10 The composite juvenile arthritis10-joint disease activity score 
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JAMAR Juvenile Arthritis Multidimensional Assessment Report 
JCA Juvenile chronic arthritis 
JIA Juvenile idiopathic arthritis 
JRA Juvenile rheumatoid arthritis 
LEfSe Linear discriminant analysis effect size 
LOM Limited range of motion 
MDgloVAS The physician global evaluation of overall disease activity on a 10-cm visual 
analogue scale (VAS) 
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MIO  Maximal incisal opening 
MRI Magnetic Resonance Imaging 
NGS Next Generation Sequencing 
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NSAIDs Non-steroidal anti-inflammatory drugs 
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OMFS Oral and Maxillofacial Surgery 
OSA Obstructive Sleep Apnea 
PAS Posterior airway space  
PCoA Principal Component Analysis 
PICO criteria Patients, intervention, comparison and outcome criteria 
PRgloVAS Patient reported global assessment of well-being VAS 
PRpainVAS Patient reported pain VAS 
PRINTO The Pediatric Rheumatology International Trials Organisation 
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PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
QIIME Quantitative Insights Into Microbial Ecology 
QoL Quality of Life 
RA Rheumatoid arthritis 
RCT Randomized Controlled Trial 
RF Rheumatoid factor 
ROC  Receiver operating characteristic analysis 
sJIA Systemic onset JIA 
TNFα Tumor necrosis factor α 
TMJ Temporomandibular joint 
TMJaw The Temporomandibular Joint Juvenile Arthritis Work group 
(previously euroTMJoint) 
US Ultrasound 





Research in the field of temporomandibular joint (TMJ) arthritis in juvenile idiopathic 
arthritis (JIA) has been growing the last decades despite the effective biologic 
treatment available today, probably because the TMJ arthritis is not always 
responding. There is increasing focus on this small joint, called “the silent joint” "or 
“the forgotten joint" in the literature. This may be because TMJ arthritis is not always 
symptomatic, the general definition of arthritis can not be applied to the TMJ, 
and that many specialists share interest in the same facial area, resulting in missing as 
well as overlapping responsibility for the TMJ. Furthermore, the incidence of JIA in 
the northern countries is quite high compared to the rest of the world. Therefore, as a 
specialist in oral and maxillofacial surgery (OMFS) in Tromsø, Northern Norway, I 
was quite early exposed for these patients, both regarding local TMJ injections and 
surgical correction of dentofacial deformities. 
Together with my main supervisor Associate Professor Ellen Nordal, I am 
collaborating with several of dental and medical specialists in this field in Norway 
and also with international researchers and working groups. Going into research was 
therefore a natural thing to do for me combined with my clinical position as a 
consultant in OMFS. My wish with this thesis is to bring new knowledge in the field 









Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children 
with an incidence of 1-2 per 1000 children per year.  The temporomandibular joint 
(TMJ) is commonly involved in JIA, and may lead to impaired mouth opening, pain, 
facial growth disturbances, a reduced posterior airway space with related comorbidities. 
The rate of TMJ arthritis varies from 40-90% in different studies using magnetic 
resonance imaging (MRI). The management of TMJ arthritis is a challenge because 
TMJ arthritis may be asymptomatic and diagnosed late in the disease course, and 
because the generally accepted clinical criteria for arthritis in JIA usually cannot be 
applied to the TMJ. The overall objectives with this study were therefore to provide 
new knowledge of disease activity and quality of life (QoL), the oral microbiome and 
intervention in patients with JIA and TMJ arthritis. 
 
In an international cross-sectional study with JIA the prevalence of clinical TMJ 
involvement was assessed and found to be 12%. Clinical TMJ involvement was 
associated with higher levels of disability, higher disease activity, and impaired QoL 
scores in children with JIA. Special attention should be drawn to TMJ involvement in 
children with cervical spine involvement, polyarticular course, and longer JIA disease 
duration. 
 
In a Norwegian cross-sectional study, the oral microbiome was studied in children 
with JIA. There were no significant differences between JIA and healthy controls 
salivary microbiome according to species richness (alpha- diversity) or microbial 
composition, Principal Component Analysis (PCoA) (beta-diversity). We found in 
JIA overabundance of genera associated with chronic inflammation in saliva such as 
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TM7-G1, Solobacterium and Mogibacterium, together with increased gingival 
bleeding. Haemophilus and bacillus species were overabundant in healthy controls. 
Gemella morbillorum, Leptotrichia sp. oral taxon 498 and Alloprevotella oral taxon 
914 positively correlated with the composite juvenile arthritis10-joint disease activity 
score (JADAS10), while Campylobacter oral taxon 44, among others, particularly 
correlated with the number of active joints. 
 
In a Norwegian 2-year prospective multicenter pilot study we studied single 
corticosteroid injections in combination with systemic treatment in adolescents with 
JIA and TMJ arthritis. A single injection was found to improve MRI-assessed 
inflammation but clinical improvement of maximal mouth opening and pain was 
minimal. MRI-assessed bone damage was mostly stable, and no side effects were 
seen.  
 
In a systematic review, including 28 papers and 172 patients with JIA, the surgical 
correction of patients with JIA induced dentofacial deformity was studied. TMJ 
function and skeletal alignment was improved by any surgical technique and 
morbidity was low. Orthognathic surgery is recommended in skeletally mature 
patients with controlled or quiescent JIA and a stable dentofacial deformity, and 
distraction osteogenesis for severe deformities. Costochondral grafts were associated 
with unpredictable postoperative mandibular growth, as reported by some authors. 
Alloplastic TMJ reconstruction was efficacious but should be used cautiously in 
skeletally immature patients. However, the level of evidence was low with mostly 




In conclusion, the present work showed that quality of life scores are reduced in 
children with JIA and TMJ arthritis compared to those without TMJ arthritis and 
healthy controls. Taxa associated with chronic inflammation in saliva are more 
common in JIA compared to healthy children and some of these bacteria were 
associated to disease activity in JIA. Single corticosteroid injections in adolescents 
with JIA and TMJ arthritis, with an age not thought of as critical regarding 
mandibular growth retardation due to steroid injection, seem to be safe and may be 
efficient as a supplement to systemic treatment. Finally, surgical intervention of 
dentofacial deformities in patients with JIA-induced TMJ arthritis can be 
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INTRODUCTION AND BACKGROUND 
General aspects of juvenile idiopathic arthritis 
Clinical features 
 
Juvenile Idiopathic Arthritis (JIA) is the most common rheumatic disease in 
childhood (1-6). It is a heterogeneous group of chronic arthritis of unknown origin 
persisting for at least 6 weeks with onset before 16 years of age. There is a female 
predominance of 60-70% (3). Onset of JIA may occur any time before the age of 16, 
but with a peak onset in girls 1-3 years and in boys 10-15 years of age (7, 8). In 
contrast to adult rheumatoid arthritis (RA) typically affecting small joints in the hands 
and feet, JIA may present with a broad range of clinical patterns and often involves 
large joints including knees, wrists and ankles (7, 8). Because JIA occurs in growing 
children, a treatment goal is to avoid growth disturbances such as leg length 
discrepancies and dentofacial deformities with micrognathia and asymmetry (7, 8). 
Definition and classification criteria 
 
The definition of arthritis is based on the clinical signs of inflammation: “Swelling 
within a joint, or limitation in the range of joint movement with joint pain or 
tenderness (9). Classification of JIA is based on the number of joints affected and the 
presence or absence of specific serologic findings and systemic manifestations, such 
as skin rash, fever, iridocyclitis, cardiac disease, generalized lymphadenopathy, 
serositis, splenomegaly, and hepatomegaly (8, 10). 
In the literature there have historically been different classification systems for JIA, 
making it difficult to compare research results. In 1995, the International League of 
Associations for Rheumatology (ILAR) introduced a classification system that would 
unify and replace the JRA and JCA criteria. The term was Juvenile idiopathic arthritis 
and the classification criteria has been revised twice, lastly in 2001 (9). According to 
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the ILAR criteria JIA is classified in seven different categories and a set of exclusion 
criteria for each of them (9) (Table 1.) Many children with JIA fit into no category or 
more than one JIA category and will therefore be placed in the undifferentiated 
arthritis category. There is an ongoing debate on the ILAR criteria and criticism has 
been raised towards the complexity. A new classification criterion for JIA is 




Reported annual incidence of JIA differs from 1.3 to 22.6 per 100 000 children (3, 6). 
In the Nordic countries, incidence of JIA is reported to be 15 per 100 000 children per 
year (12). The oligoarticular category of JIA is the most common among Caucasian 
populations with European ancestries while enthesitis-related arthritis (ERA) and 
systemic onset JIA categories are most common in some Asian countries such as 







Table 1.  International League of Associations for Rheumatology (ILAR) classification of JIA. * (9) 
Category Definition Exclusions 
 
Systemic onset JIA 
 
Arthritis in one or more joints with, or preceded by, fever of at least 
2 weeks’ duration that is documented to be daily (‘‘quotidian†’’) for 
at least 3 days and accompanied by one or more of the following: 
1. Evanescent (non-fixed) erythematous rash  
2. Generalised lymph node enlargement 
3. Hepatomegaly and/or splenomegaly 
4. Serositis‡ 
 
A. Psoriasis or a history of psoriasis in the patient 
or a first-degree relative 
B. Arthritis in an HLA-B27 positive male beginning  
after the 6th birthday 
C. Ankylosing spondylitis, enthesitis-related 
arthritis, sacroiliitis with inflammatory bowel 
disease, Reiter’s syndrome, or acute anterior 
uveitis, or a history of one of these disorders in a 
first-degree relative 
D. The presence of IgM rheumatoid factor on at 




Arthritis affecting 1–4 joints during the first 6 months of disease. 
Two subcategories are recognised: 
1. Persistent oligoarthritis: affecting not more than 4 joints 
throughout the disease course 
2. Extended oligoarthritis: affecting a total of more than 4 joints 
after the first 6 months of disease 
 
A–D above, plus 





Arthritis affecting 5 or more joints during the first 6 months of 
disease; a test for RF is negative 
 





Arthritis affecting 5 or more joints during the first 6 months of 
disease;  
2 or more tests for RF at least 3 months apart during the first 6 
months of disease are positive 
 
A, B, C, E 








Arthritis and psoriasis, or arthritis and at least 2 of the following:  
1. Dactylitis§ 
2. Nail pitting** and onycholysis 
3. Psoriasis in a first-degree relative 
 





Arthritis and enthesitis††, or arthritis or enthesitis with at least 2 
of the following: 
1. The presence of or a history of sacroiliac joint tenderness and/or 
inflammatory lumbosacral pain‡‡ 
2. The presence of HLA-B27 antigen 
3. Onset of arthritis in a male over 6 years of age 
4. Acute (symptomatic) anterior uveitis 
5. History of ankylosing spondylitis, enthesitis-related arthritis, 
sacroiliitis with inflammatory bowel disease, Reiter’s syndrome or 
acute anterior uveitis in a first-degree relative 
 
A, D, E 
 
 
Undifferentiated arthritis  
 







*Adapted from McCann LJ et al in Arch Dis Child Educ Pract Ed 2006 and Petty R et al in J Rheumatol 1994 (18, 36).  
†Quotidian fever is defined as a fever that rises to 39˚C once a day and returns to 37˚C between fever peaks. 
‡Serositis refers to pericarditis and/or pleuritis and/or peritonitis. 
§Dactylitis is swelling of one or more digits, usually in an asymmetrical distribution, which extends beyond the joint margin. 
**A minimum of 2 pits on any one or more nails at any time. 
††Enthesitis is defined as tenderness at the insertion of a tendon, ligament, joint capsule, or fascia to bone. 





The etiology of JIA remains unknown. It is thought to be an autoimmune disease and 
the result of a combination of genetic and environmental causes. The human 
microbiome might be a contributing factor to disease etiology and there are reports 
describing the microbiome to be different in children with JIA compared to healthy 
children (14-16). Host-microbe interaction is important for recognition and 
development of the immune system (17). Imbalanced composition, i.e. dysbiosis, of 
the subgingival microbiome has been associated to the presence of rheumatoid 
arthritis (RA) and periodontitis (18, 19). Infections and vaccinations have also been 
suggested as causative agents in JIA but there is so far very little evidence for this, 
except for in Lyme´s disease (20, 21). The species borrelia burgdorferi has been 
isolated from the joint cavity in Lyme´s disease, an infectious disease with joint 
inflammation. Probably, in a genetically predisposed individual, a series of 
environmental events may lead to the onset of JIA (20). Early life antibiotic use is 
associated with the development of JIA (22, 23). Arvonen et al. found that previous 
early and repeated exposure to antibiotics may predispose individuals to develop JIA. 
Alternatively, the apparent association may reflect shared susceptibility to infections 
and JIA (22). Furthermore, antibiotic exposure may play a role through alterations in 
the human microbiome (23). 
Genetic susceptibility 
Multiple specific susceptibility genes have been identified, which can be broadly 
subdivided in human leucocyte antigen (HLA) and non-HLA genes and differ 
between subtypes of JIA.  Oligoarticular and polyarticular rheumatoid factor (RF)-
negative JIA categories are associated with HLA-DRB1*13 (24). In the juvenile 
psoriatic arthritis category no genetic associations have been found (24) but 
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associations are seen between systemic JIA (sJIA) and the HLA-DRB*11 (25). HLA-
DRB1*13 has been found to be a risk factor in both seropositive rheumatoid arthritis 
(RA) in adults and in rheumatoid factor (RF)- positive category where a glycine 
residue at the same amino acid position drives the association (26). Only 8 to 13% of 
the variation in JIA susceptibility is explained by HLA-genotypes, the remaining part 
should therefore be explained by non-HLA genes or environmental influences (27). 
Non-HLA genes linked to JIA mostly relate to the innate immune system and its 
cytokines. For example gene variants linked to elevation of pro-inflammatory 
cytokines such as tumor necrosis factor α (TNFα), interleukin (IL)-6, IL-8, and 
intracellular adhesion molecules are found (28). In systemic onset JIA (sJIA) some 
authors have found dysregulation of the pro-inflammatory IL-1, IL-18 and the anti-
inflammatory cytokine IL-10 (29, 30). 
Pathogenesis 
 
The most common clinical feature in JIA is joint swelling due to increased joint fluid, 
hypertrophy and hyperplasia of the synovial lining layer. The synovium becomes 
hyperemic and edematous due to infiltration by immune cells such as T- and B-
lymphocytes, plasma cells, macrophages, and synoviocytes. This infiltration leads to 
production of cytokines, i.e. pro-inflammatory mediators. Increased number of 
inflammatory cells are recruited and activated by the cytokines and may lead to fever, 
fatigue, and pain as well as destruction of bone and cartilage through proliferating 




The oral microbiome and the immune system  
 
The human microbiota is a collecting term for all the microorganisms that inhabit the 
gut, the respiratory tract and the skin. The human microbiome is the collection of 
genes encompassed by the microbiota i.e. the oral microbiome code for the oral 
microbiota. In recent years increasing evidence has emerged on contribution of the 
microbiota to development of immune-mediated diseases such as inflammatory bowel 
disease, type 1 diabetes, rheumatoid arthritis and JIA (15, 31-33). There is a complex 
interplay between the immune system and the microbiota, which is essential for 
normal development of the immune system and for protecting the host against 
pathogens (15). If this interplay is disrupted, an imbalance in the composition of the 
microbiota, i.e. “dysbiosis”, will occur (Figure 1).  Composition of both the gut (34) 
and the oral microbiota (35, 36) have been investigated. Today new methods such as 
the Next generation sequencing (NGS) are used for exploring microbiota (37). 
Environmental factors associated with dysbiosis are lifestyle, diet, pathogens and 
antibiotics (38-40). As mentioned above, increased antibiotic use in childhood is 
associated with increased risk of developing JIA (22, 23). Dysbiosis may lead to 
immunological imbalance and trigger inflammation, where immune cells can reach 
extra-intestinal and also extra-oral sites such as joints, and trigger local inflammation 
with the release of different inflammatory mediators, including cytokines (41, 42).  
There are several theories of how microbes can trigger autoimmune responses and 
contribute to autoimmune disease: 
 
Bacterial translocation hypothesis refers to bacteria migrating through the gut 
epithelium due to increased permeability, enters the circulation and then finally distal 
tissues like the joints where local immune responses are triggered (43). 
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Cross-reactive epitope hypothesis or Molecular mimicry refers to a foreign antigen 
with structural similarities with self-antigens, typically leading to the formation of 
cross-reactive antibodies and T cells (44). Rheumatic fever is a well-known example 
in which severe systemic disease is caused by the generation of cross-reactive 
antibodies against group A streptococcus. 
Bacterially derived metabolite hypothesis or Bystander activation refers to an 
indirect activation of autoreactive cells caused by the release of pro-inflammatory 
cytokines during inflammation or tissue damage, for example as a result of a dysbiotic 
environment. 
Mucosal immune dysregulation hypothesis. When dysbiosis occur some microbes 
might alter host proteins, thereby creating new antigens that are recognized by the 
adaptive immune system as non-self (45). An example is Porphyromonas gingivalis, 
inducing antibodies to citrullinated protein antigens (ACPAs) in RA. (46). 
 
The microbiome in JIA is reported to differ from healthy individuals (14-16) where a 
lower abundance of Firmicutes and a higher abundance of Bacteroidetes, on the 
phylum level, were found in the gut microbiota in patients with new-onset JIA (16).  
Furthermore, the genera Actinobacteria and Fusobacteria have been seen only in gut 
microbiota in JIA patients and Lentisphaerae only in healthy controls (16). The 
patterns of the JIA gut microbiome also resembles the microbiome reported in other 
autoimmune diseases such as type 1 diabetes, Crohn’s disease and ankylosing 
spondylitis (32, 47). Different studies present different changes in microbiota, so it is 
possible that the impact of disruption of microbial ecology is more important for the 
host than the actions of just one single microbe in both JIA and RA (43, 48). Most 
studies on the human microbiome in JIA have investigated the gut microbiome and 
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not the oral microbiome (16, 34, 49-54). There is a need for more studies on the oral 
microbiome and JIA. 
 




Verwoerd, A, Ter Haar, N.M., de Roock, S. et al. The human microbiome and juvenile idiopathic 




Disease activity and Quality of Life  
 
Disease activity measures. Validated tools for assessment of disease activity and 
outcome in JIA are important. Reliable assessment of self-reported health, functional 
status, remission and damage is necessary when evaluating treatment effects in 
clinical studies (55). Examples of disease activity measures are: the number of active 
joints, tender joints, joints with limited range of movement, laboratory markers, visual 
analogue scales (VAS) of pain, and global assessment of disease severity. The 
Juvenile Arthritis Disease Activity Score (JADAS) is a validated composite disease 
activity measure that is increasingly used and available in several versions. JADAS 
includes the sum of four measures: 1, number of joints with active arthritis assessed in 
10, 27, or 71 joints 2, parent/patients global assessment of well-being 3, physician´s 
global assessment of well-being and 4, erythrocyte sedimentation rate (ESR) (56). 
The ACR pediatric response criteria (ACRpedi30, 50, 70) define clinical change over 
time by calculating improvement between two time points in a core set of six 
variables: the JADAS variables, the CHAQ score and the number of joints with 
restricted movements (57). 
Patient-reported outcome. Different validated questionnaires on Health Related 
Quality of Life (HRQoL) are developed. This is important for evaluating the patient´s 
subjective assessment of the impact of the disease and its treatment on daily life, 
physical, psychological, social functioning and overall well-being. In younger 
children questionnaires on the self-reported measures are filled in by the parents / 
proxies. Two commonly used HRQoL-questionnaires are the Child Health 
Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 
validated and translated into several languages, also available in Norwegian (58, 59). 
CHAQ evaluates physical functioning with 30 items divided into 8 domains: dressing, 
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arising, eating, walking, hygiene, reach, grip, and activities. Using aids and devices 
and help from another person for physical functioning are also registered. CHAQ 
further includes two visual analogue scales (VAS) on pain and overall well-being. 
This questionnaire is the most commonly used patient-reported outcome measure in 
JIA reported to have a high reliability, a moderate correlation to other disease activity 
indices, and with a low responsiveness to change. Many children with JIA report low 
levels of disability according to the CHAQ, thus a ceiling effect may be a problem 
(59). The CHQ is a generic quality of life measurement tool with in total 15 subscales 
(physical and psychosocial domains), covering daily functioning. The CHQ includes a 
physical and psychosocial summary score (60). 
Disease status is defined as active disease, inactive disease, clinical remission on 
medication, or clinical remission off medication according to the ACR provisional 
criteria (61). Inactive disease status require all the following: 1) no active joints; 2) no 
fever, rash, serositis, splenomegaly or generalized lymphadenopathy attributable to 
JIA 3) no active uveitis; 4) normal ESR or CRP; 5) the physician global evaluation of 
overall disease activity on a 10-cm visual analogue scale (MDgloVAS) =0; and 6) duration 
of morning stiffness of ≤15 minutes. 
As mentioned earlier, assessment of HRQoL is important when evaluating treatment 
effects in clinical studies. There are few studies on HRQoL and TMJ arthritis in JIA 







There is no cure for JIA. However, with optimal medical treatment and 
multidisciplinary follow-up disease activity in JIA can often be controlled and many 
children can live active lives (61-63). The primary goals in treatment are therefore to 
eliminate active disease, to normalize joint function, to preserve optimal growth and 
to prevent long-term joint damage (64). The ACR recommendations for treatment in 
JIA are published in 2011, in 2013 on systemic arthritis and in 2019 with a consensus 
on medical treatment of non-systemic polyarthritis, sacroiliitis, and enthesitis (65-68).  
Disease-modifying antirheumatic drugs  
 
Early aggressive intervention with disease-modifying antirheumatic drugs 
(DMARDs) is recommended in JIA children with high or moderate disease activity 
and / or features of poor prognosis (65, 69). Methotrexate is the most commonly 
used DMARD and often considered the gold standard of treatment in JIA. It is 
effective on improving joint inflammation, health-related quality of life, and physical 
function (70-72). However, its effect on radiological progression is poorly 
documented. Other synthetic DMARDs such as salazopyrine and leflunomide are 
also available. 
Biologic treatment  
 
Biologic treatment was introduced and available first time in 1999, interfering with 
key cytokines of inflammation. These targeted drugs are biologic products and 
generally larger complex molecules in contrast to methotrexate and the other synthetic 
DMARDs. The first available biologic agents were the TNF-antagonists etanercept, 
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infliximab and adalimumab. A range of potent cytokine inhibitors has become 
available including anakinra targeting IL-1, tocilizumab targeting IL-6 and also 
abatacept inhibiting the T-cell co-stimulation among many others (73) . There is 
today a trend of treating the JIA patients more aggressively, with earlier use of 
methotrexate and biologic drugs, adjusted to disease category, manifestations, and 
response. The biologic drugs are not only highly effective but also expensive. There is 
also an increased risk of infections with biologic treatment.  Concerns has been raised 
on associations with malignancies (74), even if recent data seem to suggest that JIA 
itself, as in the case of RA, is associated with an increased risk of malignancy and that 
this risk is not further increased with anti-TNF treatment (75). 
 
Intraarticular and systemic corticosteroids  
 
Regardless of concomitant therapy and JIA category, the use of intraarticular 
corticosteroid joint injections (IACs) is recommended in active arthritis for most 
joints (65, 67). Triamcinolone hexacetonide is shown to be superior to other 
glucocorticoids in a randomized controlled trial (RCT) (76, 77), and may be used also 
in TMJ arthritis in children with JIA (78). Due to unwanted side effects such as 
growth retardation, metabolic alterations, and loss of bone-mass density, minimal use 
of systemic glucocorticoids in children is recommended (66, 69, 79). 
 
 
Nonsteroidal antiinflammatory drugs (NSAIDS)  
 
NSAIDS are used for pain but with a less anti-inflammatory effect than steroids and 
with unwanted side effects present such as an increased risk of gastrointestinal 
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bleeding. Paracetamol is well tolerated and used for pain as an alternative or 
supplement to NSAIDS. Opioids are associated with addiction problems and are not 




Physiotherapy can maintain and restore function and prevent disability. Surgical 
intervention may be an option to correct growth deformities or to reconstruct or 
replace joints due to contractures, dislocations or ankylosis (7, 8, 80).  Splint therapy 
has historically been used to prevent contractures in many joints, but is generally less 
used because of other effective therapies. Stoustup et al. currently suggest 
implementation of distraction splint therapy to normalize mandibular vertical 




Temporomandibular joint anatomy and physiology 
The temporomandibular joints (TMJs) connect the lower jaw (mandible) with the 
skull (temporal bone) by a bilateral synovial articulation (82). The TMJ consists of: 
the joint capsule, articular disc, mandibular condyle, articular surface of the temporal 
bone, temporomandibular ligament, stylomandibular ligament, sphenomandibular 
ligament, and lateral pterygoid muscle (Figure 2). 
 
Figure 2. The temporomandibular joint and surrounding structures, illustration: Even Elias Edvardsen (2020). 




A capsule with a dense fibrous membrane surrounds the TMJ and the articular 
eminence. The disc is unique, with a fibro- cartilaginous biconcave tissue, attached to 
the condyle medially and laterally. The lateral pterygoid muscle is coincident with the 
anterior part of the disc. The posterior part of the disc or the “retrodiscal tissue” is 
vascular and innervated, in contrast to the central thin part of the disc that gets 
nutrition from the surrounding synovial fluid. The disc divides the TMJ into the lower 
and the upper compartments with synovial fluid that is produced by the synovial 
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membrane lining TMJ capsule. The TMJs, the sternoclavicular joints and the 
radioulnar joints are the only synovial joints in the body with an articular disc. 
Branches from the external carotid artery, mainly the superficial temporal branch, but 
also the deep auricular artery, anterior tympanic artery, ascending pharyngeal artery 
and maxillary artery, provide arterial blood supply to the TMJ. The TMJ is innervated 
by the auriculotemporal and masseteric branches of the mandibular nerve (V3) of the 
trigeminal nerve.  
The TMJs develops at around 12 weeks in utero. The growth center is located in the 
head of the mandibular condyles, and consists of hyaline cartilage. This center grows 
by appositional growth in all directions, unlike a typical long bone. Over time the 
cartilage is replaced by bone, using endochondral ossification. The mandibular growth 
follows the pattern of the general human growth in children and adolescents. 
The TMJ is a hinging and a sliding joint (“ginglymoarthrodial” joint). After 25mm of 
rotation (lower joint compartment), the translational movement (upper joint 
compartment) of mouth opening follows. The muscles of mastication are the 
masseter, the medial and the lateral pterygoid and the temporalis muscle. The lateral 
pterygoid muscle protrudes the mandible, while the other three muscles are involved 
in closing the mouth. 
JIA in the temporomandibular joint 
 
The classical clinical signs of inflammation in a joint with swelling or limitation in the 
range of joint movement with joint pain or tenderness (9), are seldom seen in the 
TMJ. TMJ arthritis is sometimes even asymptomatic (83, 84). The TMJ has therefore 
been described as “the forgotten joint” (83) and imaging has an important role in 
diagnosing TMJ arthritis (85, 86). In 2018 a new standardized terminology for 
assessment of orofacial conditions in JIA were published, with recommendations 
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from an international, multidisciplinary expert group aiming to unify TMJ 
terminology in JIA (87). 
 
Magnetic resonance imaging (MRI) plays an important role in diagnosis and 
assessment of TMJ involvement in children with JIA (88). Common findings seen on 
MRI are synovial enhancement, joint fluid, bone edema and condylar head articular 
surface flattening (89, 90). Also, synovial enhancement and joint fluid fluctuate over 
time (91). Adolescents with anterior disc displacement (ADD) often have similar 
inflammatory changes in the TMJ as adolescents with JIA. However, TMJs with ADD 
showed a better-preserved and often normal shape of the glenoid fossa in the study of 
Kellenberger et al. (90). Even if ADD is not common in JIA it may occur, 
representing a challenge in differential diagnostics with regard to rheumatic or non-
rheumatic disease (92). 
Depending on the study design and examination methods used (i.e. classification 
systems, inclusion criteria, age of the subjects, applied diagnostic clinical criteria and 
differences in the imaging methods) the prevalence of TMJ arthritis varies 
substantially (40-90%) in different JIA studies, as reviewed by Larheim et al (93). 
A frequency of 40–45% TMJ involvement in consecutive series of patients with JIA 
has usually been found using panoramic radiography (85, 94). When using MRI 
frequencies of 39 - 43% are reported (95, 96). Arvidsson et al reported a frequency of 
70% TMJ involvement when the adult JIA patients were examined longitudinally for 
27 years, with both computed tomography and MRI at last follow-up. Both lower and 
higher prevalence have been reported in clinical and radiologic studies (97, 98) and in 
particular with MRI (99, 100) higher prevalence of TMJ arthritis have been found. 
However, many studies regarding TMJ in JIA are characterized by a low number of 
patients. MRI may detect findings that indicate TMJ arthritis in children with JIA 
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without symptoms or clinical findings. Contrast enhancement may also be seen in 
healthy children and adolescents (101-103). Thus, the reliability of contrast‐enhanced 
MRI to assess TMJ arthritis can be discussed (101), reflecting the complex 
diagnostics of pathology in the TMJ. Tolend et al. (104) and Kellenberger et al. (105) 
have recently presented a new scoring system for MRI and JIA in the TMJ. 
Ultrasound (US) is often found less helpful in early diagnosis of TMJ arthritis (106). 
Jaw treatment 
Intraarticular corticosteroid injections to the TMJ 
 
Some observational studies report short-term symptomatic efficacy of intraarticular 
corticosteroid injections (IACs) to the TMJ, while other studies show no or little 






Table 2. Observational studies on intraarticular corticosteroids (IACS) to the temporomandibular joints (TMJs)  





Mean age Years 
(range or SD) 



































10/13 (77%) 11/23 TMJs 
(48%) MRI 










T.acetonide 40mg/ml Pain, MIO, 
MRI 
3-4 clinical 
9 (5-15) MRI 
























8/12 (67%) 2/15 TMJs 
(13%) CT 












MIO, MRI 2.4 (1.4-7.3) 1 Not reported 9/16 patients, 
5/16 >5mm 
NA 5/6 TMJs (83%) 
MRI 
Parra et al. 
2010 (113) 











6 weeks 1-6 Not reported 81% good, 10% partial, 9% poor 
response (based on MIO, clinical 
signs and symptoms, jaw deviation) 
NA 
Habibi et al. 
2012 (114) 








6-8 weeks 1  Not reported 17/17 (100%) NA 




63 (125)* MIO 55/63, 
MRI 31/63 




MRI: 5.3  
(0.5-23) 
1-2 15/47 TMJs 
(32%) new onset 
erosions / 
flattening 






Prospective 21 (38) 21 (38) 









0.5ml = 10mg 
Pain, function 8 months 1 Not reported Significant 
improvement in 
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et al. 2015 
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Kinard et al.  
2016 (115) 
Case-series 3 (5) 3 (5) 12.5 Artroscopy 
(lysis /  
lavasje with 
steroid) 
T.Hexacetonide Pain, MIO (?) 1 (?) 
 






Retrospective 29 (50) - 12.1±1.9 IACs T.Hexacetonide 





22.9 ±4.3 (5-48) 1 Not reported 89% of 
patients 
reduction pain 
























22.9 (5-48)  Not reported No statistical differences in short-term outcomes 
between image-guiding or landmark technique, 
with regard to pain, MIO, synovial enhancement 
ratio, ER, but procedure times were longer for the 
image-guided group 
Antonarakis 
et al.  2018 
(118) 


















(?) 1 (?) 
 
Not reported 
TMJ lavage with or without IACS injection 
cannot be claimed to systematically decrease 
pain, increase mouth opening, or resolve acute 
inflammation. Despite a tendency for 
improvement, response to this treatment is very 
patient dependent and can be determined by an 
array of other variables. 
 
* Repeated IACS. ER; enhancement ratio. Adapted from Stoustrup et al. (78) according to the Oxford Centre for Evidence-based Medicine Levels of Evidence.
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Other studies however, demonstrate mandibular growth impairment that may be induced by 
the arthritis itself and/or the treatment with repeated IACs (120, 121). The use of IACs is 
recommended for treatment of active arthritis in other joints of the body, regardless of 
concomitant therapy (65, 66). Triamcinolone hexacetonide seem to be superior to other 
corticosteroids in a RCT of IACs to the knee joint (76). In TMJ arthritis in children 
with JIA, IACs with triamcinolone hexacetonide is reported in several studies to be a 
useful treatment (78) and can be safely performed with or without radiologic guidance 
by trained specialists (108, 117).  However, the role of IACs in the treatment of TMJ 
arthritis is not clarified. There are no prospective studies in children with JIA and TMJ 
arthritis showing the short and long-term safety and efficacy of IACs in terms of 
improving clinical symptoms and findings, reducing disease progression on MRI, and 
improving mandibular growth (78). 
 
Surgical correction of dentofacial growth disturbances 
 
If not timely and successfully treated, TMJ arthritis can lead to reduced mouth 
opening, impaired mastication, pain, reduced mandibular growth, and dentofacial 
deformities (122). Facial asymmetry and/or an occlusal cant may be the result of 
unilateral TMJ arthritis (123). Clockwise rotation of the mandible due to bilateral 
involvement may lead to micrognathia, anterior open bite, and a reduction in posterior 
airway space (PAS) (124) (125). A small PAS is associated with obstructive sleep 
apnea (OSA) and related comorbidities (126). Orthodontic and orthognathic treatment 
aiming to improve occlusion, facial esthetics, and self-confidence can be important 




The treatment of dentofacial deformities can sometimes be improved with 
orthopedic/orthodontic treatment during growth (81). It is however, many times a 
need for reconstructive surgery in most cases after final growth is reached for 
normalization of TMJ function and/or occlusion, skeletal alignment, facial esthetics, 
and/or OSA. Two strategies are found in the literature for the surgical correction of 
JIA-induced dentofacial deformities: (1) TMJ preservation (i.e. orthognathic surgery, 
distraction osteogenesis (DO)), and (2) TMJ reconstruction (i.e. resection of the 
remaining condyle, synovial lining, and disc, and reconstruction with an autologous 
graft (128) or an alloplastic prosthesis (129). 
There is no consensus regarding the most appropriate reconstructive approach of 
dentofacial deformities in JIA. Therefore, there is a need for more research in this 
















AIMS OF THE STUDY 
The overall objectives with this dissertation was to provide new knowledge of TMJ 
arthritis in JIA with regard to QoL and disease activity, the oral microbiome and 
intervention in patients with JIA and TMJ arthritis, with the following specific aims: 
 
 
I. To describe in a cross-sectional cohort with JIA: (1) the prevalence of clinical 
TMJ involvement, (2) the associations between TMJ involvement and other 
disease characteristics, and (3) the associations between TMJ involvement and 
QoL measures (Paper I). 
 
II. To describe the oral microbiome in saliva of children with JIA and relate this 
to disease activity, including presence of TMJ arthritis and gingival bleeding 
(Paper II). 
 
III. To assess efficacy and safety of single IACs in the TMJ in terms of (I) improving 
maximal mouth opening capacity and pain, and (II) reducing disease inflammation and 
bone damage, in a 2-year prospective multicenter pilot study of adolescents with 
JIA and TMJ arthritis, by using validated clinical outcome measures and a 
newly established MRI scoring system (Paper III). 
 
IV. To assess the level of evidence for surgical correction of dentofacial 




MATERIAL AND METHODS 
Collaboration 
 
All papers in this thesis are based on an interdisciplinary collaboration between dental 
and medical specialists through local, national and international research networking.  
 
Paper I was initiated and designed in collaboration with The Pediatric Rheumatology 
International Trials Organisation (PRINTO). PRINTO is a not for profit, non-
governmental, international research network founded by Alberto Martini and 
Nicolino Ruperto in 1996. PRINTO include today about 90 countries, 656 centers 
with 1383 members worldwide, with the goal to foster, facilitate and coordinate the 
development, conduct, analysis, and reporting of multicenter studies and international 
clinical trials and/or outcome standardization studies in children with pediatric 
rheumatic diseases (www.printo.it). 
 
Paper II and Paper III is part of a larger Norwegian multicenter cohort study on JIA; 
“NorJIA multicenter study on temporomandibular involvement, oral and bone health 
in Juvenile Idiopathic Arthritis (NorJIA)”. Dr. Karen Rosendahl, professor and 
specialist in radiology at the Haukeland University Hospital and at the University 
Hospital of North-Norway, is the initiator of this cohort study (www.norjia.com) 
registered in Clinical Trials.gov (NCT03904459). The multidisciplinary national 
collaboration between medical and dental specialists at the main four University 
Hospitals of Norway and Public dental competence centers makes this project unique. 
 
Paper IV was initiated and conducted by the TMJ Surgical Task Force through the 
Temporomandibular Joint Juvenile Arthritis Work group (TMJaw) (earlier: 
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euroTMJoint), an international, multidisciplinary research network founded in Oslo, 
Norway in 2010, which focus research of TMJ arthritis related to JIA. The 
terminology of Paper (II), (III) and (IV) adheres to the TMJaw consensus-based 
standardized terminology by Stoustrup et al. (87). Drs. Ellen Nordal, Josefine Halbig 
and Paula Frid are members of the working groups on clinical examination, IACs, 
medical and surgical intervention in the TMJaw. Professor Tore A. Larheim has been 
leading the working group on imaging since the first European Meeting in Oslo 2010, 




All papers in this thesis are based on projects with different study design and cohorts, 
with the purpose to answer our aims on gaining more knowledge of TMJ arthritis in 
JIA, including two cross-sectional studies with multicenter cohorts, one prospective 
intervention study and one systematic review on surgical intervention. 
 
Paper I is based on a descriptive cross-sectional multicenter study about clinical TMJ-
involvement in children with JIA, with data extracted from two studies of the 
Pediatric Rheumatology International Trials Organisation (PRINTO); the MTX-trial 
(72) and the HRQoL-study (130). The MTX-trial was a RCT comparing standard 
dose to high dose of MTX in JIA with 633 study subjects. The HRQoL-study with 
2715 study subjects was a multicenter-study validating the CHAQ and CHQ in 
different languages. 
 
Paper II is based on a descriptive Norwegian cross-sectional multicenter study on the 




Paper III reports on a Norwegian 2-year prospective multicenter pilot study on 
efficacy and safety of single IACs in the temporomandibular joint (TMJ) in adolescents 
with JIA.  
 
Paper IV is a systematic literature review on surgical correction of dentofacial 
deformities in patients with JIA and TMJ arthritis based on the Preferred Reporting 





All papers in this thesis include children with JIA and TMJ arthritis with different 
study inclusion criteria and different time periods. However, all children with JIA 
were classified as per the ILAR criteria (9) (Figure 5). 
 
In paper I a total of 3343 children with JIA and 3409 healthy pears were included 
from 32 different countries (Figure 5) in the time period of 1998-2001 (MTX-trial) 
and in the time period of 1998-2000 (HRQoL-study). Disease activity was assessed 
by the JIA core set activity variables (9). In this study assessment of TMJ activity was 
defined as; presence of TMJ pain and/or limited range of motion (LOM), registered 
by the local pediatric rheumatologist in the PRINTO joint examination form, 
according to standard pediatric rheumatology textbooks. 
 
In paper II in the period of 2015-2019, 93 Norwegian children in total were 
consecutively recruited at the participating pediatric rheumatology centers in Tromsø, 
Oslo and Bergen. Children with JIA and TMJ arthritis (JIA-TMJ) (n=15), JIA without 
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TMJ arthritis (JIA-nonTMJ) (n=44) and healthy controls (HC) (n=34) (Figure 5). All 
eligible children with a diagnosis of JIA aged <18 years and with a saliva sample 
available were included. Among the totally 59 children with JIA in this study three 
were not included in the main NORJIA study in Tromsø, due to either origin in Oslo 
(n=2) or an age older than 16 years at time of inclusion (n=1). We included the 34 
healthy children from Tromsø with available saliva samples also participating in the 
main NorJIA multicenter study. 
 
In paper III in the period of 2015-2019, 15 children with JIA and TMJ arthritis from 
three participating centers received IACs (Figure 5). Children with JIA aged <18 years at 
time for inclusion in the study, and arthritis activity in one or both TMJs were 
included. Children requiring sedation or general anesthesia for MRI and/or IACs were 
included in this study only if there was a clear clinical indication for imaging and 
intervention. Alternative treatment options for TMJ arthritis such as systemic 
medication, physiotherapy/specific jaw exercises and activation device/splint for 
myalgia were first considered. Due to emerging findings of possible negative effect of 
steroids on mandibular growth in the study period, IACs were used in our study in 
treatment resistant symptomatic TMJ arthritis in adolescents in whom most of the 
expected growth had taken place. IACs were performed on the following indications, 
judged by each participating center: (1) Clinical signs of TMJ-inflammation such as 
pain on movement, limitation of MIO, limitation of laterotrusive or protrusive jaw 
movements and/or dentofacial growth disturbance AND (2) MRI signs of TMJ arthritis 
(i.e. active arthritis in the TMJ) such as contrast enhancement of synovial tissue, bone 
marrow edema and/or effusion. TMJ-injections were not performed in Trondheim 
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during this time period, and children with active TMJ arthritis that did not receive any 
IACs to the TMJs were not included in this study.  
 
In paper IV the primary search was conducted in June 2017 and updated in February 
2018. The following studies were included according to the PICO criteria (patients, 
intervention, comparison and outcome): patients with a diagnosis of JIA and 
involvement of the TMJ, receiving a reconstructive or orthognathic surgical 
intervention (Figure 5). 28 papers were finally included in this systematic review for 
full-text evaluation; 24 were case reports or case series, three were retrospective chart 































Figure 5. Flow chart of the participants enrolled in Paper I-IV.  
 








































All papers in this thesis collect data from children with JIA and TMJ arthritis: 
demographic data, laboratory data reported according to the PRINTO case report form 
(CRF) for study I, NORJIA CRF for studies II and III, PRISMA guidelines and the 
Oxford Centre for Evidence-based Medicine (OCEBM) level of evidence guide for 
study IV. In paper II and III all specialists performing the examinations of the study 
subjects and healthy controls were calibrated repeatedly. 
 
In paper I demographic, clinical and laboratory data was collected by the local 
pediatric rheumatologist according to the PRINTO CRF together with validated 
patient/ proxy-reported outcomes; CHQ, PRgloVAS and PRpainVAS score. 
 
In paper II demographic and clinical data were collected from clinical registrations of 
the NorJIA CRF including a modified version of the validated DC/TMD examination 
and diagnosis protocol (132) and the validated EuroTMJoint Clinical Recommendations 
protocol (133) . Laboratory data including saliva samples for microbiological analyses was 
also collected. A modified version of the Gingival bleeding index (GBI) (134) was used 
for registering gingival inflammation according to a gingival bleeding cut-off score ≥ 
10% (135). A modified version of the Simplified Oral Hygiene Index (OHI-S) was 
used for registering dental plaque and calculus (136). 
 
In paper III demographic, clinical and laboratory data was collected from clinical 
registrations using a modified version of the validated diagnostic criteria of 
temporomandibular disorders (DC/TMD) examination and diagnosis protocol (132) 
and the validated EuroTMJoint Clinical Recommendations protocol (133) together with 
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MRI assessments according to the  recently published MRI scoring systems for TMJ arthritis 
in JIA . 
 
In paper IV data was collected and independently assessed by two authors (PF, SEN) 
in a systematic literature search at three occasions. The first selection was based on 
titles, the second on abstracts, and the third on full text review. The selected studies 
were assessed for risk of bias: prospective study design, sufficient description of the 
outcome variable, uniform inclusion criteria, standardized examination protocol, 
outcome assessor blinded to imaging findings, and information on outcome variable 
variation. The level of evidence was scored according to the Oxford Centre for 
Evidence-based Medicine (OCEBM) level of evidence guide. 
Statistical methods 
 
In the statistical analyses of thesis the SPSS software, version 21, 24, 25 and 26 was 
used, except for paper IV being a systematic review where the collected data was not 
sufficient for a meta-analysis. Paper I also used the SAS software version 9.3. In 
paper II Downstream bioinformatics analysis was performed with QIIME and LEfSe 
software. In all studies a p-value <0.05 was considered statistically significant, except 
for p-values adjusted for multiplicity with Benjamini-Hockberg method (FDR ≤0.1) 
in paper II. 
 
Paper I, II, III: For clinical and demographic data, descriptive statistics were used, 
such as median (1st and 3rd quartile), mean (standard deviation) and frequencies 
(percentage). In paper I associations between TMJ and other disease characteristics 
were analyzed by chi-square test for categorical variables, and Student´s t-test for 
continuous variables if normally distributed, otherwise Wilcoxon test was used. To 
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identify factors differentiating JIA patients with or without TMJ involvement (Paper 
I), univariate logistic regression was performed, using as exploratory measures the 
JIA core set, the CHAQ and the CHQ domains. Multivariable logistic regression was 
performed to identify factors independently associated with TMJ involvement. In both 
univariate and multivariable regression analyses the continuous variables were 
dichotomized as per Receiver Operating Characteristics (ROC) analysis (Paper I). 
 
Paper II: Associations between microbiome and different disease characteristics were 
analyzed by chi-square test for categorical variables (Fisher´s exact test) and 
Student´s t-test for continuous variables if reasonably normally distributed, otherwise 
Wilcoxon´s test was used. Significant differences between three different medication 
groups were analyzed with the Kruskal Wallis test. Associations between gingival 
bleeding index (GBI) and JIA were analyzed with multivariable logistic regression 
analysis.  
 
Paper III: When testing continuous variables for differences between two time-points, 
Wilcoxon Signed Ranks Test was used for not normally distributed data and paired 
sample t-test for normally distributed data. For nominal data and dependent samples 
tested for differences between two time-points; McNemar Chi-square test was used. 
Multiple testing of four time-points and Bonferroni correction for 6 comparisons with 
a p-value <0.008 was analyzed and considered, but not used in the final manuscript. 
Percentage of patients was used for absolute improvement of the variables pain, MIO 
and MRI. For the MRI assessment, the intra-observer agreement for the MRI-scoring 




Ethical approval and considerations 
 
Approval from appropriate medical ethical committees and data authorities was 
obtained according to the requirements of each participating country (Paper I-III).  In 
paper IV all of the included studies had the necessary approvals. 
Research involving children is strictly regulated because this patient group is 
considered a vulnerable group. Research should be in accordance with the United 
Nations Convention on the Rights of the Child (Article 24): “States Parties recognize 
the right of the child to the enjoyment of the highest attainable standard of health and 
to facilities for the treatment of illness and rehabilitation of health. States Parties 
shall strive to ensure that no child is deprived of his or her right of access to such 
health care services”. 
Children included in Paper I-III had reduced autonomy and were dependent on 
parental/proxies responsibilities and rights. Age-adapted informed written consent 
was therefore obtained from the child and his/her parents/proxies and information 
about the study (aims, benefits, potential adverse events, principle of voluntary 
participation etc.) was given. However, if a situation had arisen where the child of any 
age did not want to further participate in the study, he or she would of course have 
been excluded from the study. One example of this in my thesis was a child 
participating in the study and described in paper III, who did not prefer to take follow-
up MRIs after the baseline, but she was still included and participated in the clinical 
assessments of the study. All papers in this PhD were performed according to the 
Declaration of Helsinki: ethical guidelines for research with human subjects (137). 
Furthermore, the authors were not influenced by any financial support or other 
conflicting interests in the present research projects presented in papers I-IV.
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SUMMARY OF THE RESULTS 
 
Paper I 
Temporomandibular joint involvement in association with quality of life, 
disability, and high disease activity in juvenile idiopathic arthritis. 
Paula Frid, Ellen Nordal, Francesca Bovis, Gabriella Giancane, Tore A.Larheim, 
Marite Rygg, Denise Pires Marafon, Donato De Angelis, Elena Palmisani, Kevin 
J.Murray, Sheila Oliveira, Gabriele Simonini, Fabrizia Corona, Joyce Davidson, 
Helen Foster, Michel H.Steenks, Berit Flato, Francesco Zulian, Eileen Baildam, 
Rotraud K. Saurenmann, Pekka Lahdenne, Angelo Ravelli, Alberto Martini, Angela 
Pistorio, Nicolino Ruperto for the Paedriatic Rheumatology International Trials 
Organisation (PRINTO). 
 
• Clinical temporomandibular joint (TMJ) involvement is associated with higher 
levels of disability, high disease activity, and impaired quality of life in 
children with juvenile idiopathic arthritis (JIA). 
• Clinicians should pay special attention to TMJ involvement in children with 
JIA and cervical spine involvement, polyarticular course, and longer disease 
duration. 
• Observations were based on 387 of 3343 children with JIA, representing those 





Salivary oral microbiome of children with juvenile idiopathic arthritis: A 
Norwegian cross-sectional study. 
Frid P, Baraniya D, Halbig J, Rypdal V, Songstad N.T, Rosen A, Berstad J.R, Flatø B, 
Alakwaa F, Grut Gil E, Cetrelli L, Chen T, Al-Hebshi N.N, Nordal E, Al-Haroni M.  
 
• A total of 216 bacterial species belonging to 58 genera and 8 phyla were 
identified across all samples, with Prevotella, Streptococcus, Actinomyces, 
Haemophilus, Porphyromonas and Rothia accounting for the bulk of the average 
microbiome.  
• There were no significant difference between JIA and healthy controls in 
species richness or in principal component analysis (PCoA), i.e. alpha or beta 
diversity. Differential abundance analysis revealed genera TM7-G1, 
Solobacterium and Mogibacterium to be associated with JIA, while 
Haemophilus and Bacillus were overabundant in healthy subjects. 
• Gemella morbillorum, Leptotrichia sp. oral taxon 498 and Alloprevotella oral 
taxon 914 correlated positively with the composite juvenile arthritis10-joint 
disease activity score (JADAS10), while Campylobacter oral taxon 44, among 
others, correlated with the number of active joints. 
• We found a significantly higher gingival bleeding index (GBI), plaque-index 
and simplified oral hygiene index (OHI-S) in the JIA group compared to the 
healthy group. When adjusted for dental plaque and calculus (OHI-S), GBI 
was not found strictly significantly associated to JIA. 
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• There was no significant difference in GBI between the three groups of 
children with JIA using no systemic medication, methotrexate or biologic 
agents. 
• Overabundance of microbiota associated to chronic inflammation in JIA did 
not overlap with microbiota associated to increased GBI, even if the 











Efficacy and safety of intraarticular corticosteroid injections in adolescents with 
juvenile idiopathic arthritis in the temporomandibular joint: A Norwegian 2-year 
prospective multicenter pilot study. 
Frid P, Augdal T, Larheim T.A, Halbig J, Rypdal V, Songstad N.T, Rosen A, Tylleskär 
K.B, Berstad J.R, Flatø B, Stoustrup P, Rosendahl K, Kirkhus E, Nordal E.  
 
• Most patients received a single IAC, including five (33%) with bilateral IACs. 
In two patients the IACs were repeated once unilaterally.  
• The majority of patients had persistent oligoarthritis or polyarthritis RF 
negative JIA category. 
• Systemic medication was adjusted during the 2-year observation period in 
10/15 (66.7%) patients.  
• At the 2-months study visit after injection there was a minimal improvement 
in maximal incisal opening (MIO) from median 44.0 (36.0, 48.0) mm to 45.0 
(43.0, 47.0) mm, p= 0.045 and decreased MRI mean additive inflammatory 
score from 4.4±1.8 standard deviations (SD) to 3.4±2.0, p= 0.040.  
• Pain improved in 6/11 patients but pain scores were not significantly improved 
at the 2-months follow-up. 
• MRI-assessed damage was mostly stable, but increased in two patients with 
repeated IACs, and improved in three other patients over the 2-year follow-up.  
• Intra-rater repeatability of the domains of the MRI scoring systems varied 
from poor to excellent. Synovial thickening and disc abnormalities had the 
best scores for intra-rater repeatability. 





Surgical correction of dentofacial deformities in juvenile idiopathic arthritis: a 
systematic literature review 
 
P.Frid, C.Resnick, S.Abramowicz, P.Stoustrup, S.E.Nørholt, on behalf of the 
Temporomandibular Joint Juvenile Arthritis Work Group TMJaw.  
 
• The database search identified 255 citations, of which 28 met the eligibility 
criteria.  
• Of these, 24 were case reports with a low level of evidence that did not allow 
for meta-analysis, three were retrospective and one a prospective cohort study 
(n=172 participants with JIA in total).  
• Extrapolated evidence supports orthognathic surgery in skeletally mature 
patients with controlled or quiescent JIA and a stable dentofacial deformity.  
• Distraction osteogenesis may be recommended for severe deformities.  
• Some authors demonstrated unpredictable postoperative mandibular growth 
with costochondral grafts.  
• Alloplastic TMJ reconstruction was reported efficacious, but should be used 
cautiously in skeletally immature patients.  
• TMJ function and skeletal alignment was reportedly improved with 







Study design and strength and limitations 
 
Papers I and II was designed as descriptive cross-sectional studies. The advantage 
with this study design is that the participants are not deliberately exposed, treated or 
not treated; therefore this seldom imposes ethical dilemmas. The studies are also 
relatively inexpensive to perform and it is possible to study multiple outcomes. 
However, cross-sectional studies do not provide an explanation for the results, only 
information on associations and not on causation. It is impossible to control for 
confounding factors. 
A strength with paper I is the large international cohort and healthy controls included. 
However, selection bias may have occurred because many children with high disease 
activity were included in this study. Data was extracted from two different studies of 
the PRINTO; the HRQoL study to validate the CHAQ and the CHQ into 32 different 
languages, and the second study was the PRINTO high dose of MTX trial with 
patients in high disease activity state.  
Furthermore, the primary research questions in the two original studies did not 
include assessment of TMJ involvement and in addition TMJ imaging was not 
performed. Also, we do not know to what extent children with asymptomatic TMJ 
arthritis and growth disturbances in terms of dentofacial deformities from previously 
active arthritis were identified as TMJ arthritis in this study. Pediatric rheumatologists 
and not trained dental specialists performed the TMJ examination. The prevalence of 
TMJ involvement was therefore probably underreported in this study. Another 
limitation was to distinguish clinical variables associated with TMJ involvement from 
associations with arthritis in any specific joint or polyarticular disease in general. 
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Adjustments for polyarticular disease course and other disease activity measures were 
therefore performed in the multivariable logistic regression analyses. 
 
In the cross-sectional study in paper II, the cohort consisted of children with JIA 
without TMJ arthritis (n=44), JIA with TMJ arthritis (n=15) and healthy controls 
(n=34). A limitation regarding this cohort was that the children with JIA were not 
new-onset nor treatment naïve. 
 
Paper III was designed as a prospective Norwegian multi-center pilot study, where 
a cohort of 15 children with TMJ arthritis treated with IACs was followed for 2 years 
according to potential effect and safety. The prospective study-design has the 
advantage of being tailored to collect specific exposure data and may be more precise 
than cross-sectional studies. The disadvantage of a prospective cohort study is the 
need for the long follow-up period while waiting for events or diseases to occur, thus 
the risk for loss to follow-up increases with longer follow-up time, and thereby 
inflicting selection bias. The ideal research design would have been to randomize the 
children in a RCT to either corticosteroid or saline injection. However, recruiting 
enough patients for sufficient statistical power would have been time-consuming and 
very difficult for our study. Furthermore, it would have been interesting to compare 
mandibular growth in children with JIA and TMJ arthritis after IACs, with healthy 
controls. We were not able in our study to assess mandibular growth because the 
children had mostly finished their growth at time for IACs, and a suitable control 
group with active TMJ arthritis and alternative treatment strategy was not available. 





Paper IV was designed as a systematic literature review according to the PRISMA- 
guidelines. The level of evidence was scored according to the Oxford Centre for 
Evidence-based Medicine (OCEBM) level of evidence guide 
(http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-
march-2009/). A limitation with this systematic review was that no meta-analysis 
could be performed due to the low level of evidence of the included studies and the 
high risk of bias. The risk of bias was assessed according to the following variables: 
prospective study design, sufficient description of the outcome variable, uniform 
inclusion criteria, standardized examination protocol, outcome assessor blinded to 
imaging findings, and information on outcome variable variation. Of the 28 included 
papers, 24 were case-reports; three were retrospective studies and only one 
prospective. Most of the studies had a small patient sample, and no study had a 
control group. Only 172 of the 232 included patients had JIA, the remaining patients 
had different craniofacial syndromes including a dentofacial deformity, thus having 
the same surgical procedure done. Therefore, it is difficult to ascertain that the results 
are specific to JIA and not to other conditions. The majority of the outcome assessors, 
i.e. the oral and maxillofacial surgeons that performed the surgical procedure, were 
obviously not blinded to the intervention performed in the included studies. Only two 
databases were used for the literature search, which may have inflicted bias at the 
review level. The study heterogeneity did therefore not allow for meta-analysis. The 







Discussion of main findings 
 
The present papers contribute to the current understanding of JIA and TMJ arthritis, 
by describing in papers I-IV disease activity and quality of life, the oral microbiome 
and intervention with both IACs to the TMJ and surgical correction of dentofacial 
deformities in children with JIA. 
 
Disease activity and quality of life 
 
The TMJ is a special joint because of few symptoms and diagnostics may be challenging 
(122). Paper I pointed out to the need for an internationally accepted definition of TMJ 
arthritis based on clinical findings and symptoms as well as MRI. Standardizations of 
terminology according to orofacial examination in JIA have later been published by 
Stoustrup et al (87). It is a short clinical protocol assessing orofacial symptoms, TMJ 
dysfunction, and dentofacial deformity, taking less than three minutes to complete. In 
addition, suggested MRI scoring systems for the TMJ is published by Tolend et al 
(104), and Kellenberger et al. (105). Prospective longitudinal studies using these new 
internationally suggested definitions will hopefully make it easier to identify and 
compare future studies on early predictors of severe facial growth disturbances, 
intervention and outcome over time. 
 
There has been increasing focus on the TMJ in recent years, and the rate of TMJ 
arthritis varies significantly (40-90%) in different JIA-cohorts using magnetic 
resonance imaging (MRI) (95, 99, 138). In our international cohort comprising a large 
number of children with JIA with or without TMJ arthritis and healthy children, the 
prevalence of clinical TMJ involvement was found to be low (12%), most probably 
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because diagnostic imaging was not used. TMJ involvement was based on clinical 
assessment of the variables “active arthritis” and “limitation in range of movement”.  
We found associations between clinical TMJ involvement and impaired QoL, 
polyarticular disease course, longer disease duration, physical disability, and 
cervical spine involvement in children with JIA. To our knowledge, this is the first 
study to analyze the relationship between QoL and TMJ involvement in children with 
JIA. We found an association with increased pain, difficulties in eating, arising, and 
reaching, and having limitations in physical functioning measured by the child health 
assessment questionnaire (CHAQ) in multivariable analyses compared to the non-
TMJ group.  This is in agreement with studies on healthy children, young adult JIA 
and adult JIA patients, showing that temporomandibular disorders (TMD) may lead to 
impaired oral health and influence daily life (139-143). Many JIA cohorts are small, 
adjustment for disease severity is not always done and general orofacial symptoms are 
most often studied. In our study the TMJ involvement was specifically studied. 
Furthermore, we found associations between clinical TMJ involvement and impaired 
physical and emotional wellbeing according to the TMJ (144). However, lower self-
esteem (SE of the child health questionnaire (CHQ)) and eating difficulties (CHAQ) 
were not significantly associated with clinical TMJ involvement in multivariable 
analysis, only in univariate analysis. A lower self-esteem may be explained by 
dentofacial deformities, but also by high disease activity in general, because it was not 
significantly associated to clinical TMJ involvement in the adjusted analyses in our 
study. Several studies show a positive psychosocial effect in JIA patients after 
orthognathic surgery (145, 146). It is reported that facial attractiveness may influence 
education, relationships, and employment (127). 
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The TMJ plays an important role for daily life activities (141, 147, 148). Our results 
of the association between TMJ involvement and eating problems and also with oral 
hygiene are in agreement with other studies (147-149), even if medication and general 
disease activity also might have an impact on these problems (147). CHAQ used in 
our study is not a specific tool for assessing TMJ dysfunction. Other questionnaires 
such as “Juvenile Arthritis Multidimensional Assessment Report (JAMAR)” (150) 
and the EuroTMJoint Clinical Recommendations protocol similar to, but shorter than 
the established and validated Diagnostic Criteria for Temporomandibular Disorders 
(DC/TMD) (151, 152), is now developed in the EuroTMJoint network, and may better 
explore eating difficulties and TMJ involvement.   
We found longer disease duration in the group with TMJ involvement in 
contrast to the other children with JIA (95). Evolving growth disturbances can 
influence this finding and asymmetries following active TMJ arthritis that may be 
increasingly easier to recognized over time. Peak onset of TMJ arthritis according to 
age and time after disease onset are best studied in prospective JIA cohorts with 
radiographic assessment.   
In line with other studies, we found associations between TMJ involvement and 
upper limb involvement and also with a higher ESR (85, 95). We found a 
significant association between TMJ involvement and cervical spine involvement, and 
in contrast to other studies, this association was confirmed in multivariable analysis 
adjusting for higher disease activity (85, 95). Cervical pain and limitation in 
movement may be caused by cervical spine arthritis, but could also be the result of 
stiffness in neck and masticatory muscles.  
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The oral microbiome 
The aim of this study was to investigate the salivary oral microbiome in children with 
JIA and relate this to JIA disease activity including gingival inflammation. There is 
increasing evidence that the human microbiome may contribute to the development of 
JIA (15, 31-33) through an imbalance in the composition of the microbiota, i.e. a 
dysbiosis (15). In patients with rheumatoid arthritis, the oral microbiota is suggested 
to be involved in the pathogenesis by activation of mucosal immunity (153). 
Dysbiosis and periodontitis are reported to be associated with increasing severity of 
rheumatoid arthritis (18). 
The next generation sequencing (NGS) method was used in our study for oral 
bacterial DNA sequencing (154), allowing analysis of microbiota at a reasonable 
cost and with less extensive laboratory work compared to the earlier method of 
Sanger sequencing of 16S rRNA clones. The NGS target one or more regions of the 
16S rRNA gene, which due to their hypervariability serve as good markers of 
bacterial taxa in samples. In our study, we chose the V1-V3 region of the 16S rRNA 
gene to study the salivary oral microbiome. This region proved to provide the most 
resolution to study oral microbiome, even at the subspecies level. 
We found no significant differences between JIA and healthy controls (HC) 
regarding alpha- and beta-diversity. Alpha-diversity refers to the average species 
diversity in saliva and beta-diversity to the ratio between species diversity i.e. 
microbial composition in saliva between the two communities JIA and HC in our 
study. The average microbiome in our study in both JIA and healthy saliva were 
found to be Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria, and 
Fusobacteria at the phyla level (accounting for more than 98% of the reads). Thirteen 
genera accounted for 90% of the average microbiome, with Prevotella, Streptococcus, 
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Haemophilus, Actinomyces, Porphyromonas and Rothia alone making 70% of the 
genera. At the species level, Prevotella melaninogenica, Haemophilus parainfluenzae, 
Rothia mucilaginosa, Porphyromonas sp. oral taxon 279, Prevotella histicola, 
Actinomyces odontolyticus were the most abundant species, constituting around 40% 
of the microbiome on average. 
Operational taxonomic unit (OUT) differential abundance testing is commonly used 
to identify OTUs that differ between two sample categories (i.e. saliva in two groups). 
OTUs are proxies for species at different taxonomic levels.  
In our study, differential abundance analysis revealed that taxa associated with 
chronic inflammation also was associated to JIA: TM7-G1, Solobacterium and 
Mogibacterium at the genus level; and Leptotrichia oral taxon 417, TM7-G1 oral 
taxon 352 and Capnocytophaga oral taxon 864, among others, at the species level. An 
overabundance of Haemophilus and Bacillus was found in saliva in healthy subjects. 
Overabundance of taxa associated with chronic inflammation, i.e. dysbiosis, may 
explain the significantly higher gingival bleeding found in patients with JIA compared 
to HC in our study. The higher gingival bleeding found in JIA in our study is in line 
with some authors (147-149, 155, 156). Other authors found, however, no significant 
difference between JIA and healthy (157-163). In univariate regression analyses JIA 
was associated to higher GBI. When adjusting for the simplified oral hygiene index 
(OHI-S) including dental plaque and calculus in multivariable logistic regression 
analyses, we found that the association between JIA and gingival bleeding lost the 
clear significance, but OHI-S was significantly associated to gingival bleeding index.  
The differences across studies may be caused both by different study designs and 
different measure indices for gingival inflammation, thus making it difficult to 
compare the results. In our study a cut-off score ≥10% for the GBI was used for 
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gingival inflammation in the analyses, even if this only is validated in adults. No cut-
off score is established for children. In addition, the gingival bleeding index (GBI) 
used in our study was modified by measuring only the upper part of the gingival 
sulcus and only 6 index-teeth were used. 
We did not find overabundance of the same microbiota associated to gingival 
bleeding that was found associated to JIA. However, microbiota associated to chronic 
inflammation were found in both GBI and JIA. S.sputigena associated to GBI in our 
study is found associated to general aggressive periodontitis in other studies (164). 
Even if GBI and OHI-S was higher among children with JIA in our study, there was 
no difference in the frequency of tooth brushing between the groups. Therefore, we 
hypothesize that the dysbiosis more than specific bacteria may contribute to increased 
gingival bleeding and dental plaque formation in JIA compared to healthy. Maspero et 
al found reduced gingival bleeding in patients treated with biologic medication (162). 
We did not find significant differences in GBI between children with JIA on no 
systemic medication, methotrexate or biologics.  
Furthermore, we found JADAS10 to be positively correlated to Gemella 
morbillorum, Leptotrichia sp. oral taxon 498 and Alloprevotella oral taxon 914, while 
Campylobacter oral taxon 44, among others, particularly correlated with the number 
of active joints. Association between increased disease activity and certain bacteria is 
in line with other studies on RA (18). 
An altered microbiome profile is in accordance to other studies about the gut 
microbiota in JIA (16, 34, 49, 50, 52, 53). However, no single species has been 
identified and different studies on the gut microbiome in JIA show changes in 
different taxa (16, 34, 49-54). The species found in our study on the salivary oral 
microbiome in JIA are not found in the studies of the gut microbiome in JIA. 
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However, disruption of microbial ecology was found and this dysbiosis may have 
community effects on the host that are more powerful than the actions of just one or a 
few single microbes (43).  
 
Intervention with IACs to the TMJ 
 
In some patients with JIA, systemic treatment is not sufficient to treat TMJ-arthritis. 
In these cases other treatment options are sought, such as IACs. When we initiated 
this study 5 years ago, many clinicians worldwide had a liberal attitude towards 
performing IACs, and this local treatment was widely recommended (108). However, 
after several case series reporting severe side effects of mostly repeated IACs, 
including intra-articular calcifications and inhibited mandibular growth, there is today 
recommendations towards a more cautious use of IACs (165).  
Based on the results from our Norwegian 2-year prospective multicenter pilot study of 
adolescents with JIA and TMJ arthritis, we suggest, that a single IAC after the 
peripubertal growth might be beneficial as a supplement to systemic treatment. We 
found reduced inflammation at both 2-months and 2-year follow-up with a newly 
established MRI scoring system, but minimal improvement of MIO. Validated 
clinical outcome measures were used in our pilot study. Pain improved in 6 of 11 
adolescents in our study but did not reach significance, in contrast to some 
retrospective studies in children with JIA (107, 110, 111, 113, 114). Stoustrup et al. 
found improvement in pain one month after IACs but worsened pain after one year in 
his prospective pilot study using the same validated pain index score that was used in 
our study (109).  
Improved MIO is in line with other retrospective studies (107-111, 113, 114, 117), 
even if MIO was minimally improved in our study and is associated with variation (166, 
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167), increases with age, show a wide normal range in children of the same age (168) 
and is associated with measurement biases even if standardized protocols are used 
(132) (133). The smallest detectable difference is found to be 5mm when MIO is 
repeatedly measured in patients with JIA. 
We found a significant improvement in the reduction of MRI-assessed 
inflammation using two newly validated scoring systems, both at 2-month- and 
at 2-year follow-up after IACs (104, 105). Studies of IACs to the TMJs in JIA 
patients report a variable MRI improvement of 18-83% probably because of variable 
definitions of MRI improvement (107, 108, 110, 112, 117). There has been a clear 
need for a standardized MRI scoring system differentiating normal findings in 
growing children from pathology, and also grading the pathologic changes that are 
identified.  
We did not find any significant improvement in bone damage on MRI. Two 
patients with repeated IACs worsened during the 2-year follow-up and 3 patients 
improved. This is in line with other studies showing either stable condylar changes or 
worsening with intraarticular ossifications after IACs (107, 108, 111, 120, 169). The 
authors cannot say if these ossifications are the result of repeated IACs or due to the 
long-standing TMJ inflammatory process. Also reduced mandibular growth has been 
reported after IACs in children with JIA and TMJ arthritis (120). We were not able to 
evaluate growth since most of the study participants in our study were in the phase of 
finishing their growth at the time the injection was performed. Furthermore, the effect 
of naturally fluctuating JIA disease activity, systemic treatment changes, and TMJ 
lavage versus IACs could not be discerned in our study. Our study may still add 
evidence by assessment of efficacy and safety of one single injection and not repeated 
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injections in adolescents with an age not thought of as critical regarding mandibular 
growth retardation due to steroid injection.  
 
Intervention with jaw surgery 
 
If systemic treatment with/or without IACs to the TMJ do not prevent the 
development of dentofacial deformities in patients with JIA and TMJ arthritis, 
surgical correction may be the treatment of choice. There is no consensus regarding 
the most appropriate reconstructive approach, which may be influenced by the degree 
of skeletal maturity, level of TMJ arthritis activity, severity of TMJ and dentofacial 
deformity, and surgeon preference and experience.  
We found in our systematic review that orthognathic surgery is supported in 
skeletally mature patients with controlled or quiescent JIA and a stable 
dentofacial deformity. The reason for performing this kind of surgery after growth is 
to maximize stability (124, 170). However, reduced stability or “skeletal relapse” after 
surgery may be a problem in patients with JIA even after growth, because they are so 
called “high-angle cases” with a TMJ deformity causing posterior rotation of the 
mandible resulting in an anterior open bite (171). Early surgical intervention, before 
growth is finished, has therefore been recommended in order to provide better 
conditions for normal development of the facial skeleton (170, 172). 
Distraction osteogenesis (DO) was recommended for severe deformities, even if DO 
require careful vector planning, patient collaboration during device activation and a 
second surgery to remove the device (173). 
 In growing individuals, autologous reconstruction may be preferred because the 
graft has the potential to grow with the child. Our review found an improvement in 
functional outcome and esthetics (128, 145, 174-177), self-confidence (174, 176), and 
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OSA (176, 178), after the use of costochondral-grafts (CCG). However, there is 
controversy in the literature regarding the use of CCG, due to the risk of graft 
overgrowth (145, 177), graft resorption and ankylosis, and donor site morbidity (179, 
180).  
A temporomandibular joint prosthesis was found efficacious because the TMJ 
could be mobilized early after surgery. However, in growing individuals it should 
be used cautiously because of the risk of mechanical failure requiring reoperation. 
Furthermore, long-term outcomes of TMJ prostheses beyond 15 years are unknown 
(129). We conclude in our review that TMJ function and skeletal alignment was 
improved by all the mentioned surgical techniques and morbidity was low. Even if 
available articles were mainly case-series, we believe there is an indication for 





Clinical implications of the results 
 
Clinicians should pay special attention to TMJ involvement in children with JIA and 
cervical spine involvement, polyarticular course and longer disease duration. 
Furthermore, TMJ diagnostics should include both a standardized clinical TMJ 
examination and an MRI examination (Paper I). 
 
Children with JIA are vulnerable for oral infections and should have regular dental 
follow-up. In addition, the oral microbiome may contribute to the pathogenesis and 
disease severity in JIA. This may give implications in support of a more restrictive 
use of antibiotics in children (Paper II). 
 
A single IAC in the TMJ in adolescents with JIA may be a supplement to systemic 
treatment in refractory cases with JIA and TMJ arthritis (Paper III). 
 
The surgical correction of JIA-induced dentofacial deformities is indicated and the 
specific reconstructive approach may be chosen based on the degree of skeletal 
maturity, level of TMJ arthritis activity, severity of TMJ and dentofacial deformity, 







The work in this dissertation has contributed to new knowledge of TMJ arthritis in 
JIA with regard to quality of life (QoL) and disease activity, oral microbiome and 
intervention with the following conclusions: 
 
I. Clinical TMJ involvement is associated with impaired QoL in children with 
JIA. The prevalence of TMJ involvement is surely an underestimate of TMJ 
arthritis, but most children with clinically evident TMJ involvement were 
probably identified. Special attention should be paid to the TMJ in children 
with cervical spine involvement, polyarticular course, longer disease duration, 
and physical disability (Paper I).  
 
II. Microbiota associated with chronic inflammation was enriched in the saliva of 
children with JIA. Increased disease activity in terms of JADAS10 and 
number of active joints were associated to specific bacteria. The disrupted 
microbial ecology may have triggered a local pathological immune response 
resulting in increased gingival bleeding and dental plaque formation in JIA 
(Paper II). 
 
III. A single IAC to the TMJ in combination with systemic treatment improved 
MRI-assessed inflammation during a 2-year follow-up in adolescents with JIA 
and TMJ arthritis. However, short-term clinical improvement was minimal in 
MIO and no significant improvement in pain was seen. Bone changes in the 
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TMJ were mostly stable and no side effects were seen during the 2-year 
follow-up (Paper III). 
 
IV. Surgical correction of JIA-induced dentofacial deformities may be indicated in 






There is a need for an internationally accepted definition of TMJ arthritis whether 
based on clinical findings and/or imaging. Longitudinal TMJ studies with clinical 
assessment and imaging are warranted to identify early predictors of severe facial 
growth disturbances, the most efficacious and safe treatment modalities and outcome 
over time. 
 
Orofacial examinations and imaging of children with JIA and TMJ arthritis with 
validated standardized protocols are important basis for future research in the field. 
 
Studies on other biomarkers including cytokine levels in saliva, serum and TMJ joint 
fluid may expand our understanding of TMJ inflammation in JIA. Analyses of 
cytokines are ongoing in the study participants described in paper II on the oral 
salivary microbiome. Prospective studies with treatment-naive recent onset patients 
are warranted to further explore the possible role of the oral microbiome in the 
etiology of JIA. 
 
Prospective multi-center studies with larger samples of patients and with an age not 
critical for mandibular growth retardation due to steroid injection including a control 
group, may further explore the efficacy, safety and role of single IACs in the 




The different surgical reconstructive interventions performed in the management of 
dentofacial deformities found in children with JIA and TMJ arthritis should be 
monitored by establishing prospective intervention studies and a multi-center registry. 
A prospective multi-center study with Tromsø and Århus on surgical intervention is 
now ongoing. The TMJaw group may be a networking platform with a key role in 
establishing an international registry of surgical reconstructive interventions of the 
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ANGELO RAVELLI,18 ALBERTO MARTINI,18 ANGELA PISTORIO,19 AND NICOLINO RUPERTO,3
FOR THE PAEDIATRIC RHEUMATOLOGY INTERNATIONAL TRIALS ORGANISATION
Objective. To evaluate the demographic, disease activity, disability, and health-related quality of life (HRQOL) differ-
ences between children with juvenile idiopathic arthritis (JIA) and their healthy peers, and between children with JIA
with and without clinical temporomandibular joint (TMJ) involvement and its determinants.
Methods. This study is based on a cross-sectional cohort of 3,343 children with JIA and 3,409 healthy peers, enrolled
in the Pediatric Rheumatology International Trials Organisation HRQOL study or in the methotrexate trial. Potential
determinants of TMJ involvement included demographic, disease activity, disability, and HRQOL measures selected
through univariate and multivariable logistic regression.
Results. Clinical TMJ involvement was observed in 387 of 3,343 children with JIA (11.6%). Children with TMJ involve-
ment, compared to those without, more often had polyarticular disease course (95% versus 70%), higher Juvenile Arthritis
Disease Activity Score (odds ratio [OR] 4.6), more disability, and lower HRQOL. Children with TMJ involvement experi-
enced clearly more disability and lower HRQOL compared to their healthy peers. The multivariable analysis showed that
cervical spine involvement (OR 4.6), disease duration >4.4 years (OR 2.8), and having more disability (Childhood Health
Assessment Questionnaire Disability Index >0.625) (OR 1.6) were the most important determinants for TMJ involvement.
Conclusion. Clinical TMJ involvement in JIA is associated with higher disease activity, higher disability, and
impaired HRQOL. Our findings indicate the need for dedicated clinical and imaging evaluation of TMJ arthritis, espe-
cially in children with cervical spine involvement, polyarticular course, and longer disease duration.
INTRODUCTION
Temporomandibular joint (TMJ) arthritis in childhood
is recognized as a common problem in children with
juvenile idiopathic arthritis (JIA) and may lead to reduced
mouth opening and pain, as well as craniomandibular
growth disturbances. The growth disturbances in child-
hood TMJ arthritis are different from arthritis in other joints
because of the special anatomy of the TMJ, with fibrous car-
tilage and the intraarticular condylar growth pattern (1).
Bilateral involvement may lead to micrognathia and dental
malocclusion (2,3), and unilateral involvement may lead to
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facial asymmetry (4). TMJ arthritis may also hamper oral
hygiene and lead to dental caries (5,6).
Depending on the examination methods and study
design used, the prevalence of TMJ arthritis varies in dif-
ferent JIA studies. Rheumatologists may not have the same
awareness for TMJ as for other joints, and standardized
examination of TMJ range of motion is challenging in
small children. Tenderness is very subjective, and young
children often do not report pain in even obviously swol-
len chronically inflamed joints. An overall TMJ preva-
lence of approximately 40–45% has usually been found
using panoramic radiography (7,8). In 2 large series of
children examined with magnetic resonance imaging
(MRI), frequencies of approximately 39% and 43% were
reported (9,10). In 47 patients followed longitudinally for
27 years, Arvidsson et al (11) reported a frequency of 70%
when the adult JIA patients were examined with both
computed tomography and MRI. Both lower and higher
prevalences have been reported in clinical and radiologic
studies (12,13), and in particular with MRI (14,15) higher
prevalences of TMJ arthritis have been found. However,
many TMJ studies are characterized by a low number of
patients. It is a fact that MRI may detect TMJ arthritis in
children with JIA without symptoms or clinical findings.
However, contrast enhancement is also seen in healthy
children and adolescents (16,17), and thus the reliability
of contrast-enhanced MRI to assess synovial inflammation
is discussed (18), reflecting the complex diagnostics of the
TMJ.
TMJ pain has a negative impact on health-related qual-
ity of life (HRQOL) in adult rheumatoid arthritis patients
(19), and a high prevalence of temporomandibular
disorders (TMDs) in adult JIA patients has also been
reported (20). TMDs in general lead to reduced HRQOL in
preadolescents (21). Orofacial symptoms are frequent, and
are reported to influence daily life severely for almost a
quarter of a series of children with JIA (22). However, little
is known about the effect of TMJ involvement on HRQOL
and disability in children with JIA.
The purpose of the present study was to examine the
difference in clinical characteristics, disease activity, dis-
ability, and HRQOL in a large cohort of children with JIA
with and without clinical TMJ involvement, to compare
the results with those obtained in healthy peers, and to
identify the factors that have the greatest influence on TMJ
arthritis. The overall hypothesis was that children with JIA
and TMJ involvement have distinctive clinical features
when compared to children without TMJ involvement.
MATERIALS AND METHODS
Patients. This is a cross-sectional study based on data
extracted from 2 studies of the Pediatric Rheumatology
International Trials Organisation (PRINTO) (23). The first
relates to the HRQOL study, which enrolled 3,235 chil-
dren with JIA and 3,409 healthy controls to validate the
translation of the Childhood Health Assessment Ques-
tionnaire (C-HAQ) and the Child Health Questionnaire
(CHQ) into 32 different languages (24). The second study
was the PRINTO high dose of methotrexate (MTX) trial
with 633 participants (25); for the MTX trial, only baseline
data, from patients in a high disease activity state, were
used. Children were classified as per the International
League of Associations for Rheumatology criteria (26). Chil-
dren with psoriatic or enthesitis-related arthritis were
excluded.
Assessment of functional disability and HRQOL
measures. The national version of the C-HAQ question-
naire was completed by one of the parents, or by the child
if age .9 years. The C-HAQ is used to assess the patient’s
ability to carry out daily life activities (24,27) and the
child’s ability to perform different functions, grouped in 8
domains (range 0–3): dressing, grooming, arising, eating,
walking, hygiene, reach, grip, and activities. The C-HAQ
Significance & Innovations
 Clinical temporomandibular joint (TMJ) involve-
ment is associated with high levels of disability,
high disease activity, and impaired quality of life
in children with juvenile idiopathic arthritis (JIA).
 Clinicians should pay special attention to TMJ
involvement in children with JIA and cervical
spine involvement, polyarticular course, and lon-
ger disease duration.
 Observations were based on 387 of 3,343 chil-
dren with JIA, representing those with clinically
evident TMJ involvement.
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disability index (C-HAQ DI) is calculated with a range
from 0 (no or minimal physical disability) to 3 (very severe
physical disability). A parent’s/patient’s global assessment
of the child’s overall well-being in the previous week was
scored on a 0–10-cm visual analog scale (PRgloVAS)
(where 0 5 very well and 10 5 very poor), and a parent’s/
patient’s global assessment of the child’s pain in the previ-
ous week was scored on a 0–10-cm VAS (where 0 5 no
pain and 10 5 very severe pain) (PRpainVAS).
The national language version of the parent’s adminis-
tered 50-item version of the CHQ (also called CHQ-PF 50)
was used to assess HRQOL of patients and healthy chil-
dren. The CHQ is a generic self-administered instrument
designed to capture the physical, emotional, and social
components of health status of children ages 5–18 years,
which comprises 15 health concepts (range 0–100): global
general health, physical functioning, role/social limita-
tions emotional/behavioral, role/social limitations physi-
cal, bodily pain/discomfort, behavior, general behavior,
mental health, self-esteem, general health perception,
change in health, parent impact emotional, parent impact
time, family activity, and family cohesion. The CHQ com-
prises 2 summary measures, based on a US normative
standard, the physical summary score (PhS) and the psy-
chosocial summary score (PsS) (mean 6 SD 50 6 10).
Higher scores in the scales indicate better HRQOL (28).
Assessment of disease activity. The JIA core set activ-
ity variables (29) were assessed: the number of joints with
active arthritis (i.e., swelling within a joint or limitation in
the range of joint movement with joint pain or tenderness)
(26,29), the number of joints with limitation of motion
(LOM), the physician global evaluation of disease activity
on a 10-cm VAS (MDgloVAS), erythrocyte sedimentation
rate (ESR), the C-HAQ, the PRgloVAS, and the Juvenile
Arthritis Disease Activity Score 71 (JADAS) (30–32).
Assessment of TMJ involvement. For this study, we
defined TMJ involvement as a clinical evaluation of TMJ
arthritis based on the presence of TMJ pain or LOM, regis-
tered by the local pediatric rheumatologist in the PRINTO
joint examination form. Jaw deviation during opening and
maximal mouth opening capacity were not registered, but
LOM was assessed according to standard pediatric rheu-
matology textbooks.
Statistical analysis. For clinical and demographic data,
descriptive statistics were used, such as median (1st to
3rd quartile) and frequencies (percentage). Associations
between TMJ and other disease characteristics were ana-
lyzed by chi-square test for categorical variables and
Student’s t-test for continuous variables if reasonably nor-
mally distributed, otherwise Wilcoxon’s test was used. A
P value less than 0.05 was considered statistically signifi-
cant. To identify factors differentiating JIA patients with
or without TMJ involvement, univariate logistic regression
was performed, using as exploratory measures the JIA core
set, the C-HAQ, and the CHQ domains. Multivariable logis-
tic regression was performed to identify factors indepen-
dently associated with TMJ involvement. In both univariate
and multivariable regression analyses, the continuous
variables were dichotomized as per receiver operating char-
acteristics analysis. Statistical analysis was performed using
SAS software, version 9.3, and SPSS software, version 21.
Approval from appropriate medical ethical committees and
data authorities was obtained according to the requirements
of each participating country.
RESULTS
Study population. Of the original 2 studies we used,
2,715 of 3,235 JIA patients (84%) from the HRQOL study,
628 of 633 (99%) from the MTX trial, and all 3,409 healthy
participants from the HRQOL study, in total 6,752 sub-
jects, were analyzed (Figure 1). Participants from the MTX
trial had higher levels of disease activity and disability
and worse HRQOL when compared to the participants
from the cross-sectional HRQOL study (see Supplemen-
tary Tables 1 and 2, available on the Arthritis Care &
Research web site at http://onlinelibrary.wiley.com/doi/
10.1002/acr.23003/abstract). Of the 3,343 children with
JIA included, 2,278 of 3,243 (70.2%) were female, and
1,530 (45.8%) were diagnosed with persistent or extended
oligoarthritis (Table 1).
Demographic and disease activity parameters. Demo-
graphic and disease activity characteristics and univariate
analysis for the TMJ group and non-TMJ group are given
in Table 1. Of the 387 children with clinical TMJ involve-
ment (11.6% of the entire cohort), 75 (19.4%) had unilat-
eral and 312 (80.6%) had bilateral TMJ involvement. In
the TMJ group there was a female predominance (75.5%)
and longer disease duration, versus the non-TMJ group,
Figure 1. Flow chart of the participants enrolled in the study.
MTX 5 methotrexate; HRQoL 5 health-related quality of life;
JIA 5 juvenile idiopathic arthritis.
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but no statistically significant difference in age at onset.
Polyarticular disease course (extended oligoarthritis, poly-
arthritis rheumatoid factor [RF]–positive or -negative, and
systemic arthritis) was more common in the TMJ group
(95.1%) compared to the non-TMJ group (70.0%), and a
polyarticular RF-positive or -negative JIA category was
reported in 50.9% of the children in the TMJ group com-
pared to 31.7% in the non-TMJ group (see Supplementary
Figure 1, available on the Arthritis Care & Research
web site at http://onlinelibrary.wiley.com/doi/10.1002/
acr.23003/abstract). Disease activity measures as mea-
sured by the JADAS score, MDgloVAS, ESR, and the num-
ber of active joints were significantly higher in the TMJ
group compared to the non-TMJ group.
Disability and HRQOL. Disability and HRQOL are
reported in Figures 2 and 3 and in the related descriptive
statistics in Supplementary Tables 2 and 3 (available on the
Arthritis Care & Research web site at http://onlinelibrary.
wiley.com/doi/10.1002/acr.23003/abstract). Children with
clinical TMJ involvement had more disability compared to
children without TMJ involvement, as measured by the 8
C-HAQ subscales, PRpainVAS, PRgloVAS, and C-HAQ DI.
As shown by the arrows in Figure 2, children with clinical
TMJ involvement had scores more than 2 SD above the
mean values of healthy controls in the domains of dressing,
eating, and activities.
All CHQ health concept and summary scores (PhS and
PsS) in children with clinical TMJ involvement were sig-
nificantly lower than in children without TMJ involve-
ment, except for behavior and general behavior. In
addition, children with clinical TMJ involvement had
values more than 2 SD below the mean of healthy con-
trols for the following health concepts: global general
Table 1. Demographic and disease activity characteristics according to clinical TMJ involvement











Female, no. (%) 292 (75.5) 1,986 (67.3)
(n 5 2,951)
– 1.5 (1.2–1.9)
Age at visit 11.6 (8.5–14.9) 10.0 (6.5–13.6) .9.2 1.8 (1.4–2.3)
Age at onset 4.9 (2.3–8.3) 5.2 (2.5–8.8)
(n 5 2,948)
#8.9 1.2 (0.9–1.5)
Disease duration 5.1 (2.1–8.6) 3.2 (1.3–6.0)
(n 5 2,948)
.4.4 2.2 (1.8–2.8)
JIA category, no. (%)
Persistent oligoarthritis 19 (4.9) 887 (30.0) – –
Extended oligoarthritis† 78 (20.2) 546 (18.5) – 6.7 (4.0–11.1)
Polyarthritis† 93 (24.0) 585 (19.8) – 7.4 (4.5–12.3)











MTX study 116 (30.0) 512 (17.3) – 2.0 (1.6–2.6)
Disease activity variables















No. of patients with active joints, no. (%) 259 (66.9) 1,044 (35.3) $5.0 3.7 (3.0–4.6)
No. of joints with swelling 4.0 (1.0–12.0) 2.0 (0.0–5.0) .2.0 2.3 (1.8–2.8)
No. of joints with pain 7.0 (2.0–15.0) 1.0 (0.0–5.0) .5.0 4.5 (3.6–5.6)
No. of joints with LOM 13.0 (6.0–29.0) 2.0 (0.0–7.0) .4.0 8.9 (6.8–11.7)
No. of active joints 8.0 (3.0–17.0) 2.0 (0.0–6.0) .5.0 3.9 (3.1–4.8)
Cervical spine involvement, no. (%) 239 (61.8) 508 (17.2) – 7.8 (6.2–9.8)
* Values are the median (1st to 3rd quartile) unless indicated otherwise. Chi-square test is used for testing associations
with temporomandibular joint (TMJ) (categorical variables) together with Student’s t-test and Wilcoxon’s test (continuous
variables). Cutoff values for continuous variables were dichotomized as per receiver operating curve analyses. P , 0.05 for
all variables, except for age at onset and antinuclear antibody (ANA), which were not statistically significant. The vari-
ables are known for .95% of the total participants, except for the following: erythrocyte sedimentation rate (ESR) (90%),
Juvenile Arthritis Disease Activity Score (JADAS) (89%). JIA 5 juvenile idiopathic arthritis; OR 5 odds ratio; 95%
CI 5 95% confidence interval; RF 5 rheumatoid factor; MTX 5 methotrexate; MDgloVAS 5 physician global evaluation of
disease activity using a visual analog scale; LOM 5 limited range of motion.
† JIA category versus persistent oligoarthritis used as a reference.
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health, role/social limitations emotional/behavioral, role
limitations physical, and bodily pain/discomfort.
Univariate analysis. To evaluate the association of dis-
ease activity, disability, and HRQOL with clinical TMJ
involvement, we report the results of the univariate
analyses (odds ratios [ORs] and 95% confidence inter-
vals), with continuous variables dichotomized as per
operating characteristics analysis in Table 1 and Table 2.
A significant association with clinical TMJ involvement
was found for extended oligoarticular, polyarticular, and
systemic arthritis categories, using the oligoarticular per-
sistent category as a reference (OR range 6.7–9.8). Disease
activity measures as measured by the JADAS score (OR
4.6), MDgloVAS (OR 2.7), ESR (OR 2.8), and number of
active joints (OR 3.9) were significantly higher in the TMJ
group compared to the non-TMJ group. Children with
clinical TMJ involvement had more frequent cervical
spine involvement (OR 7.8) or upper extremity involve-
ment (data not shown).
All the C-HAQ domains had higher scores in the TMJ
group compared with the non-TMJ group, particularly for
the domains of reach (OR 5.5), difficulties concerning aris-
ing, grip, and activities (OR . 3.5 for all). In addition,
the TMJ group had higher scores for C-HAQ DI (OR 4.1)
compared with the non-TMJ group. The TMJ group also
had higher scores compared to the non-TMJ group for
PRgloVAS and for PRpainVAS (OR 3.1 and OR 2.7,
respectively). An adverse impact on physical and psycho-
social well-being was found in the TMJ group, with lower
PhS score (OR 3.2) and to a lesser extent PsS score (OR
1.7) compared with the non-TMJ group. There were signif-
icantly lower scores for the specific CHQ health concepts
concerning self-esteem, global general health, bodily pain/
discomfort, impact on general health, family activity, par-
ent impact emotional, child’s physical and emotional
behavior, and physical functioning in the TMJ group, with
an OR between 2.0 and 2.9 (Table 2). A univariate analysis
was performed for the same continuous variables, divid-
ing them into quartiles, and the results were overlapping
(data not shown).
Multivariable logistic regression. In the final regres-
sion model, we entered all variables that were found to be
significantly associated with clinical TMJ involvement at
the univariate analysis based on OR as follows: sex, dis-
ease duration, RF, cervical spine involvement, ESR, num-
ber of active joints, MDgloVAS, PRpainVAS, PRgloVAS,
C-HAQ DI, PhS, and PsS (CHQ). We excluded JIA catego-
ries (the number of joints with pain in lower and upper
extremities, LOM, and swelling) that were significant in the
univariate analysis, but for which there was collinearity
with other variables entered in the model. The 8 C-HAQ
domains and 13 of 15 CHQ health concepts were excluded,
since they were collinear with the respective total scores of
the C-HAQ DI, PhS, and PsS (CHQ). In the final model, to
Figure 2. Mean and 95% confidence intervals for the Childhood Health Assessment Ques-
tionnaire (CHAQ) for children with and without clinical temporomandibular joint (TMJ)
involvement. Vertical bars represent 12 SD of the mean of healthy children. Higher scores
indicate more disability. Arrows indicate the 3 CHAQ domains (dressing, eating, and
active) in which only children who have juvenile idiopathic arthritis with clinical TMJ
involvement have scores .2 SDs of the mean of healthy children. DICHAQ 5 CHAQ dis-
ability index; PRpainVAS 5 parent’s/patient’s global assessment of the child’s pain using
a visual analog scale; PRgloVAS 5 parent’s/patient’s global assessment of the child’s over-
all well-being using a visual analog scale.
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control for the level of disease activity, we also adjusted
(with adjusted OR) for the following measures: participa-
tion in the MTX trial, number of active joints, ESR, and RF.
The multivariable analysis (Table 3) showed that cervical
spine involvement (adjusted OR 4.6), disease duration
.4.4 years, being female, and having higher C-HAQ DI
were the most important determinants for TMJ involvement
(OR 2.8–1.5).
DISCUSSION
The present study demonstrated an association between clin-
ical TMJ involvement, disability, and HRQOL in children
with JIA, as well as independent associations between TMJ
and cervical spine involvement. We found a female pre-
dominance, longer disease duration, polyarticular course,
and higher level of disease activity in the group with clini-
cal TMJ involvement, and we found that the majority had
bilateral involvement.
The strength of the present study is the large interna-
tional cohort of 3,343 children with JIA, with as many as
387 children with clinical TMJ involvement. In this
cohort, systemic arthritis is overrepresented compared to
population-based JIA cohorts, and enthesitis-related
arthritis and psoriatic arthritis are not included, but other-
wise our cohort is representative of most JIA populations
according to sex and JIA category distribution (9,10,13,33,34).
Moreover, the observed associations between clinical TMJ
involvement and a number of disease variables are in
accordance with studies based on radiologic TMJ involve-
ment (7,9).
An obvious weakness in the present study is the assess-
ment of TMJ involvement. No data on imaging were avail-
able. Since recognizable swelling in the TMJ is rare, the
general definition of arthritis could not be applied (26).
We are not aware of any TMJ studies in children with JIA
that have used this general definition of arthritis. In line
with other studies (7,9,15,35), clinical TMJ involvement
(whether active or not) in our study was based on the pres-
ence of TMJ pain and/or LOM. The observed low fre-
quency of clinical TMJ involvement was therefore not
surprising. TMJ imaging and in particular MRI may detect
TMJ abnormalities, even in JIA children without any clini-
cal symptoms or signs of TMJ arthritis.
However, in a recent study using the same criteria for
assessing clinical TMJ involvement in JIA, Kirkhus et al
(35) reported that contrast-enhanced MRI demonstrated
TMJ arthritis in 85% of the children with clinical TMJ
involvement. Mostly, they found a combination of synovi-
tis (78%) and bone abnormalities (72%). This finding is
also in accordance with others (15,33). Koos et al (15)
found a specificity of 0.86 for TMJ pain and 0.83 for LOM
when comparing with MRI-detected TMJ arthritis in chil-
dren with JIA. Sensitivity of these clinical signs of TMJ
involvement was, however, low (15). We therefore antici-
pate that in the present study, the vast majority of the chil-
dren with clinical symptoms actually had TMJ arthritis.
It must be emphasized that symptoms and signs in these
joints are quite unspecific. We could expect that a
Figure 3. Mean and 95% confidence intervals of the 15 subscales (range 0–100) and the 2 summary
scores (norm-based values with mean 6 SD of 50 6 10) of the Child Health Questionnaire (CHQ) for
children with and without clinical temporomandibular joint (TMJ) involvement. Higher scores indi-
cate better health. Vertical bars represent 22 SD of the mean of healthy children. Arrows indicate the
4 CHQ health concepts (global general health, role/social limitations emotional/behavioral, role/social
limitations physical, and bodily pain/discomfort), in which only children with juvenile idiopathic
arthritis with clinical TMJ involvement have scores less than 22 SDs of the mean of healthy children.
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minority, as discussed by Kirkhus et al (35), might have
TMJ symptoms/signs due to myalgia or mechanical
disorders, such as disc displacement. MRI would have
been highly valuable for differential diagnostics. In the
present study, we do not know to what extent dentofacial
growth disturbances were registered. In other studies,
approximately one-third of children with JIA and TMJ
arthritis have been observed with micrognathia (2,3).
Children with JIA ages ,7 years are reported to have
almost no subjective TMJ dysfunction or symptoms (36).
They may not be able to give a precise description of their
symptoms and may develop severe facial growth
disturbances, apparently without previous symptoms (2).
With an average age at visit $10 years in the present
study, the majority should have been old enough to report
symptoms. The subgroup with TMJ arthritis constituted a
rather large number of patients, although being only a
small percentage of the whole series. Therefore, the pres-
ent study can provide valuable characteristics of a large
group of children with symptomatic TMJ involvement.
To our knowledge, no study has actually analyzed the
relationship between TMJ involvement in children with
JIA and HRQOL measures, although 1 study has reported
an impact on the daily life activities (22). Our results
showed an association with increased pain, and difficul-
ties in eating, arising, and reaching in univariate analysis,
and being disabled measured by the C-HAQ DI in multi-
variable analyses compared to the non-TMJ group. The
associations between TMJ involvement and impaired
HRQOL are in agreement with studies on non-JIA children
and young adult JIA patients, showing that TMD may lead
to impaired oral health and influence daily life (21,22,37).
This finding is in accordance also with Leksell et al (22),
who found that almost 80% of their children with JIA
reported pain from the TMJs or the face, and nearly a quar-
ter was severely influenced by orofacial pain in daily life.
However, their findings were based on a small JIA cohort
of 41 children, and adjustment for disease severity was
not performed. Leksell et al (22) studied general orofacial
symptoms, while the present study focused on clinical
TMJ involvement. A high prevalence of TMD problems in
adolescent and adult JIA patients is also reported by other
authors (11,20).
The present study showed associations between clinical
TMJ involvement and impaired HRQOL factors such as
activity and physical and emotional wellbeing (38). A
lower self-esteem (CHQ) and eating difficulties (C-HAQ)
were significantly associated with clinical TMJ
Table 2. Disability and HRQOL measures for children







Dressing .0.0 3.1 (2.4–3.9)
Arising .0.0 3.7 (3.0–4.7)
Eating .0.0 3.4 (2.7–4.2)
Walking .0.0 2.6 (2.1–3.3)
Hygiene .0.0 3.0 (2.4–3.7)
Reach .0.0 5.5 (4.1–7.2)
Grip .0.0 3.6 (2.8–4.4)
Active .1.0 3.5 (3.3–5.6)
C-HAQ DI .0.6 4.1 (3.2–5.2)
PRpainVAS .1.8 2.7 (2.2–3.5)
PRgloVAS .2.2 3.1 (2.5–4.0)
CHQ
Global general health #30.0 2.0 (1.6–2.5)
Physical function #72.2 2.9 (2.3–3.6)
Role emotional behavior #77.8 2.4 (1.9–3.0)
Role physical #66.7 2.4 (2.0–3.1)
Bodily pain #50.0 2.2 (1.7–2.7)
Behavior NA NA
General behavior NA NA
Mental health #70.0 1.7 (1.3–2.1)
Self-esteem #70.8 2.0 (1.6–2.4)
General health #51.0 2.0 (1.6–2.5)
Change in health #25.0 1.6 (1.2–1.9)
Parental impact emotional #75.0 2.3 (1.7–3.0)
Parental impact time #77.8 1.9 (1.5–2.3)
Family activities #66.7 2.0 (1.6–2.5)
Family cohesion #30.0 1.7 (1.3–2.3)
Physical score #35.1 3.2 (2.5–4.1)
Psychosocial score #50.3 1.7 (1.4–2.2)
* Cutoff values for continuous variables were dichotomized as per
receiver operating curve analyses. P , 0.05 for all variables except
for behavior and general behavior, which were not significant in
the univariate analysis. HRQOL 5 health-related quality of life;
TMJ 5 temporomandibular joint; OR 5 odds ratio; 95% CI 5 95%
confidence interval; C-HAQ 5 Child Health Assessment Question-
naire; C-HAQ DI 5 C-HAQ disability index; PRpainVAS 5 parent’s/
patient’s global assessment of the child’s pain using a visual ana-
log scale; PRgloVAS 5 parent’s/patient’s global assessment of the
child’s overall well-being using a visual analog scale; CHQ 5 Child
Health Questionnaire; NA 5 not applicable.
Table 3. Disease activity, disability, and HRQOL
characteristics associated with clinical TMJ
involvement, adjusted for measures of high disease





Cervical joint involvement 7.8 (6.2–9.8) 4.6 (3.5–6.1)
Disease duration .4.4 years 2.2 (1.8–2.8) 2.8 (2.1–3.8)
C-HAQ DI .0.6 4.1 (3.2–5.2) 1.6 (1.2–2.3)
Female 1.5 (1.2–1.9) 1.5 (1.1–2.1)
PRgloVAS .2.2 3.1 (2.5–4.0) 1.3 (0.9–1.8)
CHQ PhS #35.1 3.2 (2.5–4.1) 1.2 (0.9–1.7)
CHQ PsS #50.3 1.7 (1.4–2.2) 1.2 (0.9–1.6)
PRpainVAS .1.8 2.7 (2.2–3.5) 1.1 (0.8–1.6)
MDgloVAS .26.0 2.7 (2.2–3.4) 0.9 (0.6–1.3)
* Multivariable logistic regression analysis adjusted for the fol-
lowing measures of high disease activity: methotrexate trial par-
ticipation, number of active joints .5, erythrocyte sedimentation
rate .15, and rheumatoid factor positive. HRQOL 5 health-related
quality of life; TMJ 5 temporomandibular joint; OR 5 odds ratio;
95% CI 5 95% confidence interval; C-HAQ DI 5 Child Health
Assessment Questionnaire disability index; PRgloVAS 5 parent’s/
patient’s global assessment of the child’s overall well-being using
a visual analog scale; CHQ 5 Child Health Questionnaire; PhS 5
physical summary score; PsS 5 psychosocial summary score;
PRpainVAS 5 parent’s/patient’s global assessment of the child’s
pain using a visual analog scale; MDgloVAS 5 physician global
evaluation of disease activity using a visual analog scale.
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involvement in univariate analysis, but not in multivari-
able analysis. A lower self-esteem may be explained by
craniofacial growth disturbances resulting in asymmetries
and micrognathia, or related to high disease activity, since
it is not significantly associated with clinical TMJ involve-
ment in the adjusted analyses. However, several studies
show a positive psychosocial effect in JIA patients after
orthognatic surgery (39,40).
The TMJ is important for many daily life activities such
as eating, chewing, talking, and oral health (5,37,41). Our
results on eating problems in univariate analyses are in
accordance with Leksell et al (41), who report problems
with eating and oral health among JIA patients ages 10–19
years compared to healthy controls. Welbury et al (5)
report significantly increased levels of poor oral hygiene
and dental decay in children with JIA in general compared
to controls. Ahmed et al (6) report a greater gingivitis score
for the permanent teeth in the children with JIA and
greater TMJ dysfunction in children with JIA compared to
controls. Leksell et al (41), however, believe the problems
with eating and performing good oral hygiene, are not
only due to TMJ pain, but also due to medication and gen-
eral disease activity. Adequate nutrition is essential for
growth and general wellbeing in children with chronic
inflammation. Eating difficulties is 1 of the 8 domains in
the C-HAQ, and one question is “Is your child able to: Cut
his/her own meat?” This question probably mainly reflects
problems with fine motor skills due to finger and wrist
arthritis more than eating problems due to TMJ. The
C-HAQ is therefore not a specific tool for assessing TMJ
dysfunction. The newly developed questionnaire Juvenile
Arthritis Multidimensional Assessment Report may better
explore eating difficulties and TMJ involvement in the
question “Difficulties/limitations with bite into a sand-
wich or an apple” (42). Also, a standardized protocol for a
proper diagnostic and classification system of TMJs in
children with JIA, similar to, but shorter than, the
established and validated Diagnostic Criteria for Temporo-
mandibular Disorders (43,44), is under development in
the EuroTMjoint network. Jaw opening is also included in
the pediatric Gait, Arms, Legs, and Spine screening tool
for musculoskeletal examination in children (45).
In contrast to Cannizzaro et al (9), we found longer dis-
ease duration in the TMJ group, but not significant differ-
ences between the 2 groups according to age at onset. Peak
onset of TMJ arthritis according to age and time after dis-
ease onset are best studied in prospective JIA cohorts with
imaging. In line with other studies, we found associations
between TMJ involvement and upper extremity involve-
ment as well as higher ESR (7,9). We also found a signifi-
cant association between TMJ and cervical spine
involvement, and in contrast to Cannizzaro et al, the asso-
ciation was confirmed in multivariable analysis, adjusting
for higher disease activity (7,9).
A diagnosis of cervical spine arthritis is often based on
clinical criteria such as cervical pain and stiffness. How-
ever, these symptoms could also be the result of myalgia,
in the same way as clinical TMJ involvement may repre-
sent muscular pain instead of TMJ arthritis. The close
proximity of the neck and masticatory muscles might
partly explain this association.
Bilateral involvement was registered in 80.6% of the
children with clinical TMJ involvement, in agreement
with observations in adult JIA patients (11). At the base-
line radiographic examination of the longitudinal fol-
lowup study by Larheim et al (7), approximately 60% of
the children with TMJ arthritis were assessed with bilat-
eral TMJ involvement. This figure seems to be in accor-
dance with most radiographic TMJ studies of JIA children
(2,11,46,47), but the occurrence of bilateral TMJ involve-
ment seems to be higher when using MRI (10,48,49). Chil-
dren may have difficulties distinguishing whether there is
pain in 1 or both TMJs.
There are some limitations in the present study. It was
not designed to study TMJ arthritis specifically, and no
imaging was performed. Furthermore, pediatric rheuma-
tologists and not trained dental specialists performed the
TMJ examination. Since TMJ involvement is most com-
mon in children with polyarthritis, another limitation of
our study is to distinguish clinical variables associated
with TMJ involvement from associations with arthritis in
any specific joint or polyarticular disease in general.
Therefore, we have performed a multivariable analysis,
adjusting for measures of high disease activity such as par-
ticipation in the PRINTO MTX trial, higher number of
active joints, higher ESR, and being RF positive. However,
other activity variables not adjusted for may still have
interfered with our analyses.
In conclusion, clinical TMJ involvement is associated
with impaired HRQOL in JIA children. The prevalence of
TMJ involvement is surely an underestimate of TMJ
arthritis, but most children with clinically evident TMJ
involvement were probably identified. Special attention
should be paid to the TMJ in children with cervical spine
involvement, polyarticular course, longer disease dura-
tion, physical disability, and female sex. There is a need
for an internationally accepted definition of TMJ arthri-
tis, whether based on clinical findings and/or imaging.
Longitudinal TMJ studies with clinical assessment and
imaging are warranted to identify early predictors of
severe facial growth disturbances, treatment modalities,
and outcome over time.
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Background: The oral microbiota has been connected to the pathogenesis of rheumatoid arthritis 
through activation of mucosal immunity. The objective of this study was to characterize the salivary 
microbiome associated with juvenile idiopathic arthritis (JIA), and correlate it with the disease 
activity including gingival bleeding. 
Methods: Fifty-nine subjects with JIA (mean age 12.6 ± 2.7 years) and 34 healthy controls (HC; 
mean age 12.3± 3.0 years) were consecutively recruited in this Norwegian cross-sectional study. 
Information about demographics, disease activity, medication history, gingival bleeding index (GBI), 
simplified oral hygiene index (OHI-S), and frequency of tooth brushing was obtained. Microbiome 
profiling of saliva samples was performed by sequencing of the V1-V3 region of the 16S rRNA gene, 
coupled with a species-level taxonomy assignment algorithm; QIIME, LEfSe and R- package were 
used for downstream analysis.  
Results: There were no significant differences between JIA and HC in alpha- and beta-diversity. 
However, differential abundance analysis revealed several taxa to be associated with JIA: TM7-G1, 
Solobacterium and Mogibacterium at the genus level; and Leptotrichia oral taxon 417, TM7-G1 oral 
taxon 352 and Capnocytophaga oral taxon 864 among others, at the species level. Haemophilus 
species, Leptotrichia oral taxon 223, and Bacillus subtilis, were associated with healthy controls. 
Gemella morbillorum, Leptotrichia sp. oral taxon 498 and Alloprevotella oral taxon 914 correlated 
positively with the composite juvenile arthritis10-joint disease activity score (JADAS10), while 
Campylobacter oral taxon 44 among others, correlated with the number of active joints. Of all 
microbial markers identified, only Bacillus subtilis and Campylobacter oral taxon 44 maintained false 
discovery rate (FDR) < 0.1.  
Conclusions. Several taxa associated with chronic inflammation were found to be associated with 
JIA and disease activity. Our results suggest that oral microbial disruption may be involved in the 
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INTRODUCTION 
Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children, with an 
annual incidence of 1-2 per 1000 children (1, 2). The pathogenesis of JIA remains unknown, although 
environmental triggers of disease in genetically predisposed individuals have been suggested (3). 
Infectious agents are suspected to be environmental triggers for JIA and one of several possible 
mechanisms is molecular mimicry between bacterial molecules and self-antigens. It is well-known 
that host-microbe interaction is important for recognition and development of the immune system (4). 
The human microbiome includes the collective genomes of the microbiota, which is the term for all 
microbes in the body (3). A dysbiotic imbalance in the host microbiota might contribute as a potential 
trigger in the development of immune-mediated diseases, including JIA.  The patterns of the JIA gut 
microbiome reportedly resemble the microbiome associated with other autoimmune diseases such as 
type 1 diabetes, Crohn’s disease and ankylosing spondylitis microbiota (5, 6).The gut microbiome in 
children with JIA is reported to differ from healthy individuals (7-14), where a lower abundance of 
Firmicutes and a higher abundance of Bacteroidetes were found in the gut microbiota of subjects with 
oligoarticular and polyarticular rheumatoid factor (RF) negative new-onset JIA (7). 
Furthermore, Actinobacteria and Fusobacteria have been seen only in subjects with JIA 
while Lentisphaerae is reported exclusively in healthy controls (7). Higher abundance of Bacteroides 
is also seen in enthesitis-related-arthritis (11). In all studies on the gut microbiome in JIA, however, 
no single species has been identified and different studies show changes in different taxa (7-14). 
These studies suggest that dysbiosis in the microbiome with overabundance in pathogenic microbes, 
may result in dysregulation of the immune system through disruption of the integrity of mucosal 
barrier and altered interaction with gut immune cells (15). Aberrations in mucosal homeostasis may 



































































subjects as compared to healthy controls. The increase of urease activity is hypothesized to be the 
result of alterations in the anaerobic bacterial flora (16). It is still an open question whether the 
observed microbial dysbiosis is a cause or an effect of the disease itself.  
The oral microbiome has been proposed to play a role in rheumatoid arthritis by contributing to 
systemic inflammation (17), and may also play a similar role in JIA. Furthermore, dysbiosis and 
periodontitis has been found to be associated to increased severity of rheumatoid arthritis (18). 
Gingivitis or gingival bleeding, which is a reversible inflammation of the gingiva caused by dental 
biofilm accumulation is a prerequisite for progression to periodontitis (19). Gingival bleeding is 
found to be higher in subjects with JIA compared to healthy ones (20, 21). So far, there have been no 
attempts to characterize the salivary oral microbiome associated with JIA with the next generation 
sequencing method (NGS). The aim of this study was therefore to investigate the oral microbiome in 
saliva of children with JIA and relate it to the disease activity including gingival bleeding. 
 
MATERIALS AND METHODS 
Study design and subject recruitment 
The present cross-sectional study is a project within NorJIA, a larger Norwegian prospective multicenter 
cohort study on JIA registered in Clinical Trials.gov (NCT03904459). The clinical and demographic 
data was collected between November 2015 and December 2018 at the Department of Pediatrics and 
Adolescence Medicine, University Hospital North Norway (UNN), Public Dental Service 
Competence Centre of North Norway (PCNN), Tromso, and Haukeland University Hospital Bergen, 
and Oslo University Hospital, Rikshospitalet, Oslo. Informed consent was collected from all study 
participants and the study was approved by the Institutional Medical Research Ethics Committee 
(2015/318). Ninety-three children in total were consecutively recruited; Fifty-nine participants with 
JIA: participants with JIA and newly diagnosed TMJ arthritis (n=15) at the departments above, 
participants with JIA without TMJ arthritis (n=44) at UNN, and healthy controls (HC; n=34) matched 



































































and consisted of children attending the regular Norwegian community dental care. The clinical characteristics of 
the two groups are presented in Table 1. Inclusion criteria for subjects with JIA were fulfillment of the JIA 
classification criteria defined by the International League of Associations for Rheumatology (ILAR) 
(22), and age at the study visit <18 years, with or without arthritis activity in one or both TMJs. Subjects 
on antibiotics prior to sampling were excluded. 
 
Demographics and assessment of JIA disease activity  
Patient demographics, subtype of JIA, duration and onset of JIA, medication, general clinical 
examination, measures of disease activity and severity were collected by pediatric rheumatologists.. 
Number of active joints was defined according to the general definition of arthritis: swelling within a 
joint or limitation in the range of joint movement with joint pain or tenderness (23), while TMJ 
arthritis was based on both clinical signs and symptoms, and MRI imaging. Patient-reported global 
assessment of overall well-being (PRgloVAS) and patient-reported pain (PRpainVAS) within the last 
week on a 10-cm visual analogue scale (VAS) were collected. On this scale, 0 indicates no activity/no 
pain/best global health, and 10 indicate the maximum activity/worst pain/poorest global health, 
respectively. A routine complete blood cell count, including rheumatoid factor (RF) and human 
leukocyte antigen B27 (HLA-B27) was registered. The composite juvenile arthritis disease activity 
score (JADAS10, range from 0 to 40) was calculated as the simple sum of the physician global 
evaluation of overall disease activity on a 10-cm visual analogue scale (VAS),  (MDgloVAS, range 0–10), 
patient-reported global assessment of well-being (PRgloVAS, range 0–10), active joint count (up to 
maximum 10 joints), and the erythrocyte sedimentation rate (ESR) (normalized to 0–10) (24, 25). 
Inactive disease was defined according to the ACR provisional criteria (26) requiring all the 
following: 1) no active joints; 2) no fever, rash, serositis, splenomegaly or generalized 
lymphadenopathy attributable to JIA; 3) no active uveitis; 4) normal ESR or C-reactive protein 




































































Intraoral examination and collection of saliva.  
A modified version of the Gingival bleeding index (GBI) (27) and a modified version of the 
Simplified Oral Hygiene Index (OHI-S) (28) were used (Table 1). For GBI, a dental probe was 
carefully applied without any pain, in the upper part of the gingival sulcus, and then removed without 
doing a horizontal movement along the tooth surface. Bleeding on probing within 10 seconds was 
registered. Angulation of the dental probe of 60 degrees to the vertical axis of the tooth was applied if 
possible. The mesial, distal and central surface of the index teeth 16, 26, 36, 46, 11 and 31 were 
chosen. The number of bleeding tooth surfaces were divided to the total number of tooth surfaces 
examined and finally presented as the mean percentage (%), range 0-100% where a higher percentage 
represents a worse score in bleeding. Gingival bleeding was diagnosed according to a gingival 
bleeding score ≥ 10% (29). 
OHI-S is a sum score of plaque-index and dental calculus index and is presented as a mean score 
index, where a higher index represents a worse score in OHI-S. Plaque-index and dental calculus 
index is the buccal scores + the lingual scores divided by the total number of examined buccal and 
lingual surfaces.  OHI-S was not calculated in children with orthodontic appliances and subgingival 
status was not evaluated. All children ≥12 years filled out an oral health related questionnaire and the 
parents/proxies filled out for children <12 years. One of the questions were; How often do you brush 
your teeth: 1, never 2, most days 3, once daily 4, twice daily or more. 
Two calibrated specialists in oral and maxillofacial surgery and pediatric dentistry (PF, JH) collected 
before oral examination, unstimulated whole saliva (UWS) for 6 minutes and paraffin chewing 
stimulated whole saliva (SWS) for 3 minutes, according to a standardized protocol (i.e. restrictions to 
food and drinks 2 hours prior to sampling). Furthermore, medications taken the same day or the day 
before sampling was recorded. Only SWS were used for microbial analyses. Immediately after 






































































Seven-hundred and fifty microliters from each SWS sample was mixed with an equal amount of 
phosphate buffer saline (PBS) and spun down at 9600 g for 5 minutes, before the supernatant was 
carefully removed. The pellet was resuspended in 155 mL PBS and 25 mL MetaPolyzyme multilytic 
enzyme mix (Zigma-Aldrich, USA) and incubated on a 37o C heat block for 4 hours, for digestion of 
the bacterial cell wall. The digests were then transferred to a QIAcube (Qiagen, Hilden, Germany) for 
DNA extraction using preprogramed protocol using the QIAamp DNA Mini Kit (Qiagen, Germany) 
with 100 μL elution volume.The quality of the isolated DNA (high molecular weight and non-
fragmented DNA) was assessed by running extracted DNA samples on agarose gel (1%) with 1kb 
ladder (Termo Fisher Scientific, Invirtogen, USA). The amount of yield DNA was then measured 
using Invitrogen Qubit 3.0 Fluorometer (Termo Fisher Scientific, Invirtogen, USA) according to the 
manufacturer’s instructions. 
 
16S rRNA sequencing and bioinformatic analysis  
16S rRNA gene library preparation and sequencing were done at the Australian Center for 
Ecogenomics (Brisbane, Australia) as detailed previously (30). Briefly, the V1-3 region was amplified 
using the degenerate primers 27FYM (31) and 519R (32) in standard PCR conditions. The amplicons 
(~ 520 bp) were purified and indexed with unique 8-base barcodes in a second PCR. The tagged 
libraries were then pooled together in equimolar concentrations and sequenced using MiSeq v3 2x300 
bp chemistry (Illumina, USA). Preprocessing of data (merging of reads, primer trimming, quality-
filtration, alignment and chimera removal) was performed as detailed elsewhere (33). The high quality, 
merged reads were assigned species-level taxonomies using our BLASTn-based algorithm (33, 34).  
The resultant microbial profiles were used as input to QIIME (Quantitative Insights Into Microbial 
Ecology) software package version 1.9.1 (35) for downstream analysis including subsampling, 
generation of taxonomy plots/tables and rarefaction curves, and calculation of species richness, 



































































(PCoA) was used for clustering samples based on overall microbial similarity, while Linear 
discriminant analysis (LDA) effect size (LEfSe) (36) was used to detect differentially abundant taxa 
between the groups. To assess the association between the bacterial profiles and disease activity 
(JADAS10 and number of active joints) a Spearman correlation matrix was computed with R package. 
Correlations with P-value ≤ 0.01 were considered significant.  
 
Statistical and bioinformatic analyses 
For description of clinical and demographic data, median (IQR), mean (standard deviation) and 
frequencies (percentage) were used. Associations between study participants with JIA and HC and 
different disease characteristics were analyzed by chi-square test for categorical variables (Fisher´s 
exact test) and Student´s t-test for continuous variables if reasonably normally distributed, otherwise 
Man-Whitney U test was used. A multivariable logistic regression analysis was performed to adjust 
for OHI-S, age and gender in the association between JIA and GBI. A P-value ≤0.05 was considered 
statistically significant for clinical parameters. For testing correlation between species and measures 
of disease activity (JADAS10, number of active joints), p-values were adjusted for multiplicity with 
Benjamini-Hockberg method (FDR ≤0.1).   
 
RESULTS 
Demographic and disease activity parameters 
Demographics and disease activity parameters for the group with JIA, and HC are given in Table 1. 
There was a female predominance in both groups, and RF negative polyarthritis was the most 
common category among children with JIA (25%). The simplified oral hygiene index (OHI-S) was 
significantly higher among children with JIA with median 0.5 (IQR 0.3-0.7) compared to median 0.3 
(IQR 0.0-0.4) in HC. Also, the plack-index (PI) was higher in JIA (Table 1). There was also 
significantly higher modified gingival bleeding index (GBI) in the group with JIA with median 22 



































































JIA and GBI when adjusting for OHI-S (Supplementary Table 1). Within the JIA group no 
significant differences in GBI were found between subjects without DMARDs, on methotrexate or on 
biologics, with GBI median 10 (IQR 10-30) %, median 20 (IQR 10-40) %, and median 30 (IQR 20-
40) %, respectively. There was no difference in frequency of tooth brushing between participants with 
JIA and HC, in JIA 37 of 47 (79%) and in HC 23 of 32 (72%) brushed their teeth twice or more daily.  
Restrictions to food and drinks 2 hours prior to saliva sampling were reported in 41 of 93 study 
participants (44%). In 10 of 93 (11%) no restrictions were reported and in 42 of 93 (45%) information 
on restrictions were not available. Among the 93 participants 16 reported intake of no-DMARD 
medications, 3 methotrexate, and 6 biologics the same day or the day before saliva sampling.  
 
Sequencing and data processing statistics 
The raw data has been deposited and is publicly available from SRA (# PRJNA605805). A total of 
~8.2 million sequences were obtained (range of 30,113-526,987 reads per sample), of which about 
85% were successfully merged; however, only 35% were retained after quality filters and 20% after 
chimera removal. Of the high-quality, non-chimeric reads, 88% could be assigned species-level 
taxonomy (mean of 15,360± 18368 reads per sample). Details of the reads statistics before and after 
each quality control step are provided in Supplementary dataset 1.  
 
Overall microbial profile 
Using a minimum count of 100 reads per species as cutoff, a total of 216 bacterial species belonging 
to 58 genera and 8 phyla were identified across all samples; the relative abundances and detection 
frequencies of these taxa in each sample is provided in Supplementary dataset 2, 3 and 4 
respectively. On average, 134 species (range 90-186) and 45 genera (range 32-58) were detected per 
subject.  Fifty-seven species and 29 genera were identified in more than 90% of the samples and can 
be defined as core salivary taxa. The average relative abundances of all phyla, top genera and species 



































































shown in Figure 1. Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria, and Fusobacteria were 
the major phyla in order accounting for more than 98% of the reads. Thirteen genera accounted for 
90% of the average microbiome, with Prevotella, Streptococcus, Haemophilus, Actinomyces, 
Porphyromonas and Rothia alone making up ~ 70%. At the species level, Prevotella melaninogenica, 
Haemophilus parainfluenzae, Rothia mucilaginosa, Porphyromonas sp. oral taxon 279, Prevotella 
histicola, Actinomyces odontolyticus were the most abundant species, constituting around 40% of the 
microbiome on average. 
 
Bacterial diversity and differentially abundant species  
There were no significant differences between children with JIA and the healthy group neither in 
species richness and alpha diversity, or in PCoA (beta diversity) as shown in Figure 2. However, 
differential abundance analysis did reveal significant differences (Figure 3). At the phylum level JIA 
was associated with enrichment of Spirochaetes and Saccharibacteria and depletion of Proteobacteria. 
Genera TM7-G1, Solobacterium and Mogibacterium were associated with JIA, while Haemophilus 
and Bacillus were associated with healthy subjects (Figure 3B).  Haemophilus parainfluenzae, 
Leptotrichia species oral taxon 223, Haemophilus pittmanae, Prevotella denticola and Bacillus 
subtilis were key bacterial species associated with the healthy group, whereas the JIA group showed 
higher abundance of 11 bacterial species of which Leptotrichia species oral taxon 417, TM7 G1, 
Capnocytophaga species oral taxon 864, Veilonella atypica and Mogibacterium diversum were most 
enriched (Figure 3C).  
The relative abundances of the top six differentially abundant taxa (based on LDA score) are shown 
for individual samples in Figure 4. These microbial associations between the JIA and the healthy 
group were independent of the differences between the two groups in GBI. The microbial 
associations with the GBI are shown in Supplementary Figure 1.  Notably, after adjustment of p-



































































subtilis maintained a false discovery rate (FDR) of ≤ 0.1 and the per-sample relative abundance plot 
for B. subtilis is shown in Supplementary Figure 2. 
 
Microbial association with disease activity 
Correlation analysis revealed significant association between a group of bacteria species and disease 
activity (Figure 5). Gemella morbillorum, Leptotrichia sp. oral taxon 498 and Alloprevotella oral 
taxon 914 correlated positively with the JADAS10, primarily through their association with 
MDgloVAS.  G. morbillorum also correlated with PRgloVAS. Several species correlated positively 
with the number of active joints but Campylobacter oral taxon 44 showed the strongest association 
and was the only species that maintained FDR ≤ 0.1 when P-values were adjusted for multiplicity 
with the Benjamini-Hockberg method.   
JIA subjects with TMJ arthritis showed a different microbial association compared to JIA subjects 
without TMJ arthritis (Figure 6).  Haemophilus parainfluenzae, Prevotella pallens, actinomyces 
species oral taxon 180 were the top species differentially enriched in JIA with TMJ subjects. 
Campylobacter oral taxon 44 also showed an association with TMJ arthritis (Supplementary Figure 
3), although opposed to its association with the number of active joints, it did not maintain FDR ≤ 
0.1. Rothia mucilaginosa, Atopobium parvulum and Oribacterium sinus were significantly more 




This study is to our knowledge, the first to examine the salivary oral microbiome in subjects with JIA 
and healthy controls using the NGS method. We found no significant differences between children 
with JIA and HC in species richness or in PCoA, i.e. alpha or beta diversity. Differential abundance 
analysis, however, revealed that JIA was significantly associated with taxa associated with chronic 
inflammation, and that several of these species including Campylobacter oral taxon 44 correlated 



































































A strength of the study is that a majority of the children with JIA were females diagnosed with either 
oligoarthritis persistent or RF negative polyarthritis in accordance with most population-based 
studies, pointing to representability of our study cases. The oral environment is a complex 
environment that contains distinct microbial niches each with its distinct microbial inhabitant. One 
can argue that salivary microbiome represents oral microbiome but a limitation is that we did not 
sample multiple oral sites to study the full spectrum of the oral microbiome. In contrast to our study 
Grevich et al performed sampling from the dental plack when studying the oral microbiome in JIA 
(37). Additionally, our findings must be evaluated in the context of a limited sample size and being a 
cross-sectional study. In our study, saliva samples for collecting oral microbiota were directly frozen 
and aliquoted before further processing. However, other collection methods for sampling of oral 
microbiota, such as mouthwash sampling methods are available (38) and appear to be stable 
concerning bacterial diversity at ambient temperature after 4-7 days, thus making immediately 
freezing of microbial DNA not necessary. Some distinct differences in relative abundance of specific 
microbial taxa are seen between these methods compared to samples that are frozen immediately 
(38), thus indicating that directly freezing of samples is still the best choice. Other strengths with this 
study are the food and drinks restrictions prior to sampling taken in 41 of 93 children, and that a 
majority of the participants had no intake of systemic medication the same day or the day before 
saliva sampling. In our study between 90 and 186 different species were found in the salivary 
microbiome of the study subjects with fifty-seven species shared in more than 90% of the subjects. 
The core salivary microbiome in the study subjects comprised 22 species detected in all individuals. 
In other studies the core microbiome was found to be similar or even in a lower number (39, 40). 
The predominant bacterial genera found in the salivary microbiome in both JIA and healthy saliva 
in our study consisted of Prevotella, Streptococcus, Haemophilus, Actinomyces, Porphyromonas and 
Rothia, which is similar to other studies in both children with JIA and healthy (41). The microbial 
diversity and richness of the salivary oral microbiome between the JIA and healthy controls were 



































































subjects with chronic inflammatory diseases, i.e. rheumatoid arthritis, and healthy controls (42, 43). 
Differential abundance analysis revealed several taxa to be associated with or depleted in JIA. At 
phylum level, we found an overabundance of Spirochaetes and Saccharibacteria and depletion of 
Proteobacteria. This is in line with Xu et al. showing Proteobacteria (Neisseria) and Firmicutes 
(Selenomonas) as a healthy core salivary microbiome, together with the phyla Bacteroidetes 
(Porphyromonas). They also showed that the salivary microbial composition shifts with aging in 
children, and a strength of our study is age-matching between children with JIA and healthy controls 
(44).  
At the genus level, Haemophilus, Bacillius and Olsenella were depleted from the subjects with JIA 
while there were significant overabundance of bacteria known to be associated with chronic 
inflammation, such as TM7-G1, Solobacterium and Mogibacterium (45-47). The higher abundance of 
Haemophilus parainfluenzae, Leptotrichia species oral taxon 223, Haemophilus pittmanae, 
Prevotella denticola and Bacillus subtilis in the healthy group in our study could highlight the 
importance for health of sustaining a high proportion of these species in the oral microbiome. In fact, 
Bacillus subtilis species has been reported to have a role in limiting inflammatory response by down-
regulation of the pro-inflammatory interleukin-8 production and up regulation of inducible nitric 
oxide synthase (iNOS) protein levels (48) . The depletion of Haemophilus species in salivary 
microbiome has also been reported in subjects with rheumatoid arthritis (49).  On the other hand 
Leptotrichia species oral taxon 417, TM7 G1, Capnocytophaga species oral taxon 864, Veilonella 
atypica and Mogibacterium diversum were found to be highly abundant in children with JIA. The oral 
taxon TM7 has been associated with chronic inflammation (50). In line with our study, Grevich et al 
found depletion of genera Prevotella (phylum Bacteroidetes) in JIA, but they report an overabundance 
of the genera Haemophilus and Kingella (phylum proteobacteria) in JIA, which was not found in our 
study (37). 
The role of oral and gut microbiota in many inflammatory diseases has been suggested, and there is 



































































molecular mimicry between a peptide from the von Willebrand factor type A from the oral 
microbe Capnocytophaga ochracea can be attributed to the activation of the Sjögrens syndrome 
antigen A/Ro60-Reactive T cells (51).  
Interestingly, in our study Campylobacter oral taxon 44 showed a strong correlation with the number 
of joints affected in subjects with JIA.  Campylobacter has a well-known association with reactive 
arthritis and other inflammatory diseases in both children and adults (52). Dong et al. found in the gut 
microbiota in 32 patients with JIA a positive correlation between disease activity and increased 
abundance of Firmicutes, Bacteroidetes and Bacteroidaceae at the phyla level (14). The same authors 
found a negative correlation between disease activity and decreased abundance of Ruminococcaceae, 
Faecalibacterium, Proteobacteria or Enterobacteriaceae (14). 
The species found in our study on the salivary oral microbiome in JIA are not found in studies on the 
gut microbiome in JIA (7-14). However, disruption of microbial ecology was found and this 
dysbiosis may have community effects on the host more powerful than the actions of just one single 
microbe (53). This is in line with Dijkhuizen et al. reporting dysbiosis in subjects with JIA in gut 
microbiota compared to healthy controls. They also found that age and geographic origin were 
connected to microbiota profiles (13). In rheumatoid arthritis both oral and gut dysbiosis are well 
described and no consistent single bacterial species appears to be the causing agent (54), even if 
periodonto-pathogenic bacteria such as Porphyromonas gingivalis have been suggested to contribute 
to generation of anti-citrullinated protein antibodies (ACPAs) in rheumatoid arthritis (55-57). In 
addition, dysbiosis and periodontitis were found to be associated to increased severity of rheumatoid 
arthritis (18). Other factors reported to be associated with dysbiosis are diet, lifestyle and drug use, 
especially the use of antibiotics (58, 59). Early life antibiotic use is shown to increase the risk of 
developing JIA later in life, and may predispose due to a shift in microbiota composition (59, 60). In 
our study none of the participants were on any antibiotics prior to sampling, but previous history of 



































































The significantly higher gingival inflammation found in patients with JIA compared to healthy 
controls is in line with other studies investigating JIA and oral health (20, 21, 37, 61, 62) but also in 
contrast with some studies finding no significant difference between JIA and healthy (63-69), 
depending on different study design and measurement of gingival inflammation (70). Despite higher 
GBI, no difference in frequency of tooth brushing was found between JIA and healthy controls in our 
study. After adjusting for dental plack and calculus (OHI-S), JIA was not found to be a predictor for 
gingival inflammation in terms of higher GBI. In line with other studies (65) we found OHI-S to be a 
predictor for gingival inflammation. There were no overlap between overabundant bacteria associated 
with GBI and those associated with JIA. This may be explained by the disruption of microbial taxa in 
JIA and not by specific bacteria, resulting in more gingival inflammation in JIA. Furthermore, we did 
not sample for microbiota in dental plack but in saliva.  
There are some indications that the biologic agent etanercept might reduce periodontal inflammation 
in children with JIA (68). In our study 40% of the subjects with JIA were on biologic treatment either 
alone or in combination with methotrexate, but no significant differences were seen in GBI between 
the different medication groups. Instead, children with JIA had more gingival bleeding compared to 




Taxa associated with chronic inflammation was found to be enriched in the saliva of children with 
JIA and associated to disease activity. This disrupted microbial ecology may have triggered a local 
pathological immune response resulting in increased gingival bleeding in JIA. Prospective cohort-
studies with treatment-naïve patients with new onset JIA are warranted to further elucidate the role of 
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Figure 1. Microbiological profiles. DNA extracted from saliva was sequenced for the V1-V3 region 
of the 16S rRNA gene using paired-end chemistry. The generated reads were merged, quality-filtered 
and classified to the species level using a BLASTn-based algorithm. The stacked bars show the 
average relative abundances of all phyla and top genera and species (those with relative abundance ≥ 
1%) identified in the study groups. OT: oral taxon. 
 
Figure 2. Species richness and diversity. Taxonomic profiles were rarified and used to calculate 
observed richness, expected richness (Chao index), alpha diversity indices (Shannon’s and 
Simpson’s) and distance matrices employing standard QIIME scripts. Left: Box and whisker plots of 
species richness and aloha diversity in each group. Differences were not significant by Mann–
Whitney U test. Right: Clustering of samples with PCoA based on abundance Jaccard distance 
matrix. Plots were generated with QIIME and R Package. 
 
Figure 3. Differentially abundant taxa. (a) Phyla, (b) Genera and (c) species that showed 
significant differences in relative abundance between the two study groups as identified by linear 
discriminant analysis (LDA) effect size analysis (LEfSe) – 2.5 LDA score cutoff. OT: oral taxon. ** 
FDR ≤ 0.1 (Benjamini-Hochberg method).  
 
Figure 4. Per sample abundance plots. Relative abundances of top six differentially abundant 
species (based on LDA score) in individual samples. OT: oral taxon. ** FDR ≤ 0.1 (Benjamini-
Hochberg method). 
 
Figure 5. Heatmap of the microbial association with disease activity.  A Spearman correlation 



































































significant. The r-value for nonsignificant correlations was set to zero (blue on the heatmap). OT: 
oral taxon. ** FDR ≤ 0.1 (Benjamini-Hochberg method).  
 
Figure 6. Differentially abundant taxa by TMJ arthritis. (a) Phyla, (b) Genera and (c) species 
that showed significant differences in relative abundance between the JIA subjects with and without 
TMJ involvement, as identified by linear discriminant analysis (LDA) effect size analysis (LEfSe). 






















































































Supplementary figure 1. Heatmap of the microbial association with GBI.  A Spearman 
correlation matrix was computed using R package. Correlations with P-value ≤ 0.01 were considered 
significant.  
 
Supplementary figure 2. Per sample abundance plots for Bacillus subtilis. Relative abundances 
of Bacillus subtilis in individual samples by disease status (left) and TMJ involvement status (right).  
 
Supplementary figure 3. Per sample abundance plots for Campylobacter sp. oral taxon 44. 
Relative abundances of Campylobacter sp. oral taxon 44 in individual samples by TMJ involvement 
status.  
 
Supplementary Dataset1. Sequencing and data processing statistics.   
 
Supplementary Dataset 2. Relative abundances and detection frequencies of phyla identified in the 
individual samples.  
 
Supplementary Dataset 3. Relative abundances and detection frequencies of genera identified in 
the individual samples. 
 
Supplementary Dataset 4. Relative abundances and detection frequencies of species identified in 
















































































Supplementary table 1. Clinical characteristics associated with gingival bleeding (gingival bleeding 
index (GBI) ≥10%)* 
 
 Gingival bleeding (n=41) 
 
 
Crude OR (95% CI) p-value Adjusted OR (95% CI) p-value 
JIA 4.8 (1.7-14.0) 0.004 2.9 (0.9-9.5) 0.07 
Age 0.9 (0.7-1.2) 0.651 0.9 (0.7-1.2) 0.578 
Gender (female) 
 
0.9 (0.3-3.1) 0.917 0.8 (0.2-2.8) 0.688 








































































































Table 1. Demographic and disease activity characteristics among children with juvenile idiopathic 











Female, no. (%) 
 







Age at sampling, years 12.6 ± 2.7 12.3± 3.0  0.650b 
Age at onset 6.0 (2.0-10.0)   - 
 
Geographics, no (%) 
    
Troms county 34 (57.6) 34 (100)  - 
Finnmark county 17 (28.8)   - 
Nordland county 5 (8.5)   - 
Eastcoast county 2 (3.4)   - 
Westcoast county 1 (1.7)   - 
 
Disease duration, years  
 
5.0 (3.0-10.0) 
  - 
 
JIA category, no. (%)  
    
Persistent oligoarthritis 11 (189)   - 
Extended oligoarthritis 13 (22)   - 
Polyarthrtitis RF pos 3 (5)   - 
Polyarthrtitis RF neg 15 (25)   - 
Systemic arthritis 0 (0)   - 
Psoriatic arthritis 3 (5)   - 
Enthesitis related arthritis 7 (12)   - 
Undifferentiated arthritis 7 (12)   - 
 
Gingival bleeding index, %  
 
22 (6-44) (n=44) 
 







Simplified oral hygiene index (IQR) 0.5 (0.3-0.8) (n=43) 0.3 (0.0-0.4) (n=25)  0.002
b
 
Plack-index, % (IQR) 
 
0.5 (0.3-0.8) (n=43) 0.3 (0.0-0.3) n=25)  0.001
b
 
Disease activity variables**     
JADAS10 12.8 (7.6-18.0) n=48    
Subjects with active disease, no. (%) 44 (74.6)   - 
Subjects with active joints, no. (%) 23 (39.0)   - 
Subjects with TMJ arthritis, no. (%) 15 (25.4)   - 
Subjects with IACs to the TMJ, no. (%) 8 (13.6)   - 
No.of active joints 0.0 (0.0-1.0)     
MDgloVAS 2.5 (1.0-5.0) (n=58)    
PRgloVAS 2.5 (0.5-4.0) (n=49)    
HLA-B27 positive, no (%) 20 (36.4) (n=55)   - 
Rheumatoid factor positive, no (%) 1 (2.0) (n=51)   - 
 
Type of Medication  
    
No DMARDs, no (%)*** 15 (25)    
Methotrexate, no (%) 20 (34)    - 
Biologics comb, no (%)**** 24 (41)   - 
 
Values are the median (IQR) unless indicated otherwise. aChi-square test. bWilcoxon-Mann-Whitney test. *P <0.05 for 
statistical significance. ** remission status according to the ACR provisional remission criteria (26); ***NSAIDs and/or IACs; 
****current or previous use alone or in combination with other DMARDs; JIA, juvenile idiopathic arthritis; JADAS10, the 
composite juvenile arthritis10-joint disease activity score; TMJ, temporomandibular joint; MDgloVAS, medical doctor global 
assessment of well-being; PRgloVAS; patient reported global assessment of well-being; IACs, intraarticular corticosteroid 


















































































































































































































































































































































































































































Supplementary Figure 1. 
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Abstract 
Background. Intraarticular corticosteroids (IACs) have been used to treat temporomandibular 
joint (TMJ) arthritis. However, prospective clinical studies with magnetic resonance imaging 
(MRI) scoring are lacking. The aim of this study was to examine efficacy and safety of a single 
IAC in the TMJ in adolescents with juvenile idiopathic arthritis (JIA) in a clinical setting.  
Methods. In this Norwegian prospective multicenter pilot study 15 patients with JIA (mostly 
persistent oligo-arthritis or RF negative polyarthritis categories) and a clinically and MRI-
verified diagnosis of TMJ arthritis were treated with IACs and followed for two years. 
Demographics, systemic medication, general disease activity and outcome measures were 
recorded including a pain-index score and maximal incisal opening (MIO). Inflammation and 
bone damage scores were assessed, using two recently published MRI scoring systems with 
masked radiological evaluation. 
Results. Among the 15 patients, 13 received a single IAC (5 bilateral), and 2 repeated IACs 
once unilaterally. Thus, the total number of IACs was 22. Median age was 15 years and the 
majority had an age not thought of as critical regarding mandibular growth retardation due to 
steroid injection. During the 2-year observation period systemic medication with disease 
modifying antirheumatic drugs (DMARDs) including biologics was initiated or adjusted in 
10/15 (67%) patients. At the 2-months study visit after injection we observed a minimal 
improvement in MIO from median 44 (1st, 3rd quartiles; 36, 48) mm to 45 (43, 47) mm, p= 
0.045 and decreased MRI mean additive inflammatory score from 4.4±1.8 standard deviations 
(SD) to 3.4±2.0, p= 0.040. From baseline to the 2-months follow-up pain improved in 6/11 
patients but pain scores were not significantly improved. MRI-assessed damage increased in 
two patients with repeated IACs, and decreased in 3 patients but most of the patients were 
stable over the 2-year follow-up. Intra-rater repeatability of the MRI scoring system domains 
varied from poor to excellent. 
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systemic treatment we observed improvement in MRI-assessed inflammation, mostly stable 
condylar bone conditions and minimal clinical improvement in adolescents with JIA and TMJ 
arthritis. No side effects were seen.  
 
Keywords: Juvenile idiopathic arthritis, Temporomandibular joint, Intraarticular corticosteroids, 





The temporomandibular joint (TMJ) is one of the most commonly involved joints in children 
with juvenile idiopathic arthritis (JIA), and may lead to impaired joint function, pain, growth 
impairment with dentofacial deformities (1-4), a reduced posterior airway space with related 
comorbidities (5, 6), and impaired quality of life (7). The rate of TMJ arthritis varies 
significantly (40-90%) in different JIA-cohorts using magnetic resonance imaging (MRI) (8-10), 
as reviewed by Larheim et al (11). TMJ arthritis may be clinically silent with symptoms and 
signs seen only late in the disease course (3). The diagnostic assessment is therefore a particular 
challenge (12).  
Both systemic and local treatments have been used in patients with TMJ arthritis (13, 14). 
Several observational studies report short-term effect of intraarticular corticosteroid injections 
(IACs) to the TMJ on pain and maximal incisal opening (MIO) (15-20). It has also been shown 
that the IACs can be safely performed by trained specialists with or without imaging guidance 
(16, 18). However, treatment with IACs has been suspected to inflict rather than improve 
mandibular growth impairment (21, 22).   
Retrospective studies with observation periods ranging from mean 2 to 23 months show a highly 
variable rate of improvement in MRI-assessed inflammation (18-83%) in TMJs receiving IACs, most 
often with stable condylar status on MRI (15, 16, 23-25). However, according to Stoustrup et al. (26) 
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studies are mostly retrospective and single center case-series, and the outcome assessors are not masked 
regarding pre- or post-treatment assessments. Randomized controlled trials are lacking, and systematic 
prospective follow-up studies with validated clinical assessments tools and imaging scoring systems are 
also missing. To our knowledge, there are no prospective studies with masked standardized MRI 
assessment addressing safety and efficacy of IACs in the TMJ in JIA. Therefore, the aim of this 
Norwegian 2-year prospective multicenter pilot study of adolescents with JIA and TMJ arthritis 
was, by using validated clinical outcome measures and two newly published MRI scoring 
systems, to assess efficacy and safety of single IACs in the TMJ in terms of (i) reducing pain and 
improving maximal mouth opening capacity, and (ii) reducing joint inflammation and bone damage. 
 
MATERIAL AND METHODS 
Study design and patients 
This 2-year prospective multicenter-study of IACs in adolescents with JIA and TMJ arthritis, is 
part of a larger Norwegian prospective multicenter cohort on JIA (www.norjia.com). The 
terminology adheres to TMJaw (earlier EuroTMJoint) consensus-based standardized 
terminology (28). Clinical and demographic data were collected between November 2015 and 
September 2019 at the Department of Pediatrics, University Hospital North Norway Tromsø, 
Public Dental Service Competence Centre of North Norway, Tromsø, Haukeland University 
Hospital Bergen, and Oslo University Hospital, Rikshospitalet, Oslo.  
Fifteen adolescents with JIA were consecutively recruited and a total of 22 TMJ injections with 
corticosteroids were performed. No control group was included due to ethical reasons. TMJ 
arthritis was defined as “clinical signs of pain on jaw movement, limitation of MIO, limitation of 
laterotrusive- or protrusive jaw movements or dentofacial growth disturbances and MRI signs of 
TMJ-arthritis (i.e. active inflammation in the TMJ based on increased contrast enhancement, 
bone marrow edema and/or effusion). Inclusion criteria were patients fulfilling the JIA diagnosis 
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Rheumatology (ILAR) (12), age <18 years, and arthritis in one or both TMJs. Exclusion criteria 
were contraindications to MRI such as cardiac pacemaker, metallic clips, contrast allergy etc. or 
previous TMJ IACs within the last 3 years. The included patients had a clinical examination and 
a MRI at baseline before the TMJ IACs were performed, and at follow-up visits after 1-3 
months, 1 year and 2 years. 
 
Clinical variables, TMJ examination, and assessment of disease activity  
Demographics, systemic medication, JIA category, disease onset and course type of JIA, 
medication, and a general clinical examination including number of joints with active arthritis, were 
registered by specialists in pediatric rheumatology at each study visit. The physician global evaluation of 
overall disease activity on a 10-cm visual analogue scale (VAS) (MDgloVAS) was also assessed at the 
visit. The specialists were calibrated by thorough discussions of all study variables assessed in the NorJIA 
study and the present NorJIA TMJ injection substudy. Patient-reported global assessment of overall 
well-being (PRgloVAS) and patient-reported pain (PRpainVAS) within the last week on a 10-
cm VAS were also collected. On these scales, 0 indicates no disease activity/no pain/best 
overall well-being, and 10 indicate the maximum disease activity/worst pain/poorest overall 
well-being, respectively (29). Number of active joints other than the TMJ was defined 
according to the clinical definition of arthritis: swelling within a joint or limitation in the range 
of joint movement with joint pain or tenderness (30). 
Clinical TMJ examination was performed by either a specialist in oral and maxillofacial surgery or a 
specialist in pediatric dentistry (PF, AR, JRB, JH) according to the DC / TMD examination and 
diagnostics protocol (31) and EuroTMJoint Clinical Recommendations protocol (32). The two 
examiners were calibrated repeatedly during the study period (33). The TMJ clinical outcomes 
for this study were: 1, Pain-index score (i.e. pain frequency last 2 weeks x pain intensity last 2 
weeks (VAS 0-10)) scored by the patient, 2, Maximal incisal opening (MIO) in mm scored by 
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patient was registered. 
A routine complete blood cell count, erythrocyte sedimentation rate (ESR) (mm/hour), and C-
reactive protein (CRP) (<5mg/l was set as 0) was obtained. Rheumatoid factor (RF) 
immunoglobulin M was analyzed twice more than three months apart. The composite juvenile 
arthritis disease activity score (JADAS10, range from 0 to 40) was assessed, based on the 
MDgloVAS (range 0–10), PRgloVAS (range 0–10), active joint count (maximum 10 joints), 
and the ESR (normalized to 0–10, <10 mm/h was set as 0)) (29, 34). Disease status was defined 
as either active disease, inactive disease, clinical remission on medication, or clinical remission 
off medication according to the ACR provisional criteria (35); inactive disease requiring all the 
following: 1) no active joints; 2) no fever, rash, serositis, splenomegaly or generalized 
lymphadenopathy attributable to JIA 3) no active uveitis; 4) normal ESR or CRP; 5) 
MDgloVAS =0; and 6) duration of morning stiffness of ≤15 minutes. Side effects were 
assessed and registered as per protocol at each study visit, including any signs of infection, 
bleeding, skin atrophy, facial palsy, or intraarticular calcifications on MRI. 
 
MRI method and outcomes 
Fifty-seven examinations were obtained on either 3-T-units (Magnetom Skyra, Siemens 
Healthcare, Erlangen, Germany) using a 64-channel head/neck coil (n=50) or a 1.5-T-unit 
(Magnetom Aera or Avanto, Siemens Healthcare, Erlangen, Germany) using 4-channel special 
purpose coils (n=7), according to protocol A or B, respectively. As a minimum the protocols 
included water-sensitive images, pre- and post-contrast T1-weighted images and one sequence 
with the mouth in the open position. Details are provided in Supplementary table 2. One 
examination had susceptibility artefact-reducing sequences (WARP).  The contrast medium 
given was 0.2 mL/kg (0.1 mmol/kg) body weight gadoterate meglumine (Dotarem, Guerbet, 
Paris, France). None of the patients needed sedation. All examinations were reviewed on a 
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two experienced specialists in radiology (TAL, TAA) at random order, masked for personal 
data, injection laterality and time point. One examination from each subject was randomly 
selected for a second reading after an interval of approximately three months.  
The image outcomes were based on inflammation and bone damage according to the two newly 
published MRI scoring systems for evaluating TMJ arthritis as described by Tolend et al. (36, 
37) and Kellenberger and Lochbuhler et al. (38, 39). The scoring systems were thoroughly 
discussed between the radiologists before the reading session. Total scores ranged from 0-8 for 
the Additive inflammatory domain (bone marrow edema (absent/present 0/1), bone marrow 
enhancement (absent/present 0/1), joint effusion (absent/small/large 0/1/2), synovial thickening 
(absent/mild/moderate, severe 0/1/2), joint enhancement (absent/mild/moderate, severe 0/1/2)) 
and 0-5 in the Additive damage domain (condylar flattening (absent/mild/moderate, severe 
0/1/2), erosions (absent/mild/moderate, severe 0/1/2), disc abnormalities (absent/present 0/1)), 
and 0-4 in the Progressive scoring system: Progressive inflammation (no inflammation/mild/ 
moderate/severe/pannus 0/1/2/3/4) and Progressive osseous deformity (normal/mild/moderate/ 
severe/destruction 0/1/2/3/4). The scores were set as missing if the images were not of 
sufficient quality due to braces or other artefacts. In case of bilateral injection, the joint with the 
most severe inflammation/bone damage was chosen for statistical analysis.  
 
Injection procedure 
The preauricular skin was disinfected with 70% ethanol and 5% chlorhexidine, before local 
anesthesia with an auriculotemporal nerve block was applied. The push-pull technique, and the 
amount of recovered synovial fluid in each sample was quantified with the hydroxocobalamin 
method, as described by Alstergren et al (40, 41). A washing solution consisting of 22% 
hydroxocobalamin (Behepan® 1mg/ml) in physiological saline (sodium chloride 9 mg/ml) was 
used. The TMJ was injected with a total of 4 ml washing solution through a stop-cock syringe. 
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fluid as possible was aspirated back. This procedure was repeated a total of three times for each 
joint leaving the same cannula inside the joint. If aspiration of the washing solution was possible 
and the resistance in the syringe was minor during injection, then the needle tip was considered 
to be placed within the joint space. After sampling of synovial fluid from the upper joint 
compartment, steroids were injected according to the landmark guiding or ultrasound guiding 
technique. Two different types of steroids were used: methylprednisolone acetate 
(Depomedrol®) and triamcinolone hexacetonide (Lederspan®). The following dosages were set: 
patients >30kg: 0.4ml triamcinolone hexacetonide 20mg/ml and children <30kg: individual 
dosage. In 15 TMJs a syringe of 25G 0.5 x 25mm and in 7 TMJs a syringe of 23G 0.6 x 30mm 
was used for the injection. The injection procedure was performed by experienced specialists in 
oral and maxillofacial surgery at all centers (PF, AR, JRB). The results of the synovial fluid 
analyses will be published in a separate paper. 
 
Statistical analyses 
For description of clinical and demographic data, median (1st, 3rd quartiles), mean (standard 
deviations (SD)) and frequencies (percentage) were used as appropriate. For the not normally 
distributed data of MRI-scoring mean (SD) was used for more informative description of the 
values. Multiple testing of four time-points and Bonferroni correction for 6 comparisons with a 
p-value <0.008 was analyzed and considered, but found to be less informative than testing for 
two time-points; with differences between baseline and 2-months, and 2-year follow-up 
because of some missing data at different follow-up time-points, varying number of follow-up 
visits from 2-4, together with the low number of participants. Based on previous studies (15, 16, 
23-25) and clinical experience we chose to assess change in clinical parameters (MIO and pain 
index) and change in the MRI inflammatory scores mainly between baseline and 2-months, 
while change in MRI osseous deformities and damage scores was assessed between baseline 
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When testing continuous data for differences between baseline and 2-months, and 2-year 
follow-up, the Wilcoxon Signed Ranks Test was used for not normally distributed data. For 
nominal data tested for differences between baseline and 2-months, and 2-year follow-up 
McNemar Chi-square test was used, and for ordinal data Wilcoxon signed rank test. A p-value 
<0.05 was considered statistically significant. For description of outcome after receiving IACs 
at the different time-points in Figure 1, percentage of patients were used for absolute 
improvement of the variables pain, MIO and MRI. For the MRI assessment, the intra-observer 
consensus agreement for the MRI-scoring was assessed with Cohen’s kappa: poor (0.01-0.20), 
fair (0.21-0.40), moderate (0.41-0.60), substantial (0.61-0.80) and almost perfect (0.81-1.00) 
agreement. Statistical analysis was performed using SPSS software, versions 25 or 26.  
 
RESULTS 
Demographic and disease activity parameters 
Demographic and disease activity characteristics at baseline are given in Table 1. In total 15 
adolescents were included and 22 TMJ injections were performed in this study. Among the 15, 
80% were female and the median (quartiles) age at baseline was 15 (1st, 3rd quartiles 11, 16) 
years. The majority of adolescents belonged to the persistent oligoarthritis (6/15; 40%) or the 
RF negative polyarthritis (5/15; 33%) JIA categories. Five patients (33%) received bilateral 
TMJ IACs. Two patients (13%) had repeated injections once unilaterally 11 and 13 months 
after baseline, on indication pain and ongoing MRI-assessed inflammation. Ten of 22 TMJs 
were sampled with the push-pull technique (46%). Follow-up visits were performed at a 
median of 2.0 (1.8, 3.3) months (n=14), 12.0 (11.0, 13.0) months (n=15), and 22.0 (22.0, 23.0) 
months (n=11) after TMJ injections at baseline. All patients had active disease at baseline. At 
the 2-year follow-up five of 11 (46%) patients were in remission either on or off medication. 
During the 2-year follow-up period 10/15 (67%) changed or increased their systemic 
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Table 1. Characteristics at baseline in adolescents with juvenile idiopathic arthritis (JIA) (n=15) receiving intraarticular 
corticosteroids (IACs) to the temporomandibular joints (TMJs) (n=22).  
 
Baseline characteristic Value 
 
Female, no. (%) 12 (80) 
Age at injections, yrs 15 (11, 16) 
Age at JIA onset, yrs  11 (8, 14) 
Disease duration, yrs  1 (0, 5) 
 
JIA-category, no (%) 
Oligoarthritis persistent 
Polyarthritis RF negative 
Oligoarthritis extended 








Disease activity, no (%)* 
Active 
Remission on medication 
















Disease activity variables 
 
JADAS10 baseline (n=8) 15.8 (12.9, 49.1) 
No.of active joints (n=14) 2.0 (1.0, 3.0) 
PRpainVAS (n=10) 4.8 (3.3, 7.6)  
PRgloVAS (n=10) 5.5 (3.3, 7.1) 
MDgloVAS (n=12) 2.5 (1.6, 4.5) 
ESR (mm/h) (n=12) 6.5 (3.5, 10.5) 
  
TMJ-examination to injection, days  14.0 (1.0, 68.0) 
Follow-up, months  22.0 (16.0, 23.0) 
Injection to 2-months follow-up, (n=14) 2.0 (1.8, 3.3)  
Injection to 1-year follow-up, months  (n=15) 12.0 (11.0, 13.0) 
Injection to 2-year follow-up, months (n=11) 22.0 (22.0, 23.0) 
  
Triamcinolone hexacetonide, dose, mg  (n=14) 20.0 (9.5, 20.0) 
Methylprednisolone acetate, dose, mg (n=1) 40.0 (n=1) 
Push-pull technique / No. TMJs (%) 10/22 (46%) 
Needle length, mm/ No. TMJs 25mm/15, 30mm/7 
 
Data are median (1st, 3rd quartile) unless otherwise indicated. Two patients received repeated injection on the same side, five 
patients received bilateral injection; JIA, juvenile idiopathic arthritis; TMJ, temporomandibular joint; PRpainVAS, patient 
reported pain visual analogue scale; PRgloVAS; patient reported global assessment of well-being; MDgloVAS, medical doctor 
global assessment of well-being; JADAS10, the composite juvenile arthritis10-joint disease activity score; ESR, erythrocyte 
sedimentation rate; MTX, methotrexate; DMARDs, disease modifying antirheumatic drugs; *disease activity status according 
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in Oslo, one patient in Bergen and twelve patients in Tromsø. 
 
Clinical outcomes 
Among the clinical TMJ parameters pain-index score changed from median 6.0 (0.0-13.0) at 
baseline to 2.0 (0.0-10.0) at 2-months follow-up, this was not a statistically significant 
improvement (p=0.263). There was a minimal, but statistically significant increase in MIO 
during the same observation period (p=0.045) (Table 2). At 2-year follow-up, scores for pain 
and jaw function improved from baseline in terms of pain frequency (p=0.016), pain intensity 
(p=0.012), VAS jaw function (p=0.034), and pain-index score (p=0.012) (Table 2). 
Absolute improvement in pain-index was seen in 6/11 (55%) of the patients at 2-months 
follow-up, 9/13 (69%) of the patients at 1-year follow-up and 8/10 (80%) of the patients at 2-
year follow-up (Figure 1). Two of 11 patients (18%) had increased pain and 3 (27%) 
unchanged pain from baseline to 2-months follow-up. At 2-year follow-up 2 of 10 patients 
(20%) had a stable pain-index score of zero, and none of the patients had increased pain-index 
compared to baseline. Absolute improvements in MIO at the three follow-up visits were 9 of 13 
(69%), 10 of 13 (77%) and 9 of 11 (82%) respectively (Figure 1). In 3 of 13 patients (23%) 
MIO decreased at 2-months follow-up (48 to 42 mm, 46 to 45 mm, 45 to 44 mm respectively). 
In 2 of 11 patients (18%) MIO decreased (40 to 37 mm, 49 to 45 mm respectively) between 
baseline and 2-year follow-up. Improvements in MIO ≥5 mm at the three follow-up visits were 
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Table 2. Disease activity and temporomandibular joint (TMJ) clinical measures during 2-year follow-up in 15 adolescents with juvenile idiopathic arthritis (JIA) and TMJ-arthritis receiving  
intraarticular corticosteroids (IACs).  
 
  
Pre- injection (T0) 
 
2-months FU (T1) 
 
1-year FU (T2) 2-year FU (T3) 
 
p-value T0-T1  
 
 
Median months after IACs  






2.0 (1.8, 3.3)  
n=14 
 
12.0 (11.0, 13.0)  
n=15 
 
22.0 (22.0, 23.0)  
n=11 
 
Disease activity, no (%)** 
Active 
Remission on medication 
Remission off medication 
 
 




7 (54) n=13 
2 (15) n=13 
4 (31) n=13 
 
 
10 (77) n=13 
2 (15) n=13 








Medication ***      
No DMARDs, no (%) 
DMARDs (MTX), no (%) 





5 (39) (n=13) 
2 (15) (n=13) 








Disease activity measures      
JADAS10 15.8 (12.9, 49.1) n=8 11.0 (6.0, 20.0) n=7 12.5 (6.8, 14.5) n=9 8.5 (3.3, 15.3) n=4 0.273b 
No.of active joints  2.0 (1.0, 3.0) n=14 0.0 (0.0, 2.0) n=13 1.0 (0.0, 1.5) n=13 0.0 (0.0, 1.0) n=10 0.076b 
ESR (mm/h)  6.5 (3.5, 10.5) n=12 6.0 (3.8, 11.0) n=10 5.0 (3.0, 7.0) n=11 5.5 (3.8, 7.3) n=10 0.445b 
PRpainVAS  4.8 (3.3, 7.6) n=10 3.5 (0.0, 5.8) n=8 3.8 (1.6, 6.3) n=10 1.5 (0.0, 4.5) n=4 0.500b 
PRgloVAS   5.5 (3.3, 7.1) n=10 3.5 (0.1, 5.8) n=8 4.0 (1.6, 5.1) n=10 0.5 (0.0, 4.0) n=4 0.345b 
MDgloVAS  2.5 (1.6, 4.5) n=12 0.5 (0.0, 4.0) n=10 1.5 (0.1, 2.8) n=12 0.0 (0.0, 1.0) n=7 0.207b 
TMJ activity measures      
Pain frequency  2.0 (0.0, 4.0)  1.0 (0.0, 2.0) n=11 1.0 (0.0, 2.0) n=13 0.0 (0.0, 2.0) n=10 0.245b 
VAS pain intensity  3.0 (0.0, 6.5) n=15 2.0 (0.0, 4.5) n=11 2.0 (0.0, 3.5) n=13 0.0 (0.0, 2.1) n=10 0.292b 
VAS jaw function  3.0 (0.0, 4.3) n=13 0.0 (0.0, 2.4) n=10 0.0 (0.0, 0.0) n=13 0.0 (0.0, 2.8) n=9 0.201b 
Pain indexγ 
 
6.0 (0.0, 13.0) n=15 2.0 (0.0, 10.0) n=11 2.0 (0.0, 8.5) n=13 0.0 (0.0, 5.3) n=10 0.263b 
MIO (mm) 
 
44 (36, 48) n=15 45 (43, 47) n=13 45 (42, 49) n= 13 46 (45, 48) n=11  0.045b 
Data are median (1st, 3rd quartiles) unless indicated otherwise. aMcNemar chi square test,  bWilcoxon rank test, *p ≤0.05 for statistical significance ** remission, status according to the ACR 
provisional remission criteria (35)***No DMARDs, Current us of NSAIDs and/or IACs; DMARDs, current use alone of MTX; Biologics comb, current use of Biologics alone or in 
combination with MTX; γ Pain index= Pain frequency last 2 weeks x Pain intensity last 2 weeks (VAS 0-10); JIA, juvenile idiopathic arthritis; TMJ, temporo-mandibular joint; LOM, limited 
range on motion; VAS, visual analogue scale; MTX, methotrexate; DMARDs, disease modifying antirheumatic drugs; PRpainVAS, patient reported pain visual analogue scale; PRgloVAS; 
Patient reported global assessment of well-being; MDgloVAS, medical doctor global assessment of well-being; JADAS10, The composite juvenile arthritis 10-joint disease activity score; IACs, 
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MRI outcomes 
There was a statistically significant reduction in the additive inflammatory domain from 
baseline to the 2-months- and from baseline to the 2-year follow-up, (p= 0.040, p=0.017 
respectively) (Table 3) (Figure 1). At the 2-months follow-up, 6 of 13 patients (46%) had lower 
score as shown in Figure 1, while 6 (46%) had unchanged and 1 (8%) had higher score in the 
additive inflammatory score. Among the 10 patients at 2-year follow-up, 7 (70%) had lower 
score, while 3 (30%) remained unchanged. The MRIs at baseline and at follow-up 2 months 
after IAC in one of the patients with improvement of temporomandibular joint enhancement is 
shown in Figure 2.   
There was no statistically significant change in the mean progressive inflammation score 
between baseline and 2-months follow-up; 4 of 13 (31%) had lower score, and 9 of 13 (46%) 
had unchanged score. At the 2-year follow-up; 5 of 11 patients (46%) had lower score and 6 
(55%) was unchanged compared to baseline. 
No statistically significant change was seen in the two bone damage scores. In the mean 
additive damage domain, 2 of 14 (14%) had lower score, 9 (64%) unchanged and 3 (21%) had 
increased score at 2-months follow-up. At 2-year follow-up 2 of 10 (20%) had lower score, 6 
(60%) was unchanged and 2 (20%) had higher score. The MRIs at baseline and at follow-up 2 
years after IAC and systemic treatment show aggravation of bone damage in one patient (Case 
10) and improvement in case 9 as shown in Figure 3. In the mean progressive osseous 
deformity score at the 2-months follow-up, 2 of 14 (14%) had a lower score, 11 (79%) had 
unchanged score, and 1 (7%) had higher score. At the 2-year follow-up 1 of 11 (9%) had lower 
score, 9 (82%) was unchanged, 1 (9%) had higher score.  
 
MRI score intra-observer agreement 
For the additive inflammatory domain, the intra-observer agreement between the readings was 
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moderate for joint effusion (kappa values 0.38 and 0.46), substantial and almost perfect for 
synovial thickening (0.63 and 0.90) and moderate and poor for joint enhancement (0.41 and 
0.00) for the right and left side, respectively. The corresponding value for the progressive 
inflammation and progressive osseous deformity score was moderate and poor (0.49 and 0.20) 
and moderate (0.52 and 0.58). For the additive osseous domain, the intra-observer agreement 
was moderate to substantial for flattening (0.48 and 0.74), fair and moderate for erosions (0.36 
and 0.44) and fair and almost perfect for disc abnormalities (0.36 and 0.84). 
 
Side effects 
No adverse events that could be related to the IACs were reported, and there was no finding of 
intraarticular calcifications on MRI. However, 2/10 (20%) had increased additive damage 
domain score and 1/11 (9%) had increased progressive osseous deformity score in the TMJ 
between baseline and 2-year follow-up. Both patients had ongoing MRI-assessed inflammation 
at 2-year follow-up and repeated IACs 11 and 13 months respectively after baseline. Among 
these one had lower pain index and the other one unchanged (=0), and both patients had 
increased MIO at the 2-year follow-up. Furthermore, two patients with only 1-year follow-up 
(cases 1 and 5) had increased scores according to additive damage domain and progressive 
osseous deformity, together with ongoing inflammation (Table 4). Also, case 1 had a trauma to 
the mandible, a blow against one of the condyles, in between the 2-month and the 1-year 
follow-ups. One of the patients, case 7, improved according to the progressive osseous 
deformity from score 1 at the 2-months follow-up to score 0 at the 2-year follow-up.  
Mandibular growth was not evaluated because the adolescents in this study had mostly finished 
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Table 3. Additive and progressive scoring system for assessment of inflammation and damage in the temporomandibular joint (TMJ) by magnetic resonance imaging (MRI) in 15 adolescents 
with juvenile idiopathic arthritis (JIA) and TMJ-arthritis receiving intraarticular corticosteroids (IACs).  
 
 Pre- injection (T0) 2- months FU (T1) 1-year FU  
(T2) 
















Additive Inflammatory domain: 
(Bone marrow edema, bone marrow enhancement, Joint 




























Bone marrow enhancement 0.4 ±0.5 
 











0.6±0.9 n=14 0.3±0.7 n=10  0.705*
 a
 
Synovial thickening 1.0±0.8 
 
1.0±0.8 n=14  
 














Additive Damage domain: (Condylar 























Erosions 0.6±0.7  
 









Disc abnormalities 0.7±0.5  
 
















Progressive osseous deformity 2.0±1.3  
 











Values are the mean±SD unless indicated otherwise. N=15 unless indicated otherwise. aWilcoxon rank test. bMcNemar chi square test. *P ≤0.05 considered statistically significant  
between T0-T1 and ** between T0-T3. Each joint is scored independently (the worst joint is chosen when bilateral injection), with possible total scores ranging from 0-8 in the Additive 
inflammatory scoring system and 0-5 in the Additative damage domain, and 0-4 in the Progressive scoring system according to (Tolend et al.) (36) and (Kellenberger et al.) (37);  
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DISCUSSION 
To our knowledge, this is the first prospective study validating and using two recently 
published MRI scoring systems to assess the efficacy and safety of IACs in the TMJ in 
adolescents with JIA. We found that a single IAC in combination with systemic therapy may 
improve short-term and long-term MRI-assessed inflammation and MIO, even though pain and 
MRI-assessed damage did not improve significantly.  
 
Clinical outcomes: Pain and MIO 
In our study the pain-index score improved in 6/11 patients at 2-months follow-up and 8/10 
patients at the 2-year follow-up median 22 months after IACs to the TMJs. Pain was one of the 
main indications for performing the IACs in our study, and the pain-index score is reported to 
be a valid and sensitive outcome measure in TMJ arthritis (17). Improvement in pain is 
reported in most retrospective studies in JIA children based on medical chart information or the 
patients' self-assessment of pain, where improvement in orofacial symptoms is seen in 67–
100%, follow-up ranging from mean 3 to 52 months after TMJ-IACs (15, 24, 42-44). However, 
none of these studies used quantified pain reports. Stoustrup et al. used the validated pain-index 
score in 13 JIA children receiving IACs to the TMJs in a prospective pilot study (17). They 
found significant short-term pain reduction, but remitting pain at long-term follow-up, 
indicating a loss of the initial effect of the IACs (17). Our study shows a trend for improvement 
in pain at the 2-month follow-up which is sustained during the observation period over two 
years (not statistically significant). The sustained tendency of reduced pain may be due to the 
systemic medication (DMARDs and biologics), which was changed in 10/15 patients in our 
study. Five of the 11 patients were in remission at the 2-year follow-up, indicating an effect of 
the treatment, which included IACs and the systemic medication. The sampling procedure with 
lavage may also induce improvement, Olsen-Bergem et al found that arthrocentesis with lavage 
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steroids did not add additional effect to the outcome (45). The natural fluctuation with waxing 
and waning disease activity over time often seen in JIA must also be considered (46). 
We found that MIO improved in 9 of 13 patients at 2-months follow-up, and in 9 of 11 patients 
between baseline and 2-year follow-up after IACs to the TMJs. This is similar to retrospective 
studies where improvements in MIO are reported between 2.7 and 6.6 mm (15-18, 24, 42-44). 
However, measurements of MIO are associated with much variation (47, 48), increase with age, 
and show a wide normal range in children of the same age (49). In our study we used 
standardized protocols and calibration of the examiners in order to avoid measurement bias 
(31) (32). Stoustrup et al. found the smallest detectable difference in repeated MIO 
measurements in patients with JIA to be 5 mm when a strict and standardized measurement 
protocol with repeated measurements were applied (48). A clinically relevant improvement ≥5 
mm was found in our study in 4 of 13 patients between baseline and 2-months follow-up and in 
5 of 11 between baseline and 2-year follow-up after IACs.  Our median improvement in MIO 
may be influenced by random error within the measurement procedure. Moreover, MIO at 
baseline was not severely reduced, and we doubt that this small change in MIO is a clinically 
relevant effect on jaw function even if statistically significant.  
 
MRI outcomes 
MRI-verified TMJ-arthritis is not always accompanied by clinical symptoms from the TMJ. 
A systematic review concluded that no single clinical finding could accurately predict MRI 
findings consistent with arthritis (50). The measurements in our study therefore included both 
standardized clinical assessment tools with pain reports, MIO, and MRI to verify TMJ-arthritis 
both at both baseline and follow-up.  
A problem in evaluating outcome after IACs has been the use of qualitative assessments and 
lack of consistent definitions and MRI-scoring systems (36, 37). In the assessment 


































































Date 07.04.20 18 
between baseline and the 2-months follow-up. Improvement was seen in 6/13 patients as 
compared to 4/13 patients in the progressive inflammation score. At the 2-year follow-up, 7 of 
the 10 patients improved significantly in the additive inflammatory domain and 3 were stable, 
whereas in the progressive inflammation score 5 of 11 patients improved at 2-year follow-up, 
but no overall significant improvement was seen.  
The improvement in MRI-assessed inflammation is in accordance with Resnick et al. who 
found reduced synovial enhancement in their retrospective study of 29 JIA patients with 50 
TMJs, even if only 18% of their TMJs experienced complete resolution of synovitis (18). Most 
studies of IACs to the TMJs in patients with JIA report an MRI improvement of 48-83% 
regarding inflammation (15, 16, 23, 24). However, these studies used different definitions of 
MRI improvement than the MRI scoring systems used in our study (36, 37).  
We found no improvement in the additive damage domain comprising condylar flattening, 
erosions and disc abnormalities or in the progressive osseous deformity score. Importantly, 
increased damage was not found at the group level, even if 2 of the 10 patients with 2-year 
follow-up in our study worsened in the additive damage domain and 1 of 11 patients worsened 
in the progressive score for osseous deformity. Furthermore, two patients with only 1-year 
follow-up worsened. We cannot discern the effect of IACs from the effect of ongoing arthritis, 
even if both patients with 2-year follow-up had repeated IACs once unilaterally. MRI showed 
persistent inflammation at 2-year follow-up in both these patients. Three patients improved 
from baseline to 2-year follow-up and one patient improved at 1-year follow-up. Furthermore, 
another patient who worsened in bone damage between injection and 2-months follow-up, 
improved at the 2-year follow-up. 
Stoll et al. (16) found in 15/47 (32%) of the TMJs injected with IACs, evidence of new-onset 
erosion and flattening. Arabshahi et al.(15) also reported post-therapeutic progression with 
bony resorption in three (16%) of 19 TMJs. Ringold et al. (42) reported that 10/15 (67%) of the 


































































Date 07.04.20 19 
progressive osseous deformation in 45 of 66 TMJs in their cohort of children with JIA and TMJ 
arthritis receiving repeated injections (mean 2.4±1.4 IACs per joint, range 0-7). 
The additive inflammatory MRI score consists of five domains. The fact that this additive 
inflammatory scoring system have scores 0 to 2 (maximum 2) for joint effusion, joint 
enhancement and synovial thickening, while bone marrow edema, bone marrow enhancement 
scores maximum 1, place less emphasis on the two latter domains. The same applies to the 
additive damage MRI score consisting of three domains, where condylar flattening and 
erosions score 0 to 2, and disc abnormalities score maximum 1 if present. It is also unclear how 
the progressive system was constructed with regard to relative weighting of findings. Whether 
this emphasis is based on data analyses or constructed for simplicity is not stated in the 
publications of the scores.  
The progressive inflammation and osseous deformity scores incorporate several features into 
one score in a progressive manner. In one of the four papers (36) where the system has been 
presented it is stated that the most severe change is the deciding feature, however, in the three 
others (37-39) this statement is not included. Deciding the most severe change can be 
challenging, and our interpretation of the system was that a given score was reliant on 
fulfillment of the previous level of pathology. This may have lowered the progressive osseous 
deformity score if erosions were present without co-occurrence of flattening, and the 
progressive inflammation score if bone marrow oedema was present without increased synovial 
enhancement. There was some variation in the kappa coefficients, both between right and left 
side in both systems and between the different variables of the additive system. The best intra-
observer agreement was found for disc abnormalities and synovial thickening, in the latter with 
substantial and almost perfect agreement. The repeatability varied somewhat more in our study 
compared to the report by Tolend et al. (36). Assessment variations may have influenced the 
outcome, particularly because of the small study sample. Furthermore, the scoring systems 
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examined. 
Whether MRI should be performed to assess the effect of interventions in TMJ remains 
unanswered. In Table 4 there is no uniform pattern, but a trend that the MRI changes in 
inflammatory scores parallell the clinical improvement. Based on our data, clinical experience 




In our study no severe side effects occurred in terms of infection, bleeding or intraarticular 
calcifications, even if a computed tomography (CT) scan may better show calcifications. 
However, 2 patients had worsening in bone damage at 2-year follow-up. In addition two 
patients had worsened score for bone damage at 1-year follow-up but have not yet reached 2-
year follow-up. However, these patients had all ongoing inflammation and one of them a 
trauma to the mandible that may explain the damage. Another patient worsened in bone 
damage between injection and 2-months follow-up but improved at the 2-year follow-up. 
Furthermore, three patients improved in bone damage from baseline to 2-year follow-up and 1 
patient improved at 1-year follow-up. 
Other studies have reported short-term adverse effects such as facial swelling, skin atrophy, 
pain, TMJ stiffness, chewing dysfunction, fever and TMJ calcifications/ossifications (15, 16, 
42-44, 51). A chart review by Ringold et al. (51) described heterotopic ossification in the TMJ 
in children receiving 1–5 TMJ IACs, but the authors were unable to say whether these 
ossifications were the result of the IACs treatment or due to severe, long-standing TMJ 
inflammation. Also Lochbuhler et al. (22) reported severe side effects such as ossifications in 
the TMJs after repeated IACs. Rate of osseous deformities increased from 51% at baseline to 
62% at the end of their study, with progression to severe condylar destruction in 26% of joints 
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mandibular growth rate was reduced compared to the normal age- and sex-matched mean 
growth rate. In that study injections were however performed repeatedly. It is unclear whether 
the adverse effect of ossifications and reduced mandibular growth is a problem mainly of 
repeated steroid injections. We could not evaluate the effects on mandibular growth since the 
patients were mostly fully grown at the time the injection was performed. Our study may point 
to a single steroid injection as a treatment option for severe symptoms of TMJ-arthritis 
unresponsive to systemic treatment in skeletally mature individuals. 
 
Study strengths and limitations 
A strength of the present study is the prospective study design with standardized examination 
and MRI protocols in a clinical setting. MRI scoring assessments were performed by two 
experienced specialists and masked regarding whether the images were pre- or post-treatment. 
In addition, the clinical examiners used standardized examination protocols and were 
repeatedly calibrated, even if recalibration not necessary always change the inter-examiner 
reliability (33). Our study sample is comparable to population-based JIA cohorts and case-
control studies regarding gender and JIA category distribution (7, 8, 16). A limitation is that 
clinical examiners and the patients were not masked before and after treatment, when assessing 
clinical variables such as MIO and pain. It must be emphasized that the patient group is small, 
and therefore the statistical analyses of the main clinical and imaging outcomes, and the 
discrepancies between the two scoring systems must be interpreted with caution. Furthermore, 
we found considerable intra-observer variability for some domains of the MRI scores, and our 
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inflammation, and improve mouth-opening capacity minimally. At the 2-months follow-up the 
pain-index score had improved in 6/11 patients but the change in pain-index score did not reach 
significance. Condylar bone damage was mostly stable but worsened during 2-year follow-up 
in two patients with repeated IACs and improved in 3 patients but no overall significant 
improvement was seen. There were no side effects. This is the first prospective clinical study 
validating and using two recently published MRI scoring systems. The combined effects of 
naturally fluctuating JIA disease activity, systemic medication changes, and TMJ lavage versus 
IACs must be considered in the assessment of the present findings. Further prospective clinical 
studies on adolescents with an age not critical for mandibular growth retardation due to steroid 
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Availability of data and material: 




ACR American College of Rheumatology 
Biologic comb Current use of Biologics alone or in combination with MTX 
CRP C-reactive protein 
CT Computed Tomography 
DC/TMD Diagnostic criteria for temporomandibular dysfunction 
DMARDs Disease-modifying anti-rheumatic drugs 
ESR Erythrocyte sedimentation rate 
IACs Intraarticular corticosteroids 
ILAR International League of Associations for Rheumatology 
JADAS The composite juvenile arthritis10-joint disease activity score 
JIA Juvenile idiopathic arthritis 
MDgloVAS Physician global evaluation of overall disease activity on a 10-cm visual analogue scale  
MIO Maximal incisal opening 
MRI Magnetic Resonance Imaging 
MTX Methotreaxthe 
NorJIA The Norwegian JIA Study 
NSAIDs Non-steroidal anti-inflammatory drugs 
PAS Posterior airway space  
PRgloVAS Patient reported global assesment of well-being 
PRpainVAS Patient reported pain VAS 
RF Rheumatoid factor 
SD Standard deviations 
TMJ Temporomandibular joint 
US Ultrasound 
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Figure 1. Percentage of patients with improvement. Percentage of adolescents with juvenile idiopathic 
arthritis (JIA) and temporomandibular joint (TMJ) arthritis with improvement in Pain index, maximal incisal 
opening (MIO) and magnetic resonance imaging (MRI) inflammatory additive domain score, damage additive 
domain score, progressive inflammation score, progressive osseous deformity score, in the time interval between 
baseline and follow-up visits (FU) after receiving intraarticular corticosteroids (IACs).  
 
Figure 2. MRI improvement of the inflammation. Oblique sagittal contrast enhanced T1 TSE images with fat 
suppression of a 16-year-old girl (case 8) (a) at baseline with increased temporomandibular joint enhancement 
and (b) at 2 months follow-up after IAC and no DMARDs with complete regression of joint enhancement. Note 




Figure 3. MRI changes of the bone condition.  
Oblique sagittal pre- and postcontrast T1 TSE images with fat suppression of the left TMJ of a 16-year-old girl 
(case 10) without improvement in inflammation: joint enhancement is only minimally reduced from baseline (a, 
b) to 2-months after IAC (c, d). She was under MTX treatment. At 2-year follow up, with a repeated injection 11 
months after baseline, there is some reduction in joint enhancement, but the disc has become perforated and 
the condylar surface discretely more flattened and irregular (e, f). 
 
Oblique sagittal T1 TSE images with fat suppression of the right TMJ of a 15-year-old girl (case 9) with 
improved bone condition: discretely flattened and irregular condyle at baseline (g) has become smooth and 











































































Supplementary Table 1. Magnetic resonance imaging (MRI) protocol for adolescents with juvenile idiopathic 






























































































Table 4. Summary characteristics, use of medication at baseline and outcome-response during 2-year follow-up in adolescents with juvenile idiopathic arthritis (JIA) (n=15) receiving intraarticular corticosteroids (IACs) 





































1  M 10 10 6 MTX MTX MTX  T0: 48 
T1: 42 
T2: 48 
























T1 and T2 
2  F 17 17 8 MTX BioCo BioCo BioCo T0: 40 
T1:  - 
T2: 37 






















3 F 11 11 8 MTX MTX BioCo  T0: 32 
T1: 35 
T2: 30 





























































repeated IACs  
(13 months 
interval) 
5 F 9 15 20 BioCo  BioCo  T0: 48 
T1:  - 
T2:  - 
T3:  - 
T0: 3 
T1:  - 
T2:  - 
T3: 0 
T0: 6 
T1:  - 
T2: 6 
T3:  - 
T0: 3 









































































MTX  T0: 45 
T1: 46 
T2: 50 


















































10 F 15 16 20 No No MTX MTX T0: 45 T0: 12 T0: 5 T0: 3 T0: 3 T0: 3 Unilateral 
Table 4 Click here to access/download;Table;Table 4.docx























 (11 months 
interval)  














































































































































*Additive and progressive MRI score (36, 37) ** Metylprednisolone acetate; Inj, injection; Medic, medication; MIO, maximal incisal opening; MRI, magnetic resonance imaging; FU, follow-up; 
MTX, methotrexate; BioCo, biologics alone or in combination with other DMARDs; disease modifying antirheumatic drugs; JIA, juvenile idiopathic arthritis; TMJ, temporomandibular  joint; 
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review, according to the PRISMA guidelines, was conducted. Meta-analyses,
randomized controlled trials, cohort studies, observational studies, and case reports
were eligible for inclusion. Exclusion criteria were no JIA diagnosis, no clearly
defined outcomes, dual publications (except meta-analyses), non peer-reviewed
studies, non English language publications, and animal studies. The outcome
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Table 1. PICO criteria.
PICO
Patients Patients with a JIA diagnosis and involvement of the TMJ
Intervention Receiving a reconstructive or orthognathic surgical intervention
Comparison Efficacy and safety of various reconstructive or orthognathic surgical
modalities in JIA
Outcome Assessment of treatment outcomes and safety profile
Databases included: MEDLINE via PubMed and Embase. Search terms were constructed for
MEDLINE and modified for Embasea
JIA, juvenile idiopathic arthritis; TMJ, temporomandibular joint.
a The MEDLINE search terms: ((juvenile idiopathic arthritis) OR (juvenile chronic arthritis))
AND ((orthognathic surgery) OR (Le Fort I) OR (bilateral sagittal split) OR (vertical ramus
osteotomy) OR (bimaxillary surgery) OR (genioplasty)).Juvenile idiopathic arthritis (JIA) is the
most common chronic rheumatic disease
in children, with an annual incidence of
1.3 to 22.6 per 100,0001–7. The temporo-
mandibular joint (TMJ) is involved in
11.6–80% of cases8–11. TMJ arthritis can
lead to reduced mouth opening, impaired
mastication, pain, disruption of condylar
growth, and dentofacial deformities12.
Unilateral TMJ arthritis may cause facial
asymmetry and/or an occlusal cant13. Bi-
lateral involvement may lead to clockwise
rotation of the mandible, resulting in
micrognathia, anterior open bite, and a
reduction in posterior airway space
(PAS)14,15. A small PAS is associated with
obstructive sleep apnea (OSA) and related
comorbidities16.
TMJ arthritis is difficult to diagnose and
control14. Uncontrolled arthritis may lead to
severe dentofacial deformities. In some
patients, growth deviation resulting from
TMJ arthritis can be improved with ortho-
pedic/orthodontic treatment during
growth17. Indications for reconstructive sur-
gery include the following: improvement in
TMJ function and/or occlusion, skeletal
alignment, desire for facial esthetic im-
provement, and/or improvement of OSA.
There are two strategies for the surgical
correction of JIA-induced dentofacial de-
formities: (1) TMJ preservation (i.e.,
orthognathic surgery, distraction osteogen-
esis (DO)), and (2) TMJ reconstruction (i.e.,
resection of the remaining condyle, synovi-
al lining, and disc, and reconstruction with
an autologous graft18 or an alloplastic pros-
thesis19). The choice of operational strategy
depends on the patient’s age, disease activ-
ity, extent of the skeletal deformity, and
surgeon preference and experience.
The aim of this study was to assess the
level of evidence for surgical correction of
dentofacial deformities in patients with
JIA-related TMJ involvement.
Materials and methods
This study was conducted by the TMJaw
Surgical Task Force. TMJaw is an inter-
national, multidisciplinary research net-
work founded in Oslo, Norway in 2010,
which focuses on research of TMJ arthritis
related to JIA. The terminology of the
present systematic review adheres to the
TMJaw consensus-based standardized ter-
minology20.
Search strategy
An electronic database search strategy was
designed based on the Preferred Reporting
Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines21. Refer-ences were archived in a RefWorks data-
base (ProQuest LLC, Ann Arbor, MI,
USA). The search strategy was developed
for MEDLINE and modified for Embase.
The search was limited to these two data-
bases because they are the most inclusive.
The primary search was conducted in June
2017 and updated in February 2018.
Search terms included the following: ju-
venile idiopathic arthritis OR juvenile
chronic arthritis AND orthognathic sur-
gery OR Le Fort 1 OR bilateral sagittal
split OR vertical ramus osteotomy OR
bimaxillary surgery OR genioplasty OR
distraction osteogenesis OR temporoman-
dibular joint surgery.
Outcome variables
The PICO criteria (patients, intervention,
comparison, and outcome) for the study
are presented in Table 1. Outcome vari-
ables included: (1) TMJ function (i.e.,
maximum mouth opening measured be-
tween the incisal edges of the central
incisor teeth, in millimeters), (2) pain,
(3) occlusion and skeletal alignment,
and (4) operation-related morbidity.
Meta-analyses, randomized controlled
trials (RCTs), cohort studies, observation-
al studies, case series, and case reports
were eligible for inclusion. Case reports
were also included due to the limited
number of publications with a high level
of evidence identified with the predefined
terms. Studies were excluded if they did
not include information on JIA diagnosis,
had poorly defined outcomes measures, or
were dual publications (except meta-anal-
ysis), non peer-reviewed studies (e.g.,
conference abstracts), animal studies, or
written in a language other than English.
Study selection and bias
Two authors (PF, SEN) independently
assessed the studies identified in the liter-
ature search on three occasions. The first
selection was based on titles only. Thesecond selection included an assessment
of the abstracts. The third and final assess-
ment involved full text review (Fig. 1).
Any disagreement between the reviewers
was resolved through discussion and the
involvement of a third reviewer, until
consensus was reached.
The following data were collected from
the eligible studies: study design, level of
evidence, patient selection criteria, num-
ber of subjects, patient sex, mean patient
age, surgical procedure, outcomes, ad-
verse effects, and other relevant findings.
The selected studies were assessed for
risk of bias on the basis of the following
variables: prospective study design, suffi-
cient description of the outcome variable,
uniform inclusion criteria, standardized
examination protocol, outcome assessor
blinded to imaging findings, and informa-
tion on outcome variable variation. Risk of
bias was classified as ‘high’ if a ‘no’ was
obtained in three or more criteria. The
level of evidence was scored according
to the Oxford Centre for Evidence-based
Medicine (OCEBM) level of evidence
guide (http://www.cebm.net/oxford-
centre-evidence-based-medicine-levels-
evidence-march-2009/), as follows: 1a:
systematic review with homogeneity of
RCTs; 1b: individual RCT with narrow
confidence interval; 1c: all or none case
series; 2a: systematic review with homo-
geneity of cohort studies; 2b: individual
cohort study including low quality RCT; e.
g., <80% follow-up; 2c: ‘outcomes’ re-
search and ecological studies; 3a: system-
atic review (with homogeneity) of case–
control studies; 3b: individual case–con-
trol study; 4: case series (and poor cohort
and case–control studies); 5: expert opin-
ion without explicit critical appraisal, or
based on physiology, bench research, or
‘first principles’.
Results
Two hundred and fifty-five articles were
identified in the first search; 85 remained
1034 Frid et al.
Fig. 1. PRISMA flow diagram of the study selection process.after title screening. Abstract evaluation
resulted in 49 articles. Articles were ex-
cluded during full-text assessment for the
following reasons: animal studies (n = 1),
studies not in English (n = 3), meta-anal-
ysis (n = 1), or lack of clearly defined
outcome variables (n = 16). The final sam-
ple included 28 papers for full text evalu-
ation (Fig. 1, Tables 2 and 3)18,22–48. The
inter-rater agreement for study selection
was 100% for all of the variables (Supple-
mentary Material, Table S1). Of the 28
articles included, 24 were case reports or
case series18,22–44, three were retrospec-
tive chart reviews45–47, and one was a
prospective cohort study48. Many of the
included articles described surgical proce-
dures in a mixed group of patients. The
included studies described a total of 172
subjects with JIA who underwent a recon-
structive surgical procedure.
The risk of bias was rated ‘high’ in 26
(93%) of the included studies; two (7%)
articles had a ‘medium’ risk of bias30,48
(Supplementary Material, Table S1).
No study included a control group. Four
studies did not have uniform inclusion
criteria, i.e. not all study subjects had a
JIA diagnosis24,29,30,32. Various methods
were used for the evaluation of outcomes,
such as cephalometric analysis and clini-
cal photographs when evaluating skeletal
alignment, polysomnography when evalu-
ating OSA, and mouth opening (in milli-
meters) to evaluate function. The
examination protocol was unclear in two
studies26,28. No outcome assessors in the
studies were blinded to imaging findings.
Detailed information on outcome vari-
ables, such as mean jaw advancement,
mean relapse, and mean mouth opening
in millimeters, were presented in 23
studies18,23–25,27,29–32,34,35,37–48. Accord-ing to the OCEBM level of evidence, all
included articles were grouped in category
four (i.e., case series and poor cohort and
case–control studies).
Surgical intervention and outcomes
TMJ preservation—orthognathic surgery
Nine case reports and case series discussed
orthognathic surgery in 80 patients (43
with JIA)30–32,34,36,37,42,45,46. Age at oper-
ation ranged from 15 years to 53 years.
Follow-up varied from <1 year to 10
years. All studies reported improved func-
tion, occlusion, and skeletal alignment.
All studies reported few complications;
these included infection, wound dehis-
cence, skeletal relapse, and continued
TMJ pain.
Kahnberg and Holmstrom described
maxillary and mandibular orthognathic
surgery with chin augmentation (implant)
in 19 of 34 analyzed patients (37 in total,
three with JIA). In 15 patients, a chin
implant was the only procedure. All
patients reported high postoperative satis-
faction30. Two patients had postoperative
dehiscence and one patient had infection
of the implant. Pagnoni et al. described Le
Fort I osteotomy and genioplasty in five
patients with quiescent JIA37. Occlusion
and skeletal movements were stable 8
months postoperatively. All patients
reported relief of TMJ pain, increased bite
strength, and a reduction of headache and
sleep respiratory distress postoperatively.
These authors advocated for Le Fort I
osteotomy with autorotation of the mandi-
ble and genioplasty, without a mandibular
osteotomy, theorizing that a mandibular
operation exacerbates condylar resorption,
TMJ pain and dysfunction. According tothe same authors, postoperative exacerba-
tion of TMJ arthritis did not occur.
Leshem et al. reported skeletal relapse of
2.1 mm after a mean 9.6 mm mandibular
advancement at 1 year postoperatively in
eight patients withJIA45. Theyalso reported
an improvement in quality of life for all
patients. These authors recommended a sur-
gical splint with a small posterior open bite
and edge-to-edge incisor relationship to
compensate for expected relapse. One pa-
tient in their series continued to suffer from
TMJ pain postoperatively.
Kreiborg et al. described a 15-year old
patient with ‘‘some relapse’’ 1 year after
bimaxillary surgery34. They hypothesized
that dysplastic mandibular growth leads to
occlusal instability and poor masticatory
muscle function. Therefore, they recom-
mended early orthognathic surgery (i.e.,
prior to skeletal maturity) to maintain
occlusal stability throughout growth.
One of seven subjects (age 10–24 years)
described by Myall et al. required a reop-
eration at age 18 years due to relapse after
sagittal ramus osteotomy and genioplasty
at age 10 years36. Oye et al. described
mean skeletal relapse of 2.3 mm after
average mandibular advancement of
5.3 mm in 16 patients46. Half of these
patients had TMJ pain before surgery
(mean visual analog scale (VAS) score
2.4), and 38% reported pain postoperative-
ly (mean VAS score 1.3). These authors




Seven studies described DO in 40 patients
with JIA23,25,33,35,39,47,48. One study was a











































FU: <1 year for 3 pts, min
1 year for 34 pts; 5 years for
17 pts





BSSO + genioplasty Stable function and
esthetics at 2 years postop.
No FU: 2 years
Kennett and
Curran32
CS 4 Selected 4 (1 JIA) 3 F, 1 M
16 (12–18)
JIA pt: VRO with
iliac BG, onlay BG
to the chin, 6 weeks








onlay BG to the chin
FU JIA pt: 1 year (3–18
months)
The need for postop. jaw
exercises is stressed









Some relapse 1 year
postop., but it did not
affect the soft tissue
profile
FU: 1 year postop.
Leshem et al.45 Retrosp.
CS
4 Consec. 8 5 F, 3 M
18 (17–22)




TMJ pain (1 pt)
Mean MA 9.6 mm: Co–Gn;
mean mandible relapse
2.1 mm (did not
significantly affect the
clinical outcome)
Some relapse 1 year
postop., but it did not
affect the soft tissue
profile
FU: min 8 months (mean 36
months)
Myall et al.36 CS 4 Consec. 7 5 F, 2 M






LFI; MMF 6 weeks
and wire/screws
6 patients with satisfactory
function and esthetic





surgery at age 10,
2nd at age 18)
FU: 6 months
No patients had ankylosis
Not the authors experience
that children with JRA are
predisposed to this
condition
Prefer to delay surgery until
growth has finished




4 Consec.d 16 12 F, 4 M
24.25 (16–53)
BSSO + genioplasty Improved profile, all
patients satisfied; may
reduce TMJ pain
Mean relapse 2.3 mm of
MA 5.3 mm (48%) (Pog–
Co); 50% of pts (8) relapsed
2 mm
Safe treatment;
reoperation for 4 pts,
infection in 2 pts;
negative tooth
sensitivity in 3 pts,
scar in 3 pts; plates
























Age (years)b Surgical procedure Outcomec Adverse effects
Follow-up
Other relevant findings
Pagnoni et al.37 CS 4 Consec. 5 4 F 21.75 (17–
29)
LFI + genioplasty Improved occlusion and
facial profile
Mean MA rotation 5.6 mm
Mean posterior–anterior
face height ratio 63.9 (S–
Go/N–Me)
None FU: min 8 months (8
months–8 years)
‘‘Mandibular procedures
may evoke further condylar
















FU: 30 months postop., 14
months after removal of
orthodontic appliances
Distraction osteogenesis






Unilateral MDO Evaluation of load transfer
mechanism to the TMJs
before, under, and after DO
No long-term FU Before DO: high peak
stresses to the affected TMJ
After DO: more
symmetrical loading to the
TMJs
Under DO: the reaction
forces in the TMJs were low
de Zee et al.25 CR simulation model
CBCT/MRI











Mackool et al.35 CR 4 Selected 1 F
26
Bilateral extraoral




apnea; MIO: 10 mm to
12 mm
Scar tissue in skin FU: not stated
Cephalometric measures
reported





ramus DO 16 mm
Skeletal deformity
corrected
Stress load is higher on
distracted side during
distraction
NR No FU data
Nørholt et al.48 Prosp.
cohort
study
4/3 Consec. 23 9 M, 14 F






At removal of DO
device: 7 LFI, 1
genioplasty








of the device, 2 pts
mild dysesthesia, 2
pts trismus
FU: min 12 months
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































retrospective study47. Five of the studies were
case reports23,25,33,35,39. Three of the included
studies evaluated load transfer to the TMJs
before, during, and after DO23,25,33.
Nørholt et al. prospectively followed a
cohort of 23 patients with JIA after unilat-
eral DO, with or without a maxillary osteot-
omy or genioplasty, for at least 12 months
postoperatively48. They found predictable
correction of asymmetry, improved func-
tion, and decreased TMJ pain after DO.
Two patients developed dysesthesia in the
lower lip. A significant improvement in
condylar translation was observed during
distraction, but postoperatively this was not
significantly improved when compared to
the preoperative conditions.
In the retrospective study of Stoor et al.,
11 patients with JIA and severe TMJ
degeneration had mandibular advance-
ments with orthognathic surgery, of whom
three had additional mandibular DO and
three had a unilateral or bilateral TMJ
prosthetic reconstruction47. An additional
patient underwent only bilateral TMJ
prosthetic reconstruction. The mean man-
dibular advancement was 10.1 mm. Mean
follow-up was 2.3 years. There was a
mean relapse at pogonion of 2.1 mm.
The occlusion was stable in 11/12 patients.
The TMJ function was good and the facial
esthetics improved in all patients.
Singer et al. reported an 18-year-old
female who had bilateral mandibular
DO, Le Fort I osteotomy, and a genio-
plasty39. At the 1-year follow-up, she had
improved skeletal relationships and good
function. Preoperative bilateral masseter
pain resolved postoperatively.
Mackool et al. described a 26-year-old
woman with JIA who had relief of OSA
and an improved facial profile after bilat-
eral mandibular DO35. However, MIO
only improved from 10 mm to 12 mm.
Cattaneo et al. and Kofod et al. pre-
sented the case of a 12-year-old boy with
JIA, unilateral mandibular hypoplasia, and
condylar erosion23,33. Using a simulation
model, the authors showed high peak
stresses to the affected resorbed condyles
before operation with DO. During active
distraction, forces in the TMJs were low.
After DO, load sharing was more symmet-
ric to the condyles compared to the pre-
operative measurement. de Zee et al. also




Seven case reports and case series (n = 48
patients, 29 with JIA) discussed TMJ re-
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No FU: 4 years (1 case)









surgery, CCG, DO, TMJ
arthroplasty, segmental Le
Fort I osteotomy and soft
tissue surgery
Improved respiration,
increased volume of naso-
oropharynx
No FU: 6–12 months
‘‘Tracheostomy leads to
social isolation for these
children’’
Felix et al.27 CR and
review






MIO 40 mm = good
function; good esthetics
No FU: 24 months
Guyuron28 CR 4 Referred 1 F
35
Ankylosis age 10
LFI osteotomy with anterior
rotation, BSSO 8 mm
advancement, genioplasty




Relapse 1–2 mm first year,
stable following 5 years;
psychological
improvement; TMJ function
good, 40 mm MIO
No FU: 5 years
Diagnosis 9 years,
prednisolone
Stringer et al.18 CS 4 Consec. 5 5 F
14–18
Orthognathic surgery
+ CCG (inverted L-
osteotomy + LFI + iliac
graft + genioplasty) = 1
surgery
Gn–N–Ba, 4 of 5 pts class I
occlusion on FU, 1 pt a
3 mm open bite postop.
Mean increase anterior–
posterior 22.7 mm T1–T2
Relapse average
1.5 mm T2–T3
Infection (n = 1)










11 F, 1 M
10–17
CCG 9 bilateral, 3
unilateral; disc removed in
12 joints, preserved in 9
joints
Good function: 11/12 had
no pain or symptoms from
TMJ; MIO 35.6 mm preop.,
41.3 mm at FU; 5 pts class I,








CCG (n = 8)







5 bilateral, 2 unilateral,
resection of condyle (disc
preserved) and coronoid
process; CCG from C5 or
C6; fixation with screws; 6
weeks of MMF
Functional treatment after 8
weeks
5/7 no functional problems
or pain; MIO after 2–4.5
years: 39 mm (range 30–








from 8 weeks postop. to
latest FU
No report of excessive
overgrowth or resorption of
CCG  longer FU needed
Alloplastic joint reconstruction




Full range of hinge
movement, good function
No FU: MIO 31 mm 6 months
later























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(CCG) in both skeletally mature and im-
mature subjects18,22,24,27,28,40,41. Age at
operation varied from 10 years to 35 years.
Follow-up ranged from 6 months to 14
years. Following CCG, six studies
reported improved functional outcomes
(defined as increased mouth opening)
and improved skeletal pro-
files18,22,27,28,40,41. Two studies reported
improved self-confidence22,28 and two
case reports found improvement in
OSA24,28. One paper suggested synovect-
omy in conjunction with CCG to prevent
progression of TMJ destruction22. Mor-
bidity at both the donor and recipient sites
was low. All seven case reports and case
series discussing autologous TMJ recon-
struction reported no or few TMJ symp-
toms or muscle symptoms after surgery.
Two studies discussed the risk of over-
growth of the CCG, resorption of the graft,
and donor site morbidity40,41. Svensson
et al. followed 12 patients with JIA
for a mean of 5.3 years after CCG and
demonstrated asymmetric mandibular
overgrowth in eight41. Resorption of
the graft was seen when bone screws
were removed 1–2 years after CCG recon-
struction.
Guyuron reported skeletal relapse of
1–2 mm at 1 year after CCG reconstruc-
tion and BSSO advancement of the man-
dible and genioplasty, but no further
change over the subsequent 5 years28.
Stringer et al. reported a skeletal relapse
of 1.5 mm at a mean of 9.6 years following




There were five case reports and case
series on reconstruction with alloplastic
TMJ prostheses in patients with
JIA26,29,38,43,44. In total, these studies in-
cluded 64 subjects, 60 of whom had a
diagnosis of JIA. Age at the time of oper-
ation ranged from 15 years to 61 years.
Follow-up ranged from 6 months to 46
months. TMJ replacement was either by
stock joint (n = 1)38 or custom joint pros-
thesis by Biomet or TMJ Concepts
(n = 4)26,29,43,44. All reported improved
functional and skeletal outcomes. One
manuscript reported improved OSA38.
All five case reports and series discussing
alloplastic TMJ reconstruction reported
low morbidity with no or few TMJ symp-
toms or muscle symptoms after surgery.
Webster et al. recommended AJR as the
most suitable treatment for patients with
JIA, condylar degeneration, and dentofa-
cial deformity43. They performed AJR
1040 Frid et al.with a simultaneous mandibular advance-
ment and genioplasty due to the extent of
condylar destruction and clockwise man-
dibular rotation.
Wolford et al. reported good treatment
results after AJR in patients who had
undergone ‘‘no or one previous TMJ sur-
gery’’ before joint replacement, based on
clinical assessment of stability, function,
and residual pain44. Paul et al. reported
improved OSA and esthetics at 10 months
of follow-up, after ‘‘dual stage surgery’’
using first an alloplastic TMJ prosthesis
followed later by mandibular advance-
ment with a body osteotomy fixed with
a titanium reconstruction plate with an
inter-positioning iliac graft bilaterally38.
Discussion
The aim of this study was to assess the
level of evidence for surgical correction of
dentofacial deformities in patients with
TMJ degeneration from JIA. Currently,
there is no consensus regarding the most
appropriate reconstructive approach for
this patient population. The choice of
operation may be influenced by the degree
of skeletal maturity, level of TMJ arthritis
activity, extent of TMJ and dentofacial
deformity, and surgeon preference and
experience.
The findings of this systematic review
suggest that all available reconstructive
surgical interventions (orthognathic sur-
gery, DO, CCG, AJR) improve TMJ func-
tion and skeletal relationships in this
patient population. Only minor to moder-
ate complications have been reported,
such as temporary nerve damage, infec-
tion, and mandibular overgrowth. Howev-
er, these reports must be evaluated in the
context of the low level of evidence.
The management of TMJ dysfunction
and pain is important for activities of daily
living such as mastication, speech, and
oral hygiene. Improvements in mouth
opening and micrognathia are critical for
airway management under general anes-
thesia50. Also, improvements in occlusion,
skeletal alignment, facial esthetics, and
self-confidence are considered important
for patient well-being, since facial attrac-
tiveness has been shown to influence edu-
cation, relationships, and employment51.
All of the included case reports and
case series on orthognathic surgery in
JIA reported improved functional out-
comes, occlusion, and skeletal
alignment30–32,34,36,37,42,45,46. Orthog-
nathic surgery is traditionally performed
after skeletal maturity to maximize sta-
bility. A major concern in this context
are the high-angle cases, i.e. cases with asteep mandibular plane angle, undergo-
ing a large mandibular advancement,
with skeletal relapse secondary to soft
tissue forces52. Children with JIA often
are high-angle cases due to TMJ arthritis
with a TMJ deformity causing posterior
rotation of the mandible resulting in an
anterior open bite. Mandibular advance-
ment has been reported to show relapse
even in non-JIA patients14,53. Thus,
some authors recommend early surgical
intervention in order to provide better
conditions for normal development of
the facial skeleton34,53.
Other investigators recommend anti-in-
flammatory medications and stabilizing
splints until the TMJs are ‘stable’ before
orthognathic surgery, with minimal post-
operative loading of the TMJs17,54. The
rationale for this approach is to avoid or
minimize the mandibular advancement in
order to avoid overloading the TMJs.
However, these treatment approaches
may also result in significantly compro-
mised function and esthetics, continued
restriction of the oropharyngeal airway,
and continued or worsening of pain.
Morbidity was low for orthognathic
surgery compared to TMJ reconstruction
(CCG or alloplastic prosthesis) or DO.
Surgical exposure when performing
CCG, AJR, or DO with an extraoral ap-
proach is usually via a combined pre-
auricular and submandibular incision.
Therefore, there is a risk of facial nerve
damage during surgery55.
In this review, improvements in func-
tional outcome and skeletal align-
ment39,47,48, OSA35, and load transfer to
the TMJs23,25,33 were reported after DO.
For patients with significant dentofacial
deformities, DO may be a suitable option.
DO is widely used to improve the mor-
phology of the facial skeleton in patients
with congenital or acquired deformities56.
DO may be more stable over time with less
skeletal and dental relapse compared to
conventional orthognathic surgery48,57.
However, DO requires careful vector plan-
ning and patient collaboration during de-
vice activation. In asymmetric cases, JIA
patients will have a period with potential
overloading of the TMJ on the affected
side. Therefore, it is argued that DO per-
formed during adolescence reduces the
time period of load to the affected TMJ,
limits the risk of nerve damage to one side
compared to both when performing the
BSSO osteotomy, and reduces the need
for a maxillary osteotomy by allowing
normal growth of the maxilla concomi-
tantly with the mandible48. However, a
second operation is required to remove
the distraction device.In skeletally immature patients, autolo-
gous reconstruction may be preferred be-
cause thegrafthas thepotential togrowwith
the child. This review of available articles
found an improvement in functional out-
come and esthetics18,22,27,28,40,41, self-con-
fidence22,28, and OSA24,28, after CCG.
However, there is controversy in the liter-
ature regarding the use of CCG, primarily
due to the potential for overgrowth40,41.
Additionally, the CCG surgical procedure
carries the risk of graft resorption and an-
kylosis, and is associated with donor site
morbidity55,58. Nevertheless, other authors
found no difference in outcomes of TMJ
reconstructionwith CCG or alloplastic graft
in rheumatoid arthritis patients, except that
the alloplastic graft group had fewer addi-
tional operations55.
Some authors favored AJR in adult
patients, advocating that this approach
provides stable long-term results and facil-
itates early mobilization. However, long-
term outcomes of AJR beyond 15 years are
unknown19. Patients who have not reached
skeletal maturity are expected to have a
long life span, and thus there is a risk of
mechanical failure requiring reoperation
or replacement of the AJR. The included
articles reported improved OSA and
esthetics38 and good functional out-
comes26,29,38,43,44, with the longest fol-
low-up of 46 months44.
Some authors suggested staged surgical
procedures with AJR first, followed by
BSSO with bone graft and plate osteo-
synthesis38. Others recommended a single
AJR procedure43. The authors claimed
that failure is likely to result when per-
forming mandibular advancement surgery
alone without TMJ surgery in patients
with active TMJ arthritis disease, because
of mandibular relapse from continued con-
dylar resorption and/or increased pain
levels. In cases of disease remission, max-
illary surgery can be performed for closure
of open bites; however, the esthetic results
are often suboptimal59,60.
This systematic review had some lim-
itations. First, the studies included had a
low level of evidence and a high risk of
bias. Most of the studies had a small
patient sample, and no study had a control
group. Additionally, the mixture of JIA
and non-JIA patients in many publications
introduces confusion for the reader. Only
some of the included patients had JIA (232
patients, 172 with JIA). Thus, it is difficult
to ascertain that the results are specific to
JIA and not to another condition. Also, the
majority of the outcome assessors were
not blinded in the included studies. Fur-
thermore, only two databases were used
for the literature search and this may have
Maxillofacial surgery in JIA 1041been a bias at the review level. Therefore,
the study heterogeneity did not allow for
meta-analysis. The strength of this review
is that it includes all manuscripts on JIA
and dentofacial reconstruction.
The research and treatment of JIA-in-
duced TMJ and dentofacial deformities
requires multidisciplinary collaboration
between rheumatologists, orthodontists,
and oral and maxillofacial surgeons, and
many other healthcare providers (e.g.,
radiologists, general dentists, physical
therapists, etc.). There is a significant need
for prospective studies with standardized
variables in patients with JIA and dento-
facial growth deviations.
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T, Herlin T, Peacock ZS, Twilt M. Standardiz-
ing terminology and assessment for orofacial
conditions in juvenile idiopathic arthritis: in-
ternational, multidisciplinary consensus-
based recommendations. J Rheumatol 2019.
http://dx.doi.org/10.3899/jrheum.180785. pii:
jrheum.180785, [Epub ahead of print].
21. Moher D, Liberati A, Tetzlaff J, Altman DG,
PRISMA Group. Preferred reporting items
for systematic reviews and meta-analyses:
the PRISMA statement. PLoS Med 2009;6:
e1000097.
22. Bowler JD. Juvenile rheumatoid arthritis:
cases from the coalfields. Ann R Australas
Coll Dent Surg 1991;11:209–17.
23. Cattaneo PM, Kofod T, Dalstra M, Melsen B.
Using the finite element method to model the
biomechanics of the asymmetric mandible
before, during and after skeletal correction
by distraction osteogenesis. Comput Meth-
ods Biomech Biomed Engin 2005;8:157–65.
24. Cohen SR, Ross DA, Burstein FD, Lefaivre
JF, Riski JE, Simms C. Skeletal expansion
combined with soft-tissue reduction in the
treatment of obstructive sleep apnea in chil-
dren: physiologic results. Otolaryngol Head
Neck Surg 1998;119:476–85.
25. de Zee M, Cattaneo PM, Svensson P, Ped-
ersen TK, Melsen B, Rasmussen J, Dalstra
M. Prediction of the articular eminence
shape in a patient with unilateral hypoplasia
of the right mandibular ramus before and
after distraction osteogenesis—a simulation
study. J Biomech 2009;42:1049–53.
26. Fanaras N, Parry NS, Matthews NS. Multi-
disciplinary approach in the management of
1042 Frid et al.absolute trismus with bilateral temporoman-
dibular joint replacements for a patient with
juvenile idiopathic arthritis. J Oral Maxillo-
fac Surg 2014;72:2262–72.
27. Felix VB, Cabral DR, de Almeida AB,
Soares ED, de Moraes Fernandes KJ. Anky-
losis of the temporomandibular joint and
reconstruction with a costochondral graft
in a patient with juvenile idiopathic arthritis.
J Craniofac Surg 2017;28:203–6.
28. Guyuron B. Facial deformity of juvenile
rheumatoid arthritis. Plast Reconstr Surg
1988;81:948–51.
29. Haq J, Patel N, Weimer K, Matthews NS.
Single stage treatment of ankylosis of the
temporomandibular joint using patient-spe-
cific total joint replacement and virtual sur-
gical planning. Br J Oral Maxillofac Surg
2014;52:350–5.
30. Kahnberg KE, Holmstrom H. Augmentation
of a retrognathic chin: I. Use of HTR-poly-
mer implants in a long-term prospective
clinical and radiographic study. Scand J
Plast Reconstr Surg Hand Surg
2002;36:65–70.
31. Kasfikis G, Antoniades H, Kyrgidis A, Mar-
kovitsi E, Antoniades K. Craniofacial surgi-
cal management of a patient with systematic
juvenile idiopathic arthritis and Crohn’s dis-
ease. J Craniofac Surg 2009;20:948–50.
32. Kennett S, Curran JB. Mandibular micro-
gnathia: etiology and surgical management.
J Oral Surg 1973;31:8–17.
33. Kofod T, Cattaneo PM, Dalstra M, Melsen B.
Three-dimensional finite element analysis of
the mandible and temporomandibular joint
during vertical ramus elongation by distrac-
tion osteogenesis. J Craniofac Surg
2005;16:586–93.
34. Kreiborg S, Bakke M, Kirkeby S, Michler L,
Vedtofte P, Seidler B, Moller E. Facial
growth and oral function in a case of juvenile
rheumatoid arthritis during an 8-year period.
Eur J Orthod 1990;12:119–34.
35. Mackool RL, Shetye P, Grayson B,
McCarthy JG. Distraction osteogenesis in
a patient with juvenile arthritis. J Craniofac
Surg 2006;17:387–90.
36. Myall RW, West RA, Horwitz H, Schaller
JG. Jaw deformity caused by juvenile rheu-
matoid arthritis and its correction. Arthritis
Rheum 1988;31:1305–10.
37. Pagnoni M, Amodeo G, Fadda MT, Brauner
E, Guarino G, Virciglio P, Iannetti G. Juve-
nile idiopathic/rheumatoid arthritis and
orthognatic surgery without mandibular
osteotomies in the remittent phase. J Cra-
niofac Surg 2013;24:1940–5.38. Paul SA, Simon SS, Issac B, Kumar S.
Management of severe sleep apnea second-
ary to juvenile arthritis with temporoman-
dibular joint replacement and mandibular
advancement. J Pharm Bioallied Sci
2015;7:S687–90.
39. Singer SL, Southall PJ, Rosenberg I, Gillett
D, Walters M. Mandibular distraction osteo-
genesis and maxillary osteotomy in a class II
division 1 patient with chronic juvenile ar-
thritis. Angle Orthod 2006;76:341–8.
40. Svensson B, Feldmann G, Rindler A. Early
surgical-orthodontic treatment of mandibu-
lar hypoplasia in juvenile chronic arthritis. J
Craniomaxillofac Surg 1993;21:67–75.
41. Svensson B, Adell R. Costochondral grafts
to replace mandibular condyles in juvenile
chronic arthritis patients: long-term effects
on facial growth. J Craniomaxillofac Surg
1998;26:275–85.
42. Turpin DL, West RA. Juvenile rheumatoid
arthritis: a case report of surgical/orthodontic
treatment. Am J Orthod 1978;73:312–20.
43. Webster K, McIntyre G, Laverick S,
McLoughlin P, Tothill C. Treatment of a
class 2 skeletal malocclusion with degener-
ative arthritis of the condyles using custom-
made temporomandibular joint replacements
and genioplasty. J Orthod 2017;44:55–8.
44. Wolford LM, Cottrell DA, Henry CH.
Temporomandibular joint reconstruction
of the complex patient with the Techme-
dica custom-made total joint prosthesis. J
Oral Maxillofac Surg 1994;52:2–10. dis-
cussion 11.
45. Leshem D, Tompson B, Britto JA, Forrest
CR, Phillips JH. Orthognathic surgery in
juvenile rheumatoid arthritis patients. Plast
Reconstr Surg 2006;117:1941–6.
46. Oye F, Bjornland T, Store G. Mandibular
osteotomies in patients with juvenile rheu-
matoid arthritic disease. Scand J Rheumatol
2003;32:168–73.
47. Stoor P, Hodzic Z, Arte S. Surgical treatment
of dentofacial deformities caused by juvenile
idiopathic arthritis. J Craniofac Surg
2018;29:e51–7.
48. Nørholt SE, Pedersen TK, Herlin T. Func-
tional changes following distraction osteo-
genesis treatment of asymmetric mandibular
growth deviation in unilateral juvenile idio-
pathic arthritis: a prospective study with
long-term follow-up. Int J Oral Maxillofac
Surg 2013;42:329–36.
50. Belanger J, Kossick M. Methods of identi-
fying and managing the difficult airway in
the pediatric population. AANA J
2015;83:35–41.51. Cunningham SJ. The psychology of facial
appearance. Dent Update 1999;26:438–43.
52. MobarakKA,EspelandL,KrogstadO,Lyberg
T. Mandibular advancement surgery in high-
angle and low-angle class II patients: different
long-term skeletal responses. Am J Orthod
Dentofacial Orthop 2001;119:368–81.
53. Stabrun AE. Impaired mandibular growth
and micrognathic development in children
with juvenile rheumatoid arthritis. A longi-
tudinal study of lateral cephalographs. Eur J
Orthod 1991;13:423–34.
54. Stoustrup P, Kristensen KD, Kuseler A,
Verna C, Herlin T, Pedersen TK. Manage-
ment of temporomandibular joint arthritis-
related orofacial symptoms in juvenile idio-
pathic arthritis by the use of a stabilization
splint. Scand J Rheumatol 2014;43:137–45.
55. Saeed N, Hensher R, McLeod N, Kent J.
Reconstruction of the temporomandibular
joint autogenous compared with alloplastic.
Br J Oral Maxillofac Surg 2002;40:296–9.
56. Ow AT, Cheung LK. Meta-analysis of man-
dibular distraction osteogenesis: clinical
applications and functional outcomes. Plast
Reconstr Surg 2008;121:54e–69e.
57. Norholt SE, Jensen J, Schou S, Pedersen TK.
Complications after mandibular distraction
osteogenesis: a retrospective study of 131
patients. Oral Surg Oral Med Oral Pathol
Oral Radiol Endod 2011;111:420–7.
58. Saeed NR, Kent JN. A retrospective study of
the costochondralgraft in TMJ reconstruction.
Int J Oral Maxillofac Surg 2003;32:606–9.
59. Mehra P, Wolford LM, Baran S, Cassano DS.
Single-stage comprehensive surgical treat-
ment of the rheumatoid arthritis temporo-
mandibular joint patient. J Oral Maxillofac
Surg 2009;67:1859–72.
60. Wolford LM, Reiche-Fischel O, Mehra P.
Changes in temporomandibular joint dysfunc-
tion after orthognathic surgery. J Oral Max-




Division of Oral and Maxillofacial Surgery
University Hospital North Norway and Public
Dental Service Competence Centre of North
Norway and Department of Clinical Medicine
Faculty of Health Sciences
The Arctic University of Norway
Tromsø
Norway
E-mail: pfr28.pf@gmail.com
 
 
